var title_f25_15_25840="Mesoscissioning procedure 1";
var content_f25_15_25840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesoscissioning procedure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mesoscissioning produces multiple small holes in the nail that allows subungual hematoma drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Path Scientific. Available at: www.pathscientific.com (Accessed on May 6, 2009).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25840=[""].join("\n");
var outline_f25_15_25840=null;
var title_f25_15_25841="Ultrasound atrophic triceps and deltoid";
var content_f25_15_25841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of atrophic triceps and deltoid muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 269px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAENAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5u8K+HbzxNqMllp7QrMkRmJlYgYBA7A88iu80r4DeNNWtRc6dDZT25YpvWYgZHXqtc58KdSGleI552UsGtWTAOOrIf6V9t/APUP7S+H63GzZ/pcy4+jUAfJWpfALxvptubi9t7OKAEKXMxIBJwP4c1mJ8IPETsFWbTifTzX4/8cr7J+P17PYfDa7uLXHmC4gHJ7GQZr5kTxXeKys7ruz3oA48/CTX1zm500YOP9Y//wARTD8KNcA+a80sHOMGV/8A4ivUrPxqioFnUtuGDgYP45py+L9JRXSWzuHPXfkigDy0/CbXh1udNH/bR/8A4ipH+EHiBU3G50zGM/6yT/4iu+l8WCSTdBEUhPJBYA1AfF14EBRhu7E5IoA4L/hU/iHftElkfcM+P/QKbJ8K9di/1k9gvsWk/wDiK75PGuuQ71jlhBfr8mOKjPjzVVYF2iBA4wgyTQBwX/Cr9b2F/tFht9d0n/xFKvws11lBE1jz/tSf/EV3k3j3Up0RTDEsXceX196E8aXmV/dBgDzhivFAHDP8KfECDLSWI/4G/wD8RTE+F2uOxVJ7FmHYNJ/8RXokni0xAs1msxJzhjnH61aXxhBMnz2YhbHRVyPzoA8xHwt105/fWIx1+aT/AOIpP+FW68FyZLPHruk/+Ir0ibXGVR5UgGfmAU5/PmqUniK9OGIT0HagDg4/hfrrgFZLPB6ZMn/xFOk+F2uJ1uNPP0kf/wCIrvI/Fl1AAJWVlxztq6njnSRCFktZzL1O1uDQB5k3wy1teGls8/70n/xFA+GWuEE+ZaYHcmT/AOIr0h/iCoJ+yaYiE9CxJzVObxld3TZmjRE9FGKAOCPw11nj9/ZHPoz/APxFH/CtNaAyZrID3aT/AOIr0BPESFVULnJ5yTT5PEke4CSJsDoVOKAPPV+GmsN0ubD8WkH/ALJQfhnrIJ/0ix4/2pP/AIivS5fFNiYF/c3DEY6Himz+K7dkCWWnyjHJYsSc/hQB5sPhnrJIAuLHJ/2pP/iKlHwr18qW8yy2Dq26TA/8cr0KLxJfFwFhRC3OHT/61W11/UZT8zQsBwABj8hQB5fN8L9ciUs81jgDPDSf/EVz9h4bvL600a4hkg26rqEmmwBmIKyoISS3HC/6QnIyeG46Z9xfWNRWCTdCXypHAznivMtHQyeE/AyKSC3iW9AI7fu9PoA22+Ani4HHnaT1wMTvz/45Vy3/AGcfHlxGkkUWnFHGQxnYf+y16WbS7i5uGlAAwpWVs/pX0F8PVZfBOiq5YsLZcljk0AfGz/s1+PkKh10sBu5ujj/0Gkf9m7x2p5GlEeouTj/0GvqD44QSz6bpIhnnh23LEmI4JGw9a8mWO8t1I+1XpXPBMpGf8aAPMx+zp46Iyq6Y3sLgn/2WkP7OnjpRlo9NUe9wf/ia9LUairZa9vIcn7pc4J9aZs1OUky6nebV+7+9PFAHlz/ALxqmS8dioHUmVv8A4mo0+BPi5v4tNH1mYf8AsteqJBeMMSXt5KD3aY8fjUP9mTSuEe6ugfUynpQB57b/ALO/jW4/1TaSf+3lv/iam/4Zu8e4yI9NI9RcH/4mu/8AsV1ER9mv7pQpxkOw596S5i1VFw2oXQB7NIxB+lAHnrfs7eNEfZLNo0bf7V03/wARTj+zp4zC7vtGi4zj/j5b/wCIruWtrsrmd7t2HRgxJJoaxm2oWubtS3JHmEf1oA4CX9nrxtHjA02RT/Ek7Ef+gVH/AMKA8Zhgp/s0E8DNw3P/AI7Xop+0KirHfXLH+67k0+C1unEZ33Y7cOxyPpQB5u/wA8ZIOW0vPcC4Ykf+O0h+AnixRl7rRVHqbpv/AImvR4rCJJHaa61AFugVifwqCTT7RVk8qa6cqepl60Aef/8AChfFJKiO/wBDkJOMLcv/APEUjfATxcud02kAjt9pb/4mvRLXSBLHvjkuAx/6a7cD86Q2ksUjeTLOSP4fMY//AK6APOP+FF+KMEm60cY9bh//AIilT4F+J3YKL7RAT63TD/2SvRJY2XBbzAzckNmomiaVMxmRTnnDkY/GgDhf+FBeLSRsutFf/dum4/8AHKcfgB4tC5+16L1x/wAfTf8AxFdyli+GdZpfX/WHmnpp8q4O+ck9f3h//VQB57cfAnxRb5El7omQMkC6Y/8AslV4/gn4lc/8fekL2+adx/7JXo5h8mQllkI6ffJzRIkU2NgkUEc5J/QUAcHD8B/EkhGdU8Pxqf4nunA/9AqK9+B+vWmRJrHh1j6JdSN/7TrvILODljJJIf7oYjFP8iHzQyq4Po2aAPGvGHgHUPCumRXt7fabcJJMIQltI7OCVY5IKAY+X17iuPr134vqP+Eet2Xft+1qMlcD7j15FQB03w/eKPW5GnJEfkHOO/zLX2z8Abu0/wCFdRNp5byTeTj5hg53DNfC/hhlW/kLHA8oj9RX2J+z7dBfhnCF4H2647e60Adb8b4E1b4d3drJdR2oa4gxLIcKCHBA/HFfM954Vv7RT5U8F1F1/dyA5r3D4+XO/wCF96Mn/j7tjx/v183W99dwsPJmO0fwtQBOyPbuRJG8bjjDHI/CqzyqGys/PQhjk1qLrXmRsupW0E5PAYckD0pGh8P3mCs7QN3BAPNAGQtwSGyTjtuzxRHPsGJgTjsG6Vtnw20kZazuoJVHO0tg1XfRp1ciaMhQPvEDmgDOaccESkfXqarykmTcXyT6HtVm407bJmRwPUY5zTJljj3JbwGVs/fYZNAE9sSYuJNq4xlmqVCUACyq3OTg4NZJa7chtkvy+qYqN4txLMwOeuRQBvLJp4l3TXEhbHRf8alGpadD8ixl2xnc0hwfwxXOB0UAKEDZxnNSqwwV8xVPoOc0AaM16JUxE3lgnPC4qjNcsSN0mcHGcmqbEmQ8nPtU8EExbAiZ8jrigCSO53kL2PHztxT1uEXKgAEcNzVq2tnwjT2zKD03Z6VrkaSkQ3adKZTxl5Op9sUAY0M0MsimSRokHcA81d36WqkyTzS/7A4qldNDKzN5axbOig9qp3DwlR5WFPcEigC8NStihSKAdeGJ5FQre5JJJLepaslWVSTlgSCMVCLkxnoD7GgDcN0XxyfbnrT4tRMLNuaZV9RWGl0w3dQD9KVpwyrnPPHBzQB0yeIoo1AETSHr85/rV6Pxfdpt+z21vGT0PlqTiuPjlJyArZ7DFWYmYnEisu7vjpQB0dx4r1OaCRbi5ZUOflGAP0rnNJl8nwl4HlxnZ4lvWx64j0+kl+WIhWO3uGHNR2j+V4H8GyHoniK/b8otPoA9ouvFhliYLa4lHRj1x/KvoH4daibjwHoE5yDJaK3P418lveNcEnzHCk8AKK+k/h5c7PAXh9AeBZqP1NAD/jHrENjpGmSTrv33DqMDJGEzXlJ8W6dJEFdL5wT82MDH0rp/jzcltD0bbgsLqQ4P/XOvHYZ5HjC7N7noGHB/CgDsj4stFI+z21yUH3S8nT9Kb/wlckkZQzOiH7wGCT+lcpJLM0XCLHkYUYwB+dVN6pKm44I++x5oA7221iLaNznA/iAyKc3iGwEW0RSSSE43BQAPyrzxLmONtySHHQ5HarNvftM2cIADkHbQB3MXiSJBJH5TDfxk84qVNShldRJcFVAznOcEdq4sXe3Y6yIXPRuDn6inZMo8x0B65CqAD+VAHfx6tY4YSTFGA6Abgaj/ALa0QupmgeUL2JI574NcSZEnKJHbRxyKOHL4z+ZqCSO4iYOoTbklsSK1AHoF74k8O28e2DT3aTt+84qq3inTjbjMbxMR8uBuI+npXDgdHMWQx4Yn7tTYtnRwJGOBj5x0oA6iHW4Zo/3hkYrzgDBH41Ul8U2Klk+wtKcYQvgfyFZUNlE2DEYpCBn5mIGPwqC8NtD8xitjz91SxIoA1YvFHzZg06FD03HjFXk1Bpo/NEKhj3E22uQE0TyAwy+Xz9BVwwpKuY3kmkHZVOB75oA6NtYhW4UyiMFByGYHNKmr6SY3MpUoTuG1enr3rj5bLDBnScOM/eXAP1qAxANhh2/iHFAHbR6xoTgt5rRknjk4x9KfLrGhoAIJ7qVm7jFcKkEe/cxUYGTtB5qGZ41RlRshuBkEcUAemS6vYS26qwvW7hGUYPvkVkza9ofPmi48wf3BmuHglfLIsYABwA2eBU84WUfLGqSN1JXFAHWL4j0JUwlrcTKezgZH5VOdd0x7dhBayhv9/la45bUxkN5i7s/d6E/jVjcn2c9Rnqcg80AYvxd1GzuvDttFarIHF2rHPT7j/wCNeR16L8RJEfQ4gOHFyvHtsavOqANPQV3Xj9eIyePqK+rfgXc7Ph3CDx/pk/8AMV8seFrSa81CSK3iaVxESQqkkDI5r6V+FQlsPBsVvcRtFILiVtrDBwSMGgDd+MUguvh/eRMwA+0QNz7PXzkQqk7QxIP4V9BeNdNvvE3h2XStKUveSyxuoHorZNcTF8HPEOFWW9tbdz98ckr+lAHmscjhiDx3w3GaWNDL8xTLMepAr2S1+EkcKL/aWsocjDBAO3ua17f4deDBF5P9rwpdAZDu2aAPGbGwnXkyBQTnDHiuisHtkQpf3MRj6gEn5TXV6n4F8MqxaXxrbqw4KxpWa/hvwqkhEOt3F2SMNtiyDQBmSSeGL3KXUrIQMK248e4q5D4PtbmPzNF8SWCFh9yc7TU9j4L8P6kwFy2oJFnGYo+CK0T8MfBSTDbd64HPBwuKAOZ1PwH4ueEMkltfRL08mVWP161yOp+HNdty0c+nXII6/ITXtWm+DPDWmsDby65K3bEm3+VdJZXcNmSsUd7JJ/B50nI96APmBtB1jaD/AGReN6Eoa0rLwpr98FFtol0vQfMuCa+nBq99J80Usm5cZ2jJH6Vow6peGMrdvcurDPzOF/pQB88W3wu8TRIJnjhtxx/rHXI/WtOH4e+Mt2Le405i38KTrkj869L8Q6baXW54llZz1DOea52HQ7ENiWyulfsYJWU0Acpc/DX4iXC/LZ2kg7fvl/xqCf4W+PliK3Nlbxp3IZfl/Gu6j8NabI+LfUtatJOh3ylh+lXJvCFrJBtn8R6ncL3Uu2TQB5K3wr8RyqAbiyWQnBUzgCnyfBzxjDjYlk27gYmU/wBa6y98J2HnhILm/wCBwzs3FMh+H1/dB2ttalgA/vSnmgDlV+EHi5X2yfYImPBDSDH86uWvwT1xvmurqxAHXEy/41sXPwo1WSLe3i6MMOdrMx/lWbP8L/EEWY7bW7ecNzkSgZ/M0AR3/wAObO12QNqNmso+8TKOtSWvwxvJ43l0zVtI3nojyjJrPn+FviKBxueGckf89Rn+dRn4X+KDkpHJCo/iEvB/WgDbtPgt4wkmDpc6U6julwmf51OvwV8SRRs19qGmQ57tMpx+tYdn8OdcUFpdbngB4I3nGfrmtOP4cauQok1OWT+IlpDtIoAsTfBu/ihZ7rxJpYCqThXBzXl1hCbjwV4LhUZMniO+Qc46x6eK9OXwQYIHN7fqAAcEsT2rzCylMPgjwZKv3k8RXzD8ItPNAHqQ8GX7OBDGHkPbd0r2Dwws2meG9MsLoBLi2gEbr6Hn0+teMjxbOiqFLQ569j9c16PoGpNcaHYTPIZGkiDFyfvdeaAHfEzSNS8S6bYQ6TAJ3t52kkyfuqVwD+defHwlqNkNt9LFaqDjcZMfpW38UtZurPSLH7FK8bSzMrFGIOAue1eUTXc1wyveTzyk9MsT+dAHebdDtdv2vU2lZW6KuR/9arK6/wCGYyF/s6Wddv3yMEn19685CxqR5SbmPUnt9au25IwQg44GScUAdre+LNGMIjh0sRsP7yA8VnC5tb2by4THDu4zt4GfSudjjZ2P7zgD+IUnlJGMMSqA8NyOaAOy/sO0tmjMlyjRsMll6j8BWbqEmn20oS1uJZlHQY2g1n2cpilQvcCXJxgZ6e9bZ0m2uyGzsV+mSDj16UAYDTrcOQ2AAe5zilSdwQB8yKcDaRXbWXh7Ro4QboTA9FAH3jVG/g0uCVlSyljYdM8j8qAMq1adYnCRBt3dgDiq91HcxrkxowPfH6VopDvb92QoB4D8c/SrEWhXN2HU31rCh5ycn8gKAObs728hlBj5XGTkcGtmy8YalaBI5NO02YZ482Mfzqnd2VtYu8c92J2UcBFx/Wsy7gZxmMjafuryTigDqn+IV986NoGjYPdIlx+FZNz4xvpVw0cEStxsiULgfUVjQ2zPHh1fj/Zzinm1jXmSOTjr2zQBpLrEs8ChZHkUHlGY8fjTJryOVgETYTwcndzWY0KRt8kZAPPJFbGjiykYefnzB0XIH60AQRWs1y5wcRg/eYcE/jU1xp84gYtsVf4SMflxXS3F1ZW9qqosSuoHDyEk1lXGpi3kWSCEGZRkAcqaAOfVtjlZCVZuue1SXMkIXaLlGk6g56fjW4njgwPi/wDDlndp3JG1vwNaUPjT4cX0Q/tfwbcxyjvFOQD9KAOXt1a4jVCm4jowqb+z02HfLsPcbDW7c6z4TmmYaHplxawlf45mOPrWXd3KgHypIFGMKOoNAHn/AMQYwukRMCD/AKQBgf7rV5/XoHxFleWwjMmP9cvQf7LV5/QB2vwn1abRvEk9zbojubVkw5wMbkP9K9707Xn1azS6kgS2Ykp5a9OO/wCNeI/BDT7DUfF1xFqis0K2buoBx829AP0Jr2DVY7TTLv7Lpy7LYIGA3Z5PXmgDdtbrUHnC6OxF6QdpGCdv8XX2q5JpHiC6bNxduXx8wMmGOfSsPwjeoNdjMgZ18qTheT0ru7RLiaZZLSIg/wALSNkigDib3wt4hk3+VDK6r1LyhjVWD4f6ncSI7wyMW/hTJH516v8AaZ7MbbkxzEggmNST9OKqzXl15e62WWJB0LNtA/XNAHG6T8MbPDvdafGSD83mSdPqK1m/sfRP3drb2kTL8h+Xg1k61rmrJO0f2sEEnhXzu/KuXubl5Di8cvt7MM5+lAHYXerWcSgtdQbT8w2/Lg/Ss9vEUSl2gjdnA55J/WsG3mt1B8q3iJBziTBx+FbMNy9zCY7O1sxIOW+Tk/jmgBsfiS4I8uBZgc5B2cZ+pqZr2+uVLGCdpsfejUN/KmpBrAjUwTwZU/cAxiknm1qHbGCGZmBJjYZFADGudUVWjVp+27KkYzUy6Xf3g3OLvy0GQRJtBp8kl/bKXvbhoVbttyx/DNc/d65qNx5kFtqhiiBIG4YzQBqz6bcwZH2yaIj5sM276Cp9J1S7t7vy7q7AQdV3Vys816IxJ9ujnwMEqTkVBb6onSe3yT/EDk/WgD1eTXtLO0o6O49MZzT118eR+5sZJT/eJ4H1rzmymgnVzHuRmPHA5/OmTx68mRDcy+XnAGBgD3oA3dc127kk2/u4R2AA6VnKlzOd7wySlx95Mhf0rm5jexFmlceYo6Z4J96uQ6zJ5YR/3bYxuzjB/CgDamFvbYjaMMxGW3lhg+3NVvs8NwC6yMhP8OD+lUn1BmYutwpAHJHXP5U4Xc7uWwCu375XANAExgdf9XcXCsOxkwfwFWFvLiIbDdSBDzln5+nWshVM9wjMsWSD90kfqavJagwrlo9wP3i2ce1AG5YxR3oVEunMgGdu3jNbFvBLbsUmeN4wMj5RXIWsW27/AHkm1hyuxN361t22ofbj9nbYwX7u4AEUAT3qwSQSSywxGMoQFUbT06185oSPh/4SI6jX9QPH/XKwr6H1K3ENm6uqbipw4fI6flXhPhiCK50H4fQXP+ol8VXaSf7pXTgf0oA1FkimYhmCygc7m4r07w3c+V4e06MMCFhAyD7mvSh4a8G2p8mPToJm7lhk5PvivNPEXkafr+oWdpGILaCYpHEP4F44oAxfiNMJtOsc5JWZiAD/ALNcL5e6NmQMpUcjdzXt3w8sdN1q+v01aLzUghV4hnoxbBP5V1N34X8KFi1xYwtGONw3LQB8yIcEbhH06Z7+9X7OGSQrJy6DqF/hr3i40D4bAlrmylypzhX4qgt58KtPkdR4fuGbuQ7nP60AeP3yxRRhkjYr1O3Jx+dSabbm73COxuJWJA4yMe9etat8SfB2lWYj0LwzC0hGFE6k/wA642X4hahfvsFnbWUTHBWFQp/z9aAKVpoNzE6ySxIVB6bc/rXQWclgqL++gglUkHc3P4VxN/rsgnYJMzgZ3bjWDcXxdmcqjL659aAPdbaDTiBMdQhdmXGTcbdv9KebPT3l25j3kD94blWzXhdrdSM6MEZccDANa0V7KjETk57dxQB6ne+HLSdC1vNEHBwQX3H61h69oRggaW2vLVjt5GSn5ZNczbXiI2VO1MDc2Tk/SrT6vEfMUusygZ+Ycgf0oAx8KkieZHvyerHGafvV5H+zx7XPC85/Kul0m+0PUF8nUINrHjcONtSz+DI7qJW0fM2D91c8j60AcmXkRcHO4npkHioA0ZWT5ssORk963D4c1W3do5NGvyoPBAzRF4O1y7JMemXKAHgEY/nQBzM0m5/vlRjJU85x6GnwSDJkTcQBjbG1dS3w31ORwbqeG3H93dub8qydZ0C50ksu13QfxlcZoAy5GfZ8vQnkM3IqEi4lYlZQirwMtjimneT0Iyc4YU4zyJvBjXBOPunn8aAIpPn/ANdNvYDHBJxT5IY3iQKQoHHIxSWds8soCAYHOCCa2pYbWGILKYknxzndmgDCkSRQMOwwcZLYFOUssed2TnjDZ/8A1Ut5gvtiZGI5zjinWbbGaMH5/YjFAHP+N0/4kkL44NwOT1+61cLXovxE3JoUMeVA+0KxUdjsavOqAPRPgaQvi65Z2jVRZOTvGeN6dPevSPFd7C2sn7MymLykHA2jPOeK8x+C9vJc+KrlYpEjK2bsS/pvSuw8aN9k15ovOEv7mNt2MdQeMUAb/hDVpLLXo54FjeQRSKA/TkV1/wDwlF+04UhWf0jyteY+CsX/AIjgtjcCAPHJ85Geg6fjXqVlp4sGP2dmuZyMLtU4H40ATR6nqbkkbsk8JvJP/wBerUeq6kqGO4VYEByd2c4/Gqkx1yRVaOG1jAypJTDfpUX9kXN5ETq+ofux2jOWHtzQBDqz2rRsY7iJbhz1B6/jXPXEYiXf89xk5OTkCtC/0uwsT5sQnmX+8FII/CqcN6kSqqFzH0AxzQBQZrhk5gEWTw2MHFaVtH5aZF2VOMAF8c1ONMsbhPNubqfaw3Y6hT/jVqztNBhQyfaJJApyAyHn8aALMbanDFHte1uYwQwTzQSfannUtQZyYbSK2cccDJH51UbVRPOf7LsF2jrujIX61qhfEcgM5+wjIGERsZ/DFAHnvj+41G90jUmurofu7WXKs3bYeley+MfBtppfifQrLTvD3w9W01m8e1jE/hcSPbhYHlyWEyh8+XjgL19ufOPFWl6hqHhvWGuLcib7JMI4lQlpH2HAAA5OelereIPHfg/V9b8O3/8AamqQnR7t7ry/7Bvm83dDJFtz5Q248zOcHpjvmgDzf4meDYbLx2bLSo9I0x10a0knWwtVs4ZpDNcguIwTjhQOSTgDmsKz8J6q67IJLS4yeQTjmut8d+IdI8S+O73UNNuJvsy6ZaW6vc2U0GZFluWYASKp4Doc4x81c+ltO8waC/PrtQMR+lAFeXwvq1uTJdWMaRAdVJ/rWPMIrQqs1zLv/uLk4rr5pNfFobeG5SVO4kO0/rVeeyu5LPzrzT7MkDr5oyPfFAHHPMol5chOp3L3q/bXcC5X5IyeTgE5qO9t0tpmaWaEEnoD2qBHsjuAy3PQHrQBoRXzozoJIjuHfk4prbSwZZlz3Uviq6mzCAp5wBPKqBxUk1zZsEBUkDOcx4NAD45djMHlA7jAzn8atxapZYKzTuxPTA4FYstyJEwrOVJwueKjN2IvuxK7Y2k7f60Abh1tgzRW6LIieqjNTQa9Lbs7JHCjN2YDNc8sq/Z2O4KT/wA8wMiiHMkJwEwPTJNAHR32ttfwMk0kCDachevSvILOZ7fwR4Nni/1kfiK/dfqItPIrundUjKsqxHYc8HNcBGceAPCRPIHiDUP/AEVYUAenxePPEi7TBcCJc45XNU7jVJ7ueS5vJTJcysWkc/xN61hfbWhzwVQjjtzVY3ZzyeaAN241K6gMb2U5ifdyQTyPwq5D4l18OzG7L8Y2ueDXMJdFicbTjqSelPFyyfMAAmOSuKAOqj8RaqGU3NvbjByG2dR6VfPioCDb9ltmkcfM/lDGK5C31AsdjMCnXn/PFSy3MbhGVceu1f6UAaV2zTyGeeKP5uvAqvLZCQrsaFM8jnp/WmJLFJGIlK5H8Wdp/OoGcL8ucsDx855oAunSLh13kIzDg4I5FNt/CyyOWkZBn/OKfDMYpCwyGx69qkGpzjKwodv3gff8aANfS/B1tKgH9qG0fp904Wuh/wCFK315GJrPxdprL94CQkZNcda6nPOfnZhKeCwOK2NOmubdgzzlQTwCeaANG/8AhR4us4wLW50u/gHTyZBuNctqnhHxVZSkXOjTAdCUj4Nd+NYt4EHmzy+auMMj9KkuPGmozMI7a9lMY6ebzigDye2srmC4aOW2mi7vuXBrbsZ9S01xPZXE6MeUC5wfrXU6nrdxfO32meJWY/NgDNZlutowPmy3BHUiNR/OgDT034meKrRv3tnaSgYHzx8/UmrE3xQ1KV83+mQ+UTz5ORj9awLm7liXZA8qqxwFPU/WqNzcs4HnAGTBBLDj+VAGrq3juOfP2WJoQem5a56TV77UCwa4D+x7/wBKg1GOGXYACMDjjgmsmW2dV3ZwwPLAdqANm30i71BHjVQ4J5yRwParC+GY7eBhOs+5T1Aqlo08ltcqZCxiB+Vu5/CvRdHvbO7h8mSaKRsAnzIwP160Aeb+VHbM6x+WwHdsg/lWVeSSFyyIo3DJwvH617FqHh3SrxSdlvFM/PyPjb74rOl+G9nc8Lq9rFGD2YHn6ZoA8c86WUgMOCcZ9atxI4UtlWbOff8AGu/1P4ZJZuWj1612DnBYfyFcpf6Zb2UpQX63BHZAfmPpQBynjyV5NDgDRhQJ1yQOp2tXA133jt4xokKIjA/aFJJOf4WrgaAO1+E5uV8SXBs4TNL9lb5QM4G5Oa2vHV1MviEi5hMEogjyh78Hn8aw/hSblfEsrWZfzFtmJ25zjctanxKGqap4qNxHaXdyfs0SFliLcgHjIoA0vhhqUdv4yt5JQzoIJuF6528V7S2o6hJbNtm2W7YO0cZ/GvBPhra6nY+LoLi5067iiWKVS0sTIvK9MkYr2CaNZZlE8UnzAHhsflQBPJqSxDadRnV+0Y5GasRalqEdmnksWYsTudclh+NVm0qyll8kQXu58EkMDnH0rp9O0/R4wIpJZY8gDbO2f1A4oAgtdduXt83TQLF0JAycf7vrWZr+p6XIQmnRtNIPlbbGBzWvrfhj7WANJa2kVeSRJkn8TWZa2ctrG0dxbQxuPlIJJz+IoAwobG5vogEhKAcFtwH8614fDlyVT7TemG17ruUZP0FW/snmg/atUt7eI8+WFO4/lVT7RFpj/upY7gMcL5qkkUAdLc6hp9rpi2lu0uT8pMcY5/HvWDAJDI7q8gA6M+cD8BUlpr0ZPlXekxTbz8roT8v5dK3bW20m8kWGKFrSVxljKzOPyoAzU8RNZqpu7qxuio/1aqxOPxqpfeL7S7tvLj0UxuTxIsQGa6KTSrLTJsKmnyHrl4V5/Wq2paijQ/uLaNgOP3EQAFAHDJbRahdMbsyWrdFwu3I9xW1YR2tiMCeadR1HkkkH6ioJ7Qs/mTqVZ+cuRxWnpuqjTFA+WRugVCV/WgCO4bRbmPm51KM55UR4GfxrGvdPtxnyWvSeg3JniuoTXopeFtd7k/xMGIpLi/1e6xHE5UZ4LW2QPxoA85utHhZWZlkJ/wBpcZqCPSY0UGJgxPZztrT8SWl6DL9suWZj1AG0GuR+2/ZnKFgWHrQBpmK2tVIXeHLAZMmRn6VBdySFyg+YjleAajg1EvtVWiCHJ5TP60y6u4w4/eRqOhZQQaAI2upC5Dgg8dFxUvlTzcqruSOgTOKjWVZ3ZYt0gx128fWtCweeEBiJcdN33eaAIItPljdRJCGXGevJq21w1s+2O3MbN1wvBq2hlu5tpiVXbknJyainF1DIySRFZF5ByORQBk6nOJIWDyZODjIwfpXCQ4HgLwgT0/4SC/z/AN+tPru7/dLG7z7WOD1Oa5nwdAlzpfw4gmQPHL4tuUZD/ECunAigC7MoCtkFiejBa5y9uPLu5kyflbHNfZ9x8MNDvQyNGbMnkBFByK+UfiT4B8SWPj3XbfSfDmtXOnpdMIJorGRkdeMEEDB/CgDL0KXz5bhcggICQT15q5KvzYUlc8A12HwN+E+reItY1SHxJZavolvHbq0ck9m8Ykbf90FgM8ele0x/ALw9AB9r1O/m5ztUAf40AfNESBZT5pXYfQ81eiMakmBSfTBr6Ug+Cvg7G101BwDkncAP0FbmmfCbwjYsjxQTMynPzSf/AFqAPA/DNvZNCFurfO4ffZCTV+68O2ZEclhbPuz/ABZFfQVx4S0naRb2UAwOAwzTR4QsDGpMcaY/uDAP60AfPk3h7UJGaSS12KR8pwDjFVI/DdxKw35QAHnbgD3xX0FN4e0uKbmTaCMEFc/lSpZ6RaLsS0DBujvjmgDyHQvAlq9uJJrx2lY8gjGa6mz8CNNEEs1yOvzYJrtxHA8wSGygQjocZNbdmxtioDIhb+HaAKAPPovhqGQyT2iNJ0POMfgOtEfwvtpuZbswqOmDjFepM3mA5c8dcEis25l2vIrIDgcFueKAOFuvhJpEsSs1/cNIBzsxz+lNX4TW3klbG8mST+8xIrqZtSZSpQkIG+XGRWhYXkhjJmOB7GgDzS5+GOtWrFo7i2mXORmMt/8AXrIn0q5tJljvrKNwuSzeWRgfSvan1ERjAkznoemazbjUZJfMRzuY9AVA/WgDxu40bStSXexhhbOAACpH4VTvPCFlBFvW6s5l44D/ADCvU9RsFuT/AMe1usv98YH61yWsaDJBJ567Ceg2Nxn6GgDhLjSYIm+/C+CQqnkj36U6KC1ICSP5bIPvqev4VtXdo25zOWEuOWA/zisqSydScEsvX5RkUAQ6lF5cYe1cnA6ucbqxf7ReHcV428gFc5+hrRuBcRgloGAHHmFOKzSgkdlLJk8/Nxn8KAHXOsT3ELBET5VyTsGTWOYYZt0ssqqSeQo5FbF3osqWwmEWM/xetc9LiEhZgy5PQnGTQBkfEwQf8I1bNDJuP2pRjbj+B+9eX16J8Q7iKbQ4ApO8XC554xtavO6AOx+Fk7W/iKZ1kMbfZmAI/wB5K9o0LxBJau8ctvBcKT1dQSfpXjvwjlgi8TzG6tjcxG1YFA2P4k5r3GXTtPuLdZbdJ7ZF7AgmgDXns9FuvLlngvVmlGSIWyv5Vo6bZaBCAu29XPRiDx+dc1bWlxgizui68bgxwf51fiivbRR5joqnpjn88UAdFdDTY0U2V1Kkm4AHYAa0XsdKnhQ3lxE7NwW3gMfxrnEulk2RpDbyMuCxP/16ffJYON0kSRxr1YP1/CgB16LLS5XbTv3zD7nzn5f6GmWl2kyZvlvEZjz5b4H59qwb25smBFlIsag9SOKkspNOVMXmpoufugA9fw4oA15tG0S5kaZbmZ9g5EsoH5HqaS407SrVN9tAsrNx5hYkLVGebRzwrMQeC2Sce+Ks2tlpVwgjS7dMcgrEefrzQBOm8xlrWbT0OONz8j6Cs2eS584l5oVlb70qynBH0rXimstOd8XK4Ufe8tR/TNYWveJYbmJhAqTdshAv5nGaAKzugd1Sd5T3YN8tXraTUWVIUlKQMMZYZ/KuTk1AmJSRtb/ZzipE1UTRCOBJ9ynlw5AH4UAdgLSzhTbLI8s3cM+3/IqKbUdEscBEgSQdAMt+ZNcNeySPIEuZpWU/dKk/rVyy8Pz6i8Zjt5SncFs5oA228dNCzRabb5ycM7KMfhiqF14r1yfcp1KYKeiqtdfp/gKKJYv9FG5uQCTkV0lt4V0+GMLdiFDnmQsB+FAHif2TVtTZWUu8zHncev8AhWhZ+CNXu3Blms7YfxFjnFetXFx4Z0U4kntxJ1AV93H4d6w5/EXhe9Bga3umUfdIlzz7UAYVl8OLN4l87WIPMB+bD4I/OtC18H6TpuSbWLUTzgnLn8gaybrTtIkkZ4Uuot+SpkfNVobPyYmli+0KoP3kbFAGvdi3sI2VdHdGPQeRt4/GqI1CwmUGe0nQIeh6Z9qqjWNSgXCXk7Z6CVgf0qhqHiG8nIFzEjnpkpigDbgh0a8k2uzwt7Kf8iqepaLYMS0GqTbv7rjPHpWG+oSqgVQiqefl5I/Gqy3YWQl0YsTxsPJoAs6laRWds6mVnUAgfL/WuI8DnFj8ND6eL7jr9NOrrr2/8y2ZXl6KcA9q43wiwXSPhyzZ2jxZdE46426dQB92pPKXG54wnoAMmnPdsWwFZsHHy5rlhewTFBDLICGzzwautcmNRLukYZ+76/jQBqzTNICG8xRngcimKtzje5yo6HPQVQt9TjkfEvmJGOecjFE+pRyHFsCwzye1AGosz7lA3SADkjip0km27vL2Z/vNmsOLUBxsYF/7oFSzXLs0YVj1+ZS2MUAXpbuWA4IM4J6BTkVFDqqsG227ZXrkYNUXmDzMGV8DglZMg1Vubu2i3RvNLhuNrdc0AW9SvWuMKIVwORnrWEROzNJiNQMjaASRSy31uyHMqqBxyD+lRC+UDabmQK5wMgf/AK6ANK1k8pVadeT04Kn8627K7tHbDFQw/vHJrmxNJ5YEVrkA8Ptz9afEjyuSJCcnoo24oAr+LvFN9p+uahFHrGm6bpdlaWUjST6VPfyyzXM08aoqwyoesKgAKSS1ZF94l1ptA8R31h4l0K6vdEsZb2fT7rw3d2k+1Y2cApLchlDbcbtpHPesfxfa3Uupa6tra3d28A8PzPHbQvPJ5aX10zMEQFjgAngHpWl8SDP4kHiXXbGw1Gz0vTfCmp2slxe2klq128sYYIqSBXKpsYklQMkYz1oA7u5iEjqFbbGT2FNiVvN5d3PY7Risie8ZSwUqqg4A+bn/AAqS3uppDsWZBGOcqvzA/j1oA055EQg7wzdyegNZ0kgjl3go/HBYip3ljkhIa5k3jqpXGfwrOaVXkaMK7Aeq8igBv9pJcO6sygjsDzWTfT27SjfO+B3I/lipr22MJLRxB06kE4J/KsfUbtpHWNIcJ3SM4I/GgBbzbLP50ZGMbfnB5H0qKXT3MIkAiTd0y+D+VP0+RFYqxIz0G/n6VPd3Iwq+QznsDg5oAqRQRqcXVuJAByxfgipH0Pw9dAObCcM3X5sD+VWkaQRgtaFMn7vX9Ka9zqh+S2tmB+oUf4UAZOpW9lpkJURRgkfKCScfWuGvdQjFyynTrefBzkgjiuv1xdXaZftkYxnKnaG/WuZurZ7iUiQlJWONxwo/KgDzr4rzQzaDbtHpUVm32pf3iEkkbH4/z6V5TXsfxj0hLDwvaTHUI5pWu1XyVOdo2Pz+n6145QB3Xwe3HxPcBduTaP8AeOP40r1oJfzONundOjqp/lXlXwWEB8VXLXP3Fs3I+bbzvSvYbrWbEHMd5Kki8BMbgKAKks1zD+7jR4j/ABDbn/8AVT4769ClI0+ZhjGOtRJcRzkuZo+SD87gE/hWik9vvDyru4xkdvwFAFzRPtFuuJdO87zOpBOQfzputJbtGyGKSKU9Q5O0Vo2MVpJH5jX6W7DnGc0txFFdBiXSTBO1mHLf0oA5hLC1ES+TukYdU3DFamlXKFXiTT7csOQXH86zriykiMjugVF5xu5/Co1z5Q8vzhJ/dLYFAHUWtzqbbkSzso4887nUDHtWXqmuTxloZBZqwPSPH8wKzoJIQ+y7dY+MFthOKjnHhSJgbmW5lbPzbUKH86AMme5866Z2+UsPuqxxUqwsxKopGRnAc5NTS6xoqArpdgQmCB5zFjUcepCSP5olj29NuF4oAvsth5KMUMbKOTnPNPttO+0gNawI5bp6n34rMtpoQztcEmFv7zfypG8SiymKacHBxgDrn8aAOvtLqLTo9l3bwtOuOHQHI9zTL3x3EHNvZWkKODjI+UV59fanc3jNLeTNtP8ACT/hVaPWILeVRhZQBgAd/rmgDrZ9Z1u8lZodSCbTkfvM8e1Vl07UNUaSR7i6mYHJVmbaTWKPEb7j5NtFH6fKCKZJ4k1AoBLeSIR90AYFAGlPoKohnlBDf3ixxVB5JLNsQRgL0Diq8muM65lu8Efwt0P4VPZ6lp8sq/aLx4weT5aZFACw6pdRsfMBbHOSSK0YNVimQCWdlfHQqWH86nebw5dfK+o3SkjGWjI/KsvVoNF82MWmoTuRwc4BP6UAaK+VKVCTRs7etWD5lvFumUFT/BjIrmZIQjZhmLKemW5BqyLm7hj3tdGTHYgmgDU82ORx+6h8vthT+tDSWcHzPB5meNq5FRaRtv5AgbynPLFcVo3GjXcat5TEoedxkwfyoAyLjUrSFHCaNEysp5ZzxXF+FyBoXw9LEhR4qu8kdQNunV1OqfaLZXSaPIwfmJzXJ+HTt8OeAW6Y8UXh/wDHNPoA+sJfJRkaKRuRkFuR+lWbfUZGk27TIoGMryorBtfPZlWGVQzc5Lf/AF604rhrdwJzGuOrcGgDTS8EnzKMlTg5PT8KtpfER7gdg9T3rEuby2kCnzWdyOFI2g1DM6PGNsKEnqpdiKAOiS8YyExkk9yDx+nFWHuQ0QkET4HfuTXJQPCkgLPJEyjhS2A1TJO6By1ydmcqqsc/nQB09vcTtE7+QzEnG3b2ph0uafMhERB5xJGcj8qyYtbmEYVWbf8A3T/jVldXuJCEUFJD97PP8qADUdGhaBzM6JIR15Ax7ZxXMS2kdiwaOfdjoTH/AFJrW1PUFjDLMGlJ5+ZCRXKT6ncea534jB4Qfw0AdBY63ChCyRSNzgsp2jPtWoNXXy28uF0x3bgVwbXbo4kidmAPO7BGfpVptZurlAv2gKV/hI4NAHTtodlf3zak0+q291LGsUj2upXFoJEUsVBETqGwXfGf7xqrq3hrTbu1ntLjVdclt5VaKWKTXL50dWGCrKZiCCCQRWLBdySARXE7kn2OP51K95PGDHHOhGO4wKAOjulgjlQI5LN1Ynv9OlV5Ua2cyrK5DH5ieOfasGLU7jafOSEbR1VfmzVuK9eaMozt7ZJGDQBry3rbCyxPv/vuxzUf2xY0YN+6c927n+dZUk8towZTO7DuDkfSs69vbveZp4SM9wefyoA07/UIPKPmStleoLMax/t0DMSFKKw7jmqbXLSKxMjJn1U5P40kYwxdCCxGMM2M/nQBoRKsqfK6lP7zDn8MVfiDFFCxRyIvVq5h7iRJUBxhf7varaXrQRsyLJuPYkGgDZLTGUtHLGqk8BsjFWblrqANIZ0VSuCc4Fc1HqfmZZ42Ueo55qlfaq1yFQbtndixzj6UAaNzrTruD3Tk4/i5rnNUuY7hQZJB64JwD9O9JPPGjsVVmJHG8ZrKeVJCdvlq3QDac/hQBxPxSt0TRLeVEYbrkDJ4/havMK9E+JjSfYY0kdm/fg8/7rV53QB2Pwt+z/8ACQzLdlhG1swBVgOdy16hJpNrLETa6hbDH8LHBryLwGqtrEocAjyG69vmXmvQgI44mSJSQeCwH+NAGn/ZjsAn2i346MCcn6VdtreW2kBknjUdwx4asuK4t7eBRcByOxUdKibW4VBQ+YU/hV1B/WgDqbV4F3Syy24H+4f0q9LqlukAMd03T7qxgVw8OpxLMNq4zzzgj9an1DU43QB0AB7xoKAOjbU2O5ijPn+//wDWqu91NLIC7Owz2OCPzrnrXWms4XSOQtz37VYj1wmTzWtI5cjAJYA0AXpJppHMdvG+/wBAOaoR2N5PcNlPKVOrP/XNRTayzn92n2c/7B5qrPqks7KGkdV6E5oA0CUtsrKIJQ/3SOn6VnsGY4j+c5/AU22MSuWMmWPcE8Vaj2wvuVD8w/iOc0AOm06WNFdcyHqRnpU0GnMwV1AZzxtPFRQSnflWXdnoo4Fb2h25llzI4Azle9AE2i+EJNRlHmEIvQgH+td9Y/CfwisaPq10qyHlhv5/OuUkvPschU3kSL3U8fpVK916NlKKS5HO49KAPSofBvwzs5DG8kzsBxhzg/lV200z4Xxlo0tkkb+66kmvGbfW4w4ZNkmeoLYFXx4qjgAW3toI2I58vOTQB6ZcaT8KgzO+nEleuFNMtNC+Gl8GFiq2xH8LELmvIbzxEWf95AFz6Lk1kXF3bTHdKMEcjBIP5UAet+IPAEMiGXQvskkY53CUE4/CvKtU8M6lBdyG5tAiLn5hzn8ajsdWmsSW06+uEbrtOa6m08c+IfswSXy7qLHIlGSaAOBkivEO14iEHfrmnRSXCExovGeQCRXoY8UaTdKIr/S1t3bhjGOv5GlbStFv42/s+SKI/wC8c/qaAOHtbeYT527Sf4lJ4rcspVtc+ZMXY9sEjNLc6CLWTaLkMD1KkGqDwLbyYaN5Mf3W6/hQBcuIHnhknPllCDglq8+0HA8MeA88j/hJ7zI/4Bp9d8t9Z+W6XHnxHacANkV5/ov/ACKvgX/sZr3r/wBc9PoA+iFnDOQibDggfNVPzLqCUZErHP8AE38qbAeCFfOOfu/1on3t5e9cHP3QKAL8N7JO+y4keONeytyf0q3cXDeUot7h1i75JrGLQuTEh8qQ9mB5/GkeCRfkExZeoAPT8KANV72dyE++oHDYz+lXbG4aRkWXzAnfsKx4mXAR7eV1AxndtNTK1lFgRhkbv1bH1oA2muIkLLA3mydQHXNWrezuZIhJAVkL9VeYjbXMySxvITJOQcZDjj86uWkVsieYLuR3I/gkBzQBJqU32EtCzxu5PQAsR+tc9dmMh2nYlyewIxVvUdRVOYZHZRxkrgj8awptUZi3yq4P8THmgDQtPJhfcXxn0PP61ej+zSOUZ5Fc8gkAYrk/tblzuK47c5BNTLdGRMhAsq+jdf1oA6ZIInlIeWRsHrnb/OpZAjORFIfl654GPrWXYXSLGPOSMlh1JNWmuUiTCzW4X+6hY/zoAsFN4JSKQR4+ZvWljnSNw0gn46YGKyri+k3YEhKf3VOKpfaLgZ2s3rjdzQBsvdKk0jKJAp9s1Tk1Hy953Kw7bhz9Kz5p2ZGUO447kjH4VNbRzrb71ginTGS2cUAILuV8bScE/dPFRSSSLc7pTGxHoScZqvcGVCWI2Z5C9MfSqovGBIdA69j60AXpJJXcL5jAA9xxj2pTPFG2FOT33Csua+uV+YSSRr2HGPwqsl7LK7BpyQO7Dn86AN5LoqTtZcHjbj+tMZnlB4BwOiqP8msaG/iRTH0OOrKDzTGvQsnCkepJwKALrGOeUCUE49Plz7VHfagluu2KGNTjqSCazvPjMhO75T0XPGaoXbBmLALx6UAcl8RZmntI3fZnzh93/dauCrtPHD7rGPj/AJbDnt0auLoA6TwIjSavMFkVMQMSScfxLXoEELBSwuUQH15zXnXgz/kKSnuITj65Wu5ER2buE9QeQaALk0Y8s77tBj+EJwfxqgJxGxXfEc9NvJqvIzlcjYF7kDmolcKxZBk+woA0klt8ZeViRzjZmlb7O6sYfNBPPOMVRW8JXny1Prjqae0+5f3kqh/SgCwjRrEy7CPQk5yajZ8rltm/tkjimozTLtxGQnfpUcg3HkYX2Gc0ASb8jdgbu/y0ojY4bIB9jmq7xjaSrDr0NXdLUM4S4I3HoM5zQBasJSoKRxmQ9Dmtays3I/es8QPOzaTTlhe3iQqroM9sCrkt35caC4cCQDIIzQB0Gg22nRR+bcW8bhedzDaaxvFniGzMwGn26Fl64JBrG1TXXki8qNwgI7mubadY5C0nzsfSgDXub1rmEyNGqyjkDGarxXMzAK5jOeegqiJwVyMZ6jJ6VIlxPj7isB124oAurIPMMbPkf3dowfxqy8pVcqoX/gfFQ2n2nUNQ0+ys0g+03dzDaxeY+1N8kioCxAJABbJwDXfv8KPEz6Z/aB1jwYNO3+V9pGqyCLfv8vbu8jbnf8uP73HWgDziWdnk+ZUYkdm/pVTG3f5vy45HOc1NqkU9jqN/YXLRx3lndTWkpibcpeORkJUkAkErkZArMkZYzl23N3GOaAJheEbl3YXtgVbt74qu5hgD+6x5rFb5Rl2+VugA5pEdCRuZ8CgDqoriCYbi2Wx91geKVyqsCibV6Z34rBtr0QrtDErnoARWqkvngKrIRjoWOaAFkkmiDYYg9jvOKkg1Jlj2SAyE1citoXh2PG7u3Qbsis25ttj7ZEkXHTHIoAV72QwuE44I5Nc/phx4P8EnGceJL3/0Xp9bF01iIyGlYEA5AArG01tng3wSx4x4kvj/AOQ9PoA9uiunSMDEik9Btyfzq1FI3mAzSyDPYHkViyX8ZTEQAlP8R/8ArURySyMBK4ORjBagDoGiS4lxHOCT1Zl5FOjtvJlBnjaZB/HyMflWeks0MQVHBHqBz+dQC8d2KSyyL9TgGgDop5bULmOMBAOgPX86xrq/8z5TGMA/Lz1rOnv5Im+aVNgHTHWqwmEmXiYoM5I6igDSIRldY2HPTceM1WhlntztE3Q8Z6D8agD7nAUrg8HnFTvCsm1Bcx7h/wA9On6UATT3lxHF+/miZG42qNxFZYeMSkRNnPTnNSSGC1lwHhmz1KZGPzqhcTI0m0R5B6MKALDTpHJjcC+OccVZt443bduUjrjqRWLGHXe4ZSM4IPWrUFw0RZtny4xx3oA1o7hkyVZwmeARiklkkn4j3IB3duSf6VWF/G8W0xBWPIJ4qKS6EiZCn5eCVoAmW5lhlZg2MdcHg/WiOZpgcksT3xWeLpRG6xoXPqaclw+xk8xY/QbP60AaIuLmBvkAx7KKkF7O6nYzLkfwtx+lZ8qgQAT3Ubrjgof8akiuYIoUWaaRl7lWwDQAv2tUcicM7d9xzWfezRtIGRJAM+taQvtMUPi0eY9nZziqkxtrn5URUU9Spxj8aAKMsu9QRIM55B5pA7AhQYth5zU7adKzYiAKjv1zTLrSLxo/lOD654xQBAbiIjYu1m9cVWZWYjfJtA+tT3Omz28KmPa8n+znJrNdJ4xiVGQnrnNAEtw2G4DYHUkHFV2uxCjAAIBzuzimsXIIDO0foTxWbMwj+/0PQLzQBleNLsz6bEmcjzgRz/stXGV0viZg1om0EDzB169DXNUAbnhCVYtTkZ13DyiP1Fdb50M7D5JEYdy3Fcd4XUtqEgC7v3R7+4rq0YkABS2OxoAmk27cLMxHpuqMFRLtjYqzDvTktw5JIP8A30KmRLZV+8zyegoAqyYKldx4PPpTWjKhQCrDrnPNWt9qoPmhi3cLTWMDjcgCp0xtoAhEjgfK6qPTaKSWUoA27kdxSrCDICeAegA60+Ro42CBMkdvWgCxb3SmNm27mI9cfpVyDbtBWM8epwarwbSu8QED3xSNNGr43Y9wMUAaA1SS33Dcrt/tnOKo3t+0mJA53dwFqhf3TDAAUr/exis2SVmzhmJNAGlNciQhmOD0zxUb7Bhmfc3YLWesm44OcjvUqSlBhfm9zzQBalk+XLLhT6HmpUdxGDs+X+8Kr+evAZVwe5FWVxKo2MMDtmgDb8Dy7/HPhZTkn+2rA5z/ANPMdexeRrn/AAorzf7R03+xf7b/AOPX7A/2j/kMY/13nbfvc/6vpx1+avDLaWayura6sbryLq2mjuImUKSkiOHU/MCDhlHBBFdsPi18SCuR4nuG/wB2ytD/AO0aAOW8dyMPHfipUJ41m/6D/p5krmxIWDF1YkdAOlbN8bu7kuby93zXN1PJcTyyKFLyOxdjhQAMljwABWJO5X5QdntQA2aRcD5gP6UgkaPBRjj65qFgw+ZmjBqCSUg4DZ+lAF7zSFzuJGc5NaNrMDEcZHrtbNc55nzAgtk+tWLdyjZDFT7DNAHa6PeeU+FfHueK6G3mtp3Amm3vjjIrzcXO0bt3Hc4q5ZXymRW34I55oA6PVvDzTvI8Dx4wTnOa5Gz/AORI8G/9jFf/APorT67ay1uM2rxMpb5T0yBXEWxx4F8Hn08Q3/8A6K0+gD1K32wsHBT/AGgSDV171AvybsE+n8q5hpNwBVk46/NmrEd1GCqDIfuB0oA6Br/aAkce0+rDNV5rpiuJrgS56qFxtFZkl75URG3p781B9tjkiLL/AKzsoOKALk8sXBB29gTk/pUAUO2d5+bn5TgGqLys64l6e1SwXG5GAZWKjjcKAJZvMz5aMFHqDVaWIR/O0j59aiu9uNxRcH72G/pT4UiaJTI2V6YxkigBolYYKuSB0GcU2S5ZiM7d/fnmllWJXGwsYx1wuKhu7iDaAsZYdmxigCxHLgZwpz2BNWoymVbcEOeAGzn61hLOxBUcE984qU3BUIrOcHjcCCKAOjmkj43bJABxhagdlUr5W1RjoTWQ00apxK2M84PNRi4QSfMzlPzoA2ZJG3cbRx0AJ5oid2y+wbjxzxWUJ4t+1cjPc8VI0kcmVZ3znpng0AXWkkLgSIPZcU0TEIcRuSD0OQKrqu3LeYQwHQjmmLc+Y5KyEYGCelAFhbnJbegA7Ak8VXxtZi0bqTyMHioy8fPmOzN6hePzqJeRgnPPAzigDVhubwY8qQ7B2Y8Vcjubk4EhiAI5w2ayII36SFgD3DVp/wBn2IgDfa5VfuAwH9aAEuL6O3gO5n354KkmsifUZJM4ABI/j4pbqNYy7LO8kfqeaypmjDfMQQep60AOuLnKZZI1J75zWZLMAGIiMhPQjtVm5fA+VyFxwNnWsyeWLllJV/pQBmeIWkezjMmQN/Q9uDXP1sazIXgXLEjeOv0NY9AG14TIGpvnvERn05Fd9FYxyKuy4iBzzivPvDQJv3ABJ8o9PqK6hC+0q/3R7daAN6fSoYsN9rRgeuccfhVKW2jjk3LhhjrnFV4rhlUKYwUH0OfxrQhNvIBuRsdQM4AoAqkoE4iyfpVNnjMvO0Y/hArWnW2lO1ncegDAis51iiYpscj6UANZf3wKBmQduDTZ3iaRTzn19KlZGABX5VI4UHms+ZirkYOR1GKANFZAkeUZsdjk5qrLMrRsuwM3rkmqruFA+XPc9qiaWUINo49MUASTSgqoJyw/hNRB8Dlc/jUZkBBDqQfUGo3ZlHD5WgCYLhtxABNKRv2+ZtUA/nUMLtv3YXp2FAdhJk7jQBbjVEAO0ufbjFXI7tFTbtwf9k1mqWd8vJgehFSAgZ+6cUAa1vcRF/kiO8/89Of5VeadxHlVSM+2awElCLyDz3Bq5BOhXhhn6kUAS3s0sqgGQkdwM1izsFBLs+ffpWlPICOHjb6msqdUyTuDH2FAEJkB+8foO1NB3uAxyv0prEEnJ7d6jG5RnBx2NADpAofhhzUiMR0PTv61ER0JANKuSx2gcevegCwsi9Cpb2p6P/CI/wAx0qFWbplQR71JGSGGSBzzQBfgcxoSjgcYJzS2/HgTweew8Q3/AP6K0+qkvlhCTIM+maspx8P/AAlj/oP6h0/65WFAHYuY+QzYB7GohI8ZBDAL245qm9y2NhC/Ujn9afDIj/dZyR64xQBbyd+7cCe+TmgSB2HmKiAflVZ5COYwQf8Ae605i7J8jocdQpoAn8xtpYMF56AVHvxIzAlhnkk4quzRk/MVHsc0GVNwCx49getAFppI8r8jpn8f1p0csqx5RWAPcd6qO20jd8vp603Pm9GHp6GgCzNMzLwZPTrxVJsgFeHz25pkhCttUuB74pryShiQy7ccHvQBLtOF3beOMGgkAAhRjuME4qOJ2ZOTu/GpHlwgVSUPcHoaAJQw3KQwK+hq0H2AsrKCeoxVKGaJVPmjcR6AD8qZPdIzBlY4HADccUAXEDc58pvqKU7NyhEw49BxVATBXJMhYdh0Ap/2iUjG9B6YNAF66wACySA4+8BiqZlC/wAXzDpyOaileXZl2wPT/wCvTFcAbmUY7DJoAfJJ5joHkBPcY6VI7KkgYS4XHbv+FUTMEYs0K5/Gmu27GFIB5x6UAaTXNwpD2uXB7MKlh1KdP9ZGob0xxWYkrbSMkAepzSNIrr8vX2IoAtXGtSjdiJAPQrVE6gXyzRKOePl4qF45G+feMDsTURGVO5gzHoM9KAEuLnkkAE+4PNUnlLA4AX1qWQMFKsP/AK1VpUOCWbPtjvQBm6nxCMkH5v8AGsytLU5N0Kr6NWbQBt+E1ZtTdVOCYj3x3FdXJbTBstkxgdsVx3hybyL9mAU/uyOfqK6OS93ldyKO+QaALfnBMcK4HYcVei1FFwdq/QoDWO1zGVH7o5HpSLMhbco2j0zQB1iX8cqcCKLj/nkBVORl3Z3W7Z7kYrF3xuMBSG7EGk850AV/Lx6kdKAL88gJIMiDHYLWdLKrgjJBHoOarzSb2PPzeoFQ7CQcjK/XFAFh7oAbWU+3HFQSyK7Dbj6HFN8xUH+rx6Zqs7r15z6daAJJjk5Axiosg5yTn0phY7D8w57EVAHKE8gE+1AFhDg5Hyn2oeUq+M8HrgVXBKjIx9RUikHhj+IoAsRlWPc1Pg8ER9KoqvzcMfripATkbtzZ44oAvrI78OmR2xTzMI/uo4J9cVn5CnHIJpyMRny2OcdxQBNcTFxjP4ZFVGbngjPtSSSMAVYfNVdmxyVzQA8sp3Z+97U0t8oGKjcs3J4pqkg/KcGgCx97GMA+9GSSckZqsWZTjIP404yYBxu59aALSsAp3AfgaBKBgKPyqpuB74pyuF4Ix70ATO+VPc1tA4+HvhP/ALD+of8AoqwrniSSW4zjpXQH/knfhXBx/wAT7UOf+2NhQBtALIxGRnuSalsT5bsdw3D1PFUR5qt6D+9mlZyM4YM3qTQBpNIJEO+Tk9uKbHNiMoNpHTnA/WswzlflZEJ/vd6lWdSAU7dc96ALMMwg3BVVifQ5pqzuXJkUZP6VUEzHIRWJPPyjBH409JCrEypI+euTjmgCw8okGIwd4/izwKQb1X5SjN3wKjjuDgsFAz9KAwYsdj59FoAfNcNIoTPTqcVFgBlCtuGOc1AC5ZmHKjoKdD907nOTz2oAs+Wcbhhj9elLDDOWBIznoMg022QyNt3EL/ukmtOMW8QAY5x6rzQBU/s2aVThSp9+BTxo8yDohPsc1c+2IOFOB27UqXhEgHGf96gDLa1mjcCRMZNMkSSPgcZ7DtXSRWz3ONkiKffBNSnRJypImjLepAoA5WNZ9o3njPGTmmF8EgtlwfTIFa9xoN6MhTG/OeWxVF9MuYj88IPuDkUAVnwQGkiWT3ApP3ZAMS5PcYNWDAqDLfePGBRJCFHzI4HtQBXyjDHlknvhcVE5jBIEbqPxrUg1H7PHiGPcPTbSS6m0yEG359xQBiOGXO07QfU1G3mBf9cp/GrF1LLgFkbbnrgYrOknbJBYEZ/CgCXzmxguCB221WnlcHKgEVHHL8xUMfwHWo5yOuSuT0xxQBT1TBt1P8W7n8jWXV+/A8oYz97/ABqhQBf0fb9qbeONh/mK2BPxy4x6EZrD04AznJwNvritMYQ4Ubs0ASmUZBUFR0OWpyyIu7lgfY1AVwCxAz6UxSMnGB+tAFvzg3I3kgdQaMgodzvn0NVQxU47e1SNgrlDk/WgCaG42ZVSD+FL55YYKjP0qkrOOQcU9ZSDkN+ZNAE7s0i/JF061E7SBclVFReY27dnJpJJS+AzDigBpLFS3H4Gk5J6Z+tI2AOAOe9NI+ufrQBJtBNKoA6Z/CoT6LknuacjY7n6UAShgxwWI+vFSZGQFYk+1Vwdx6DFSBsc4/KgCYhgfmJA9c1IihuQ34k1CpznaWz+FOVSPmJfHTigBXhJJO0n1wcVAUXOOh9+aseZEOd0h9iKgkmyTtAA+lAEMg2tx1pm7nK5pZHLHmoyfTpQAE55IyaXj2poYj0ppJJ5oAlyCMnP0oBGPemgrt6EGgYA5XNADjhRnOSa6KQkfDnwsQcY13Uf/RNhXNNg8AYHua6Sb/km/hf/ALDuo/8AomwoA0FlLKS5BIHQmosDll6nqCarHJ5KhfoKmjmWOM5AkPuaAJCRwCuc9DjrUqqVXauAPaqwZpMbQFH92gcMVwzN7dqALKP82fMyMY5FDbjnawHHIzmq6b8lWTJ7c4qXZtwTkDvkigCNRIMkKCAe4xT8sQNuM57GldZJeFYkj+HNMJMS4KHNAD13k/Kyqe/y5pzyBSG/iH4CoGmJySXH6UhdcZyMe9AFxdTdeAcY96c9w0qBid2fes4yxgjkMPejzVY5ztx2FAFh5Mj5Yvqc1PBMY1yNwPp1qg77gQWPsaSOd1G3b8n60AbEd6ygb3ZMe9XF1ZIzjMjn3XFc6JVLY25/HpT45UyMBtw7lqAOgOszk/uxtHrionurlxnccH0NZX2oKMnJ57mrkV5GQMuAPfNADJpG7uD6+ufrTDM2NxLs3ucVNJ5MhyrDJ7YNVpUUZLKT/wAC4oAaZ2OSwXn0quXYk/LtGeucU8FD0XaPcUwpHkneuT79KAIJSTkMCfqSaqGNFHzkfnVuWEBSQ/XvVF8q2NqtQBERjkDjsT3pG9OCae/I4AFRuQTk7icUAVdUUiJSTnn+lZlaGobfJHOW3f0NZ9AFiz/1p+lXARjhjn61Rtf9YfpVvhSME5oAm5x1wfWm7jnJP40nGOVz6kU3cB2xnvQBOMEHkn8KbnpnI+lRpx05980KCD1H4igBzZwOf1oTaD9459zSEjO3dk+wpjPuPqKAJMgDIcE+lG8E/N17elRqVHX+dMJ9F49aAHhgBjB69qTjnGaavr/Wgknrk0AODbTxn35p6sOoJz71GppwxjGTQA8cnOFx9akXAG5gCD0wagB25GRSq+ODg0ASq2c4A4qZJFBGVP0qmR3HNLuBGMkE+9AFx2DKT5Rz65qo5OcgcfnQXbGARj61GzkehzQAMT1Pemk56ikz2puSDx1oAdnIwcUcdqQE49KTNAC98UuSOv603dk0Dk0AOByCRgfjXST/APJNvDGP+g5qP/omwrma6afH/CtfDGen9uaj/wCibCgCISZJAJzTvmPGKIgp+VEOfXPFSgKBk/mvNADVZggBLHHvxTw7MuGP5Gk28nHT3FORVOPnGfcUAKZCzcblHT5eaer5U7m6eoFMYDdhe/qaVl2AeYQffINAEoKBQBIoJ/E00SZJBmAA+tR+dFjAk69sCmPIeiOD2wcGgCXJxnzQy/XNNeY4+XavuRVQ3DI21kXmkMucggfhQBOzg/e+8PTnNanhHRrvxL4gtNF06S0gubrzCst5IY4kCRvIxZgrEDah7VgAtsB3YHuK7X4O/wDJQtN6Y+zX/f8A6cbigDsB8BPE/wBnsbga74PMN+VW0l/tGXbcFlLKIz5OHJUEjGcgE149HKZIlZh99Q3rjIr6t0yDXE8J/BaTUNR02fTWvNP8iCCweKZP9Bl27pDMwbC5Bwi5PPHSvku0wbaHJJ+QcfhQBYjZUAxz79KVnyOCoFRN6gfhikw2ORg9+lAFlGQkbzj8ae7hcbHJHsc1TDNH0wfYipA5Iyep7CgDQgcZHVs9iamaMsPljIz6Gs2KQbvTHYitCKUp0GR6AigB3lqFwYn/ADpjxwkYAdT/ALXNWjcnZzFn0xVNpsvl0IHuKAEFuio291x6YyarFGwew9RUstxGuSqk+2MVTmuiVOIyPxoAjkGCeTx6VDJuAyD+Zppbcc4Y57VGeG4XNAFa/YmFeAPmrPrQv8/Z1+UKN3r7Gs+gCW3GZD9Ktq2BjGT6mqcH3z9Ksgn1/GgCQuWXqfypoPOSfxpA2OozS5zkcUALuJOB0+lK3DAbs0wkgdsU3nAz1oAkb5T0ApMjPT8KaScdaQZB4PNADi2Tzj8qM8+lNOehzzQOPWgBSeQeaQ+gpCeaByaAF9wDml3EcikycUdD7UAPPzEdaUsVBAxTd3y45PtQXBGMDHpQAfXgUA8+po3HAHFNPU5NADiO+aToaTJA5NIx/OgBfbt1pvfPajNBoADgdM0nfigUZwKABj7UdOnWkzRQApOR14rprn/kmnhnnH/E81L/ANE2Fcxjj0rpro4+GXho/wDUb1L/ANE2FAFdy2NmWK/SnorqPkP4VBFKQQGzz3zQzjcSD+tAE5dgcEsTTossD+8O7sDxUMLsR1/lUhZOhXJ9cigCwMoMlN2ajYMW5UL6VC8pOOWH06Ujv0wM++KAJGf5cEfiVqvnkEnntzTpHZj8wbHpTAX/AIQ344oAUbyOcFT7801i2duM/jTfNcHqR7U1nJxkDj1oAlOVAD8D860PDmu6h4e1u21bRLv7HqNqWMMwRH27kZG+V1KnKsRyO9ZBYnscetODjPTp3FAHpp+OPxK7eKm/8ALX/wCNV5qqhI0VHXAGOe9Rb1PAUk+5phfJ4A+lAFrLEY4GeM4po4U7fvDvmotx2ckEenpRuH92gCUOwwTk/wBafG7H5tw+mOlQB8dFBzSrJlj8g5oAsbh69fapo3VehANUC/zYIpwYHjAHvmgDSFy/TcSPrS/awp+YZ9c81mFiueSVPoelMzjJJ5+vNAGsb2AqFZVA+lUbiSNshOAPeq6k9lDD1xUTdyc8UAPJVhn7vPQmmNIq8A5pjMSvPegqNvJIoAgu23Rj1z1qpVm5+4OvWq1AEkH3j9KsMap0UAXAQT7UE9xVOigC4CTxR0ODVOigC5wOuPrSH6fSqlFAFsnNHriqlFAFo9aAeMGqtFAFrODS5zVSigC3nB9qX1xVOigC4Cc9qOc8LnFU6KALhz1I/CkJ9qqUUAWiKTvVaigCzSdqr0UAWKOnNV6KALJPWulu/wDkmPhr/sN6l/6JsK5GnFmKBSx2gkgZ4BPX+Q/KgDZB2n5c4HtUm84BVcD36VgUUAdAHJXAx1p3mYG1my3audooA32k6nIB9KUSg87hn2Fc/RQBvSSknIINR7+pYc+nSsWigDX3c5BUfQU5pCRyePTpWNRQBrrk9OlBPtn1OayKKANUOCeM+lDYHOP1rKooA1A4HXOadnIJJIrJooA11IAwSAPp1od1I6nj8KyKKANbcAccEfWjfkdayaKANfzCAOAaUsG5OQPzrHooA2wyhThmpjbWGCST9ax6KANI/LyF46c0HcBwRWbRQBauidgye9VaKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are axial images through the triceps (left) and deltoid (right) showing the humerus (H) in both images. Note that both muscles are atrophic and have increased echogenicity (more so in the deltoid) that reduces the distinction of the bone edge. These images are from a 72 year old man with limb girdle dystrophy and prominent proximal weakness (MRC grade 3 of 5) in these muscles. Note the similarities of the changes to those seen in old polio, a pure neurogenic disorder. (See text for link to the figure \"Ultrasound of the tibialis anterior after polio\").",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25841=[""].join("\n");
var outline_f25_15_25841=null;
var title_f25_15_25842="Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope";
var content_f25_15_25842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25842/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25842/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25842/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/15/25842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 76-year-old man with a 27-year history of type 2 diabetes is referred to you because of orthostatic hypotension and recurrent syncope. For the last six months the patient has had increasingly frequent episodes of lightheadedness, usually related to rising from a lying or a sitting position; instability on his feet; and profound weakness occurring at various times of day and night. In the last three months he has fallen one to two times a week on standing up. On at least four occasions he lost consciousness. On one occasion, he struck his head on a toilet seat, with a laceration that required multiple sutures.",
"   </p>",
"   <p>",
"    He has been in the emergency department of his community hospital five times and admitted to the hospital twice. On each occasion the blood glucose level (obtained by the patient's wife, the emergency medical technician, or the emergency department laboratory) was over 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Each time an acute myocardial infarction was ruled out and the patient was treated with volume repletion although neither volume depletion nor a cause of volume loss was specifically identified.",
"   </p>",
"   <p>",
"    During the second admission a diagnosis of adrenocortical insufficiency was considered. A cosyntropin stimulation test was performed and the patient was discharged on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    5 mg every morning. This did not alleviate his symptoms. The plasma cortisol level one hour after cosyntropin 250 micrograms IV was subsequently reported as normal at 24",
"    <span class=\"nowrap\">",
"     micrograms/dL",
"    </span>",
"    (662",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    The glucocorticoid was stopped after several weeks. The patient has been confined to home by his symptoms, and his wife and son are concerned that he will suffer serious injury in a fall.",
"   </p>",
"   <p>",
"    The patient has had type 2 diabetes for 27 years. His metabolic control had never been optimal, with A1C values in the 8 to 9 percent range. He has refused to take insulin. His most recent A1C is 8.2 percent. In recent years he has developed background diabetic retinopathy, distal sensory neuropathy, microalbuminuria, and hypertension.",
"   </p>",
"   <p>",
"    The patient's medications are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    1000 mg twice a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    10 mg before breakfast and supper,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    10 mg every morning,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    25 mg every morning,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg every evening,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    81 mg a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    (Uroxatral) 10 mg every morning, a multivitamin, and calcium 600 mg with vitamin D 400 international units twice a day.",
"   </p>",
"   <p>",
"    The patient comes to your office in a wheel chair accompanied by his wife and son. On physical examination, the blood pressure is",
"    <span class=\"nowrap\">",
"     150/80",
"    </span>",
"    mmHg right arm supine and",
"    <span class=\"nowrap\">",
"     105/69",
"    </span>",
"    mmHg right arm upright with the patient complaining of lightheadedness after standing up. The values are similar in the left arm. Pupils are equal, round, and reactive to light and accommodation. The heart rate is 88 regular supine and does not rise with standing. The chest and heart exams are within normal limits. He has evidence of distal sensory neuropathy.",
"   </p>",
"   <p>",
"    Review of the outside medical records brought by the patient reveals that the most recent values, obtained three weeks earlier, are as follows: BUN 29",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    creatinine 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (114.9",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    potassium 3.9",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    A1C 8.5 percent, urine",
"    <span class=\"nowrap\">",
"     microalbumin/creatinine",
"    </span>",
"    ratio 329",
"    <span class=\"nowrap\">",
"     micrograms/mg",
"    </span>",
"    (reference &lt;30).",
"   </p>",
"   <p>",
"    You advise the patient to arise slowly from supine or seated positions, especially on arising in the morning, to have a night light in the bedroom, and to raise the head of the bed by 20 degrees. You request visits from the Visiting Nurse Association to monitor blood pressure readings at home lying and standing. You also order home physical therapy to assess safety in the home and to improve the patient's ability to perform activities of daily living. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=see_link\">",
"     \"Treatment of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    What else do you recommend for treatment of the patient's symptomatic orthostatic hypotension?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a1?source=see_link\">",
"       \"Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       Fludrocortisone",
"      </a>",
"      0.1 mg daily and high salt intake. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a2?source=see_link\">",
"       \"Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       Midodrine",
"      </a>",
"      10 mg by mouth three times daily. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a3?source=see_link\">",
"       \"Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      0.1 mg by mouth daily. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a4?source=see_link\">",
"       \"Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A4\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4261 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25842=[""].join("\n");
var outline_f25_15_25842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a1?source=related_link\">",
"      Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a2?source=related_link\">",
"      Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a3?source=related_link\">",
"      Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?25/15/25842-a4?source=related_link\">",
"      Interactive diabetes case 20: A 76-year-old man with long-standing type 2 diabetes, orthostatic hypotension, and recurrent syncope-A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=related_link\">",
"      Treatment of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25843="Passive wrist flexion";
var content_f25_15_25843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Passive wrist flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain with passive terminal wrist flexion with the elbow in full extension occurs with lateral epicondylitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25843=[""].join("\n");
var outline_f25_15_25843=null;
var title_f25_15_25844="Biventricular pacing";
var content_f25_15_25844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biventricular pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 152px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Jordan Prutkin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25844=[""].join("\n");
var outline_f25_15_25844=null;
var title_f25_15_25845="Nevirapine: Patient drug information";
var content_f25_15_25845=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nevirapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     see \"Nevirapine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/46/9961?source=see_link\">",
"     see \"Nevirapine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viramune&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg; XR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auro-Nevirapine;",
"     </li>",
"     <li>",
"      Mylan-Nevirapine;",
"     </li>",
"     <li>",
"      Teva-Nevirapine;",
"     </li>",
"     <li>",
"      Viramune&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700492",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad liver and skin problems have been reported. Your doctor will watch you closely during the first 18 weeks of therapy. During the first 14 days, a lower dose of the drug is used for less skin rashes. If you have a bad skin reaction, an allergy, or any signs of hepatitis, NEVER take nevirapine again.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691301",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during labor in women who have HIV but have not been treated.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nevirapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had hepatitis or liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given. If liquid (suspension) is poured in a cup, rinse the cup with water and drink to get all of the drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 7 days of this drug, call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10905 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25845=[""].join("\n");
var outline_f25_15_25845=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027890\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027892\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027891\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027896\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027897\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027899\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027894\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027895\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027900\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027901\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=related_link\">",
"      Nevirapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/46/9961?source=related_link\">",
"      Nevirapine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25846="Assess LV wall motion 3";
var content_f25_15_25846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Objective detection of wall motion abnormalities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of regional wall motion time curves and regional shortening fraction (RSF) in 6 apical segments, obtained in a normal subject (left) and a patient with coronary artery disease (CAD, right) and hypokinesis in the lateral wall (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Corsi C, Lang RM, Veronesi F, et al. Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images. Circulation 2005; 112:1161. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25846=[""].join("\n");
var outline_f25_15_25846=null;
var title_f25_15_25847="Epithelial ovarian cancer: Second look surgery";
var content_f25_15_25847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epithelial ovarian cancer: Second look surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25847/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Eva Chalas, MD, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Fidel A Valea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25847/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/15/25847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strictly defined, the term \"second look\" laparotomy should be reserved for surgical reexploration of asymptomatic women diagnosed with epithelial ovarian cancer (EOC) who have no clinical evidence of tumor following initial surgery and completion of a planned course of systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the term has sometimes been used to describe a second",
"    <span class=\"nowrap\">",
"     laparotomy/laparoscopy",
"    </span>",
"    for cytoreduction of known",
"    <span class=\"nowrap\">",
"     recurrent/residual",
"    </span>",
"    disease to improve the response to subsequent chemotherapy or to relieve symptomatic disease. In this context, the term \"secondary cytoreduction\" is also acceptable.",
"   </p>",
"   <p>",
"    The role of second look surgery in the management of women with EOC will be discussed here. Primary surgical management and the use of systemic chemotherapy for this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of second look surgery in EOC also generally holds true for patients with cancer of the fallopian tube, peritoneal carcinoma, and rare patients with intraperitoneal spread of endometrial cancer who appear to have had a complete response to chemotherapy. Obviously clinical experience with these latter groups of patients is quite limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second look procedures were initially introduced to establish an end point for the number of chemotherapy cycles administered to women with an apparent clinical complete response. Initial concerns about the leukemogenic potential of prolonged chemotherapy (notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ) provided an impetus to limit the duration of treatment. The need for a second look procedure was based on the fact that EOC is usually confined to the peritoneal cavity for much of its natural history, and imaging modalities (eg, computed tomography, magnetic resonance imaging) are unreliable for assessing small volume disease. Measurement of the serum concentration of the tumor marker CA 125 also lacks sensitivity for small volume residual disease. In one report, the negative predictive value of a normal serum CA 125 concentration following systemic chemotherapy was only 54 percent; by comparison, residual disease was present in all patients with an elevated value prior to second look surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for ovarian cancer\", section on 'CA 125'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial enthusiasm for second look procedures has been tempered and its purported value has been questioned because performance of this procedure has not been associated with a clear survival advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate candidates for second look procedures are women with advanced EOC in investigational protocols who appear to be clinically and radiographically free of disease and who have a normal serum CA 125 concentration following chemotherapy treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with clinical or radiologic evidence of residual disease after first-line chemotherapy are generally",
"    <strong>",
"     NOT",
"    </strong>",
"    candidates for second look procedures, but should be considered for salvage chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second look procedures are generally not recommended for women at low risk of recurrence (eg, FIGO stage I or II disease) (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/4\">",
"     4",
"    </a>",
"    ]. We also do not recommend second look procedures in women who have received dose-intense intraperitoneal chemotherapy as first line treatment of EOC, given the significant improvement in survival with this therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the second look procedure is to thoroughly explore the abdomen and pelvis for evidence of recurrent disease. During the procedure, adhesions are lysed and removed, suspicious as well as grossly uninvolved areas are biopsied, and cytoreductive surgery performed, if possible, to minimize the volume of residual disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laparoscopy versus laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experienced gynecologic oncologists may be able to accomplish this procedure laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/5\">",
"     5",
"    </a>",
"    ]. The laparoscopic approach diminishes blood loss, length of hospitalization, and cost. Furthermore, if clearly unresectable residual disease is documented, unnecessary laparotomy may be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive adhesions are the most common reason for inability to perform a second look laparoscopy; in one series, adhesions hindered laparoscopic exploration in 12 of 20 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, some authors recommend that a negative laparoscopy be followed by exploratory laparotomy, because of a high false-negative rate (ranging from 19 to 77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. Thus, most gynecologic oncologists recommend laparotomy, if a second look procedure is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of second look laparotomy requires a complete systematic examination of the peritoneal cavity and retroperitoneum. Residual aortic and pelvic lymph nodes, infundibulopelvic vessels, appendix, and gynecologic organs (eg, uterus, fallopian tubes, and ovary, if present) should be extirpated. Pelvic washings from several areas of the abdomen and random biopsies (eg, pelvis, paracolic gutters, hemidiaphragms, bladder, vaginal apex, posterior cul-de-sac, mesentery, and bowel serosa) are taken if there is no gross tumor. Although the pelvic peritoneum and undersurface of the diaphragm are the most likely sites of persistent disease, the abdominal peritoneum and mesentery of the small and large bowel should also be sampled. Although tedious, it is necessary to attempt to run the entire small and large bowel, and to visualize both mesenteric surfaces.",
"   </p>",
"   <p>",
"    The complication rate for second look laparotomy procedures is surprisingly low. The most frequently reported complications are wound infections, urinary tract infection, and adynamic ileus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Findings at surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second look surgery demonstrates residual disease in over 50 percent of women with advanced EOC who have an apparent complete clinical response to chemotherapy. Initial tumor stage and the volume of residual disease left behind following initial debulking surgery are the factors most predictive of the result of second look surgery. In a review of 31 series, negative findings at second look surgery in women with stage I, II, III, and IV disease were noted in 81, 69, 39, and 33 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/12\">",
"     12",
"    </a>",
"    ]. Based upon the volume of residual disease following initial cytoreductive surgery, the frequency of negative second look surgery in a second series was 72, 50, and 23 percent for women who had no gross residual disease, optimally resected, and suboptimally resected disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H25#H25\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Cytoreduction procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of residual disease at second look surgery portends a poorer prognosis than if no residual disease was found. Among women with a negative second look surgery, the five-year survival rate is 69 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/14-18\">",
"     14-18",
"    </a>",
"    ] versus a median survival of 10 to 33 months in women with gross residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1,19-23\">",
"     1,19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, 30 to 50 percent of women with negative second look procedures are destined to recur with continued follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. The median time to recurrence ranges from 14 to 24 months, and the median survival following documentation of recurrent disease ranges from 11 to 45 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1\">",
"     1",
"    </a>",
"    ]. By comparison, 80 percent of women with residual disease detected at second look surgery die within 36 months of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with less than 1 cm residual disease at primary surgery and microscopic disease at second look surgery appear to have a better prognosis than those with suboptimal primary cytoreduction and gross disease at second look surgery. In one series of 262 patients, the median survival in this group was 5.9 years compared to less than 3.4 years for those who had suboptimal primary surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grossly visible disease at second look surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/25\">",
"     25",
"    </a>",
"    ]. No specific approach to chemotherapeutic salvage was identified that led to improved survival in patients with persistent disease.",
"   </p>",
"   <p>",
"    These results suggest that the second look laparotomy provides prognostic information, but they do not prove that women who undergo the procedure and who receive therapeutic intervention based on findings at surgery have better outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Effect on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;A historical argument in favor of routine performance of second look surgery is that it may identify women for whom further debulking or additional chemotherapy may improve survival. However, it appears that these interventions are no more effective in improving survival when applied at the time of positive second look surgery, as opposed to being initiated at the time of clinically obvious recurrence. The following data illustrate the lack of survival benefit in patients who undergo second look surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial sponsored by the Gynecologic Oncology Group (GOG 158) randomly assigned over 800 women with advanced EOC and optimally debulked stage III disease to six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Prior to randomization, women were asked to choose whether they wanted to undergo second look laparotomy or no second look procedure following chemotherapy. Women with a negative second look laparotomy were followed without further treatment, while those found to have residual disease underwent maximal debulking followed by further chemotherapy until disease progression.",
"      <br/>",
"      <br/>",
"      Progression free survival and overall survival were the same for both the second look and nonsecond look surgery groups [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/27\">",
"       27",
"      </a>",
"      ]. Thus, in this nonrandomized trial, early intervention based upon findings at second look surgery did not improve survival.",
"     </li>",
"     <li>",
"      A similar lack of survival benefit for secondary cytoreduction was noted in a second Austrian series in which 179 women with a complete clinical response to induction chemotherapy underwent second look laparotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/28\">",
"       28",
"      </a>",
"      ]. Among women with residual disease at second look, there was no significant survival difference when those debulked to no residual disease were compared to women debulked to &lt;2 cm or &gt;2 cm residual disease (median survival, 23,18, and 16 months, respectively).",
"      <br/>",
"      <br/>",
"      Thus, second look laparotomy provides prognostic information, but women who undergo the procedure and who receive therapeutic intervention based on findings at surgery do not live longer than those who undergo further intervention based upon clinical events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF POSITIVE FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no known treatment capable of prolonging survival in the setting of a positive second-look procedure. However, it appears that there may be an association between prolonged survival and the ability to remove all evidence of gross disease at the time of second-look laparotomy. Whether this association reflects therapeutic benefit, as opposed to selection of patients with more indolent disease, is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/18,29-32\">",
"     18,29-32",
"    </a>",
"    ]. The outcome following second-look surgery is most closely related to the amount of disease remaining after surgery. Gross residual disease may be microscopic or gross. Gross residual disease is termed \"optimal\" if the residual volume is less than 2 cm, but this is essentially an arbitrary number. Many consider optimal disease to be less than 1 cm or, even better, no residual.",
"   </p>",
"   <p>",
"    The bulk of evidence to support this view derives from studies of primary surgery. At least one report evaluated the effect of a radical second operation in 30 women with relapsed EOC after a median recurrence-free interval of 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/33\">",
"     33",
"    </a>",
"    ]. Complete resection and optimal debulking were achieved in 47 and 40 percent of patients, respectively. Women undergoing complete resection had a significantly longer median survival than those with optimal residual disease (29 versus 9 months).",
"   </p>",
"   <p>",
"    Secondary cytoreductive surgery is often followed by second-line or salvage chemotherapy, although there is no evidence from controlled clinical trials that it improves survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/34\">",
"     34",
"    </a>",
"    ]. Similarly, the benefit of whole abdominal or abdominopelvic radiation therapy is unclear, and must be balanced against the potential for bowel toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Issues surrounding the optimal timing of salvage chemotherapy are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NEGATIVE FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no known treatment capable of decreasing risk of relapse after a negative second-look procedure. As noted above, 30 to 50 percent of women with a negative second look laparotomy recur during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. In a representative series of 91 women who were followed for an average of 113 months, the 10 year recurrence-free survival was 52 percent; some of these relapses were late, as 3 of 19 women who were disease-free at five years had a subsequent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/17\">",
"     17",
"    </a>",
"    ]. It is possible that some of these late recurrences actually represented a second peritoneal carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sites of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of women relapse within the peritoneum. In one review, the sites and frequency of recurrent disease were [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdomen &mdash; 49 percent",
"     </li>",
"     <li>",
"      Pelvis &mdash; 33 percent",
"     </li>",
"     <li>",
"      Retroperitoneal lymph nodes &mdash;12 percent",
"     </li>",
"     <li>",
"      Lung &mdash; 8 percent",
"     </li>",
"     <li>",
"      Liver &mdash; 7 percent",
"     </li>",
"     <li>",
"      Extraabdominal nodes &mdash; 5 percent",
"     </li>",
"     <li>",
"      Vagina &mdash; 4 percent",
"     </li>",
"     <li>",
"      Brain &mdash; 4 percent",
"     </li>",
"     <li>",
"      Spleen and bone &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the factors that correlate with an increased risk of recurrence and shorter relapse-free survival are more advanced tumor stage or bulky disease at initial presentation, higher histologic grade of differentiation, residual tumor bulk &gt;2 cm following initial surgery, age &gt;67 years, the use of non-platinum-containing chemotherapy, and duration of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/1,15,20,37\">",
"     1,15,20,37",
"    </a>",
"    ]. Unfortunately, none of these factors has shown utility in selecting patients at the highest risk of recurrence for additional or consolidation chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Consolidation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high risk of disease relapse in women with a negative second look laparotomy, postremission therapy is an attractive idea; however, no data exist to prove its value. Consolidative intraperitoneal chemotherapy has been evaluated in several studies, but prospective controlled trials are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Nonrandomized studies of whole abdominal radiation following a negative second look procedure have failed to show survival benefit, as well; no controlled trials are available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. At this time, there are no data to support consolidation therapy after negative findings at second-look surgery.",
"   </p>",
"   <p>",
"    The use of intraperitoneal chemotherapy as consolidation or maintenance treatment in women undergoing initial chemotherapy for advanced with EOC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO SECOND LOOK SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation of systemic chemotherapy can be considered in women who are clinically without evidence of recurrent disease at the completion of primary (induction) chemotherapy. However, the available data demonstrating the efficacy of this approach are controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H1171802#H1171802\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Maintenance chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, women are followed without treatment until disease relapse is documented by the development of symptoms or radiographic relapse. Secondary surgical cytoreduction, and the issue of timing of chemotherapy treatment in women with relapsed or recurrent EOC is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-look laparotomy is not generally performed outside the setting of a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/45\">",
"     45",
"    </a>",
"    ]. A clear survival benefit for second look laparotomy has not been shown, and even those women with negative second look operations have a 30 to 50 percent chance of future disease recurrence.",
"   </p>",
"   <p>",
"    However, second look laparotomy continues to be the most accurate means of documenting the response to chemotherapy in the setting of protocol treatment. At exploration, over 50 percent of women with advanced disease who achieve a complete clinical response to chemotherapy have microscopic or gross evidence of persistent disease. In the clinical trial setting, appropriate candidates for second look procedures are women with EOC who appear to be clinically and radiographically free of disease and who have a normal serum CA 125 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25847/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who have clinical or radiologic evidence of residual disease are",
"    <strong>",
"     NOT",
"    </strong>",
"    candidates for second look procedures, but should be considered for salvage chemotherapy. The value of a second, or even third, attempt at surgical resection of residual disease prior to instituting salvage chemotherapy is controversial. There are data suggesting a possible benefit, but no consensus of opinion exists.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/1\">",
"      Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep 2001; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/2\">",
"      Potter ME, Moradi M, To AC, et al. Value of serum 125Ca levels: does the result preclude second look? Gynecol Oncol 1989; 33:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/3\">",
"      Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/4\">",
"      Rubin SC, Jones WB, Curtin JP, et al. Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/5\">",
"      Littell RD, Hallonquist H, Matulonis U, et al. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. Gynecol Oncol 2006; 103:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/6\">",
"      Husain A, Chi DS, Prasad M, et al. The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol 2001; 80:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/7\">",
"      Clough KB, Ladonne JM, Nos C, et al. Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study. Gynecol Oncol 1999; 72:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/8\">",
"      Quinn MA, Bishop GJ, Campbell JJ, et al. Laparoscopic follow-up of patients with ovarian carcinoma. Br J Obstet Gynaecol 1980; 87:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/9\">",
"      Xygakis AM, Politis GS, Michalas SP, Kaskarelis DB. Second-look laparoscopy in ovarian cancer. J Reprod Med 1984; 29:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/10\">",
"      ACOG Committee opinion. Second-look laparotomy for epithelial ovarian cancer. Number 165, December 1995 (replaces no. 100, November 1991). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996; 53:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/11\">",
"      Morgan RJ Jr, Copeland L, Gershenson D, et al. NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     Barter JF, Barnes WA. Second-look laparotomy. In: Ovarian Cancer, Rubin SC, Sutton GP (Eds), McGraw-Hill, New York 1993. p.643.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/13\">",
"      Rubin SC, Lewis JL Jr. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/14\">",
"      Podczaski E, Manetta A, Kaminski P, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/15\">",
"      Gershenson DM, Copeland LJ, Wharton JT, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985; 55:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/16\">",
"      Lippman SM, Alberts DS, Slymen DJ, et al. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988; 61:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/17\">",
"      Rubin SC, Randall TC, Armstrong KA, et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999; 93:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/18\">",
"      Gadducci A, Iacconi P, Fanucchi A, et al. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Anticancer Res 2000; 20:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/19\">",
"      Katsoulis M, Vorgias G, Panagiotides J, et al. The prognostic significance of second-look laparotomy in advanced ovarian cancer. Eur J Gynaecol Oncol 1997; 18:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/20\">",
"      Podratz KC, Malkasian GD Jr, Wieand HS, et al. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/21\">",
"      Friedman RL, Eisenkop SM, Wang HJ. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol 1997; 67:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/22\">",
"      Williams L, Brunetto VL, Yordan E, et al. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1997; 66:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/23\">",
"      Tuxen MK, Strauss G, Lund B, Hansen M. The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997; 8:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/24\">",
"      Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991; 42:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/25\">",
"      McCreath WA, Eisenhauer EL, Abu-Rustum NR, et al. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. Gynecol Oncol 2006; 102:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/26\">",
"      Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/27\">",
"      Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 99:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/28\">",
"      Obermair A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 2001; 80:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/29\">",
"      Hoskins WJ, Rubin SC, Dulaney E, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/30\">",
"      Creasman WT. Second-look laparotomy in ovarian cancer. Gynecol Oncol 1994; 55:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/31\">",
"      Podratz KC, Cliby WA. Second-look surgery in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994; 55:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/32\">",
"      Hempling RE, Wesolowski JA, Piver MS. Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival. Ann Surg Oncol 1997; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/33\">",
"      J&auml;nicke F, H&ouml;lscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/34\">",
"      Morgan MA, Rubin SC. Secondary cytoreduction in epithelial ovarian cancer. Crit Rev Oncol Hematol 1995; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/35\">",
"      Dowdy SC, Metzinger DS, Gebhart JB, et al. Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol 2005; 96:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/36\">",
"      Petit T, Velten M, d'Hombres A, et al. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 2007; 104:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/37\">",
"      Rubin SC, Hoskins WJ, Hakes TB, et al. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988; 159:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/38\">",
"      Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 1992; 46:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/39\">",
"      Tarraza HM Jr, Boyce CR, Smith WG, Jones MA. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol 1993; 50:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/40\">",
"      Dufour P, Bergerat JP, Barats JC, et al. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 1994; 73:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/41\">",
"      Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998; 69:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/42\">",
"      MacGibbon A, Bucci J, MacLeod C, et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol Oncol 1999; 75:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/43\">",
"      Fuks Z, Rizel S, Biran S. Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. J Clin Oncol 1988; 6:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/44\">",
"      Goldberg H, Stein ME, Steiner M, et al. Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up. Tumori 2001; 87:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25847/abstract/45\">",
"      Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3195 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25847=[""].join("\n");
var outline_f25_15_25847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laparoscopy versus laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Findings at surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Effect on survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT OF POSITIVE FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF NEGATIVE FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sites of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Consolidation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ALTERNATIVES TO SECOND LOOK SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3195|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25848="Causes, diagnosis, and evaluation of hyperkalemia in children";
var content_f25_15_25848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes, diagnosis, and evaluation of hyperkalemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Michael J Somers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25848/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/15/25848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23516378\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is usually defined as a serum or plasma potassium greater than 5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     (mmol/L).",
"    </span>",
"    Although children are less likely to develop hyperkalemia than adults, pediatric hyperkalemia is not an uncommon occurrence, and severe hyperkalemia (potassium level greater than 7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     [mmol/L])",
"    </span>",
"    is a serious medical problem that needs immediate attention.",
"   </p>",
"   <p>",
"    The etiology, clinical findings, diagnosis, and evaluation of pediatric hyperkalemia are reviewed here. The management of hyperkalemia in children is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=see_link\">",
"     \"Management of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958507\">",
"    <span class=\"h1\">",
"     NORMAL POTASSIUM BALANCE AND LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homeostatic mechanisms regulate potassium balance in order to maintain high intracellular levels required for cellular functions (eg, metabolism and growth), and low extracellular concentration to preserve the steep concentration gradient across the cell membrane needed for nerve excitation and muscle contraction. After a bolus of potassium intake, these normal physiologic processes preserve the intra- and extracellular balance via transcellular potassium movement regulated by cell membrane Na-K-ATPase (mediated by insulin and alpha and beta-2 adrenergic agonists), and urinary potassium excretion (mostly mediated by aldosterone). In children, positive potassium balance is needed for growth, whereas in adults, homeostasis is directed towards a zero potassium balance.",
"   </p>",
"   <p>",
"    Normal serum and plasma potassium concentrations in children and adolescents are similar to levels in adults. However, infants have a higher normal range of potassium because of their reduced urinary potassium excretion caused by their relatively increased aldosterone insensitivity and decreased glomerular filtration rate (",
"    <a class=\"graphic graphic_table graphicRef86501 \" href=\"UTD.htm?9/29/9691\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H7397120#H7397120\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Brief review of potassium physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516385\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia in children is caused by derangements of the hemostatic mechanisms that normally regulate potassium balance, which are the same as those that occur in adults. Understanding the underlying physiology is helpful in the diagnostic evaluation and treatment of children with hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H7397120#H7397120\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Brief review of potassium physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric hyperkalemia is due to one or a combination of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive increase in potassium intake",
"     </li>",
"     <li>",
"      Transcellular movement of intracellular potassium into the extracellular space",
"     </li>",
"     <li>",
"      Decreased renal excretion of potassium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent hyperkalemia generally requires impaired urinary potassium excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266365934\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the following sections, the causes of pediatric hyperkalemia are classified based on the underlying physiologic process (",
"    <a class=\"graphic graphic_table graphicRef85965 \" href=\"UTD.htm?18/36/19020\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516400\">",
"    <span class=\"h2\">",
"     Increased potassium intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal children, large increases in usual dietary sources of potassium are unlikely to lead to sustained hyperkalemia as normally intact homeostatic mechanisms protect against elevated extracellular potassium (see",
"    <a class=\"local\" href=\"#H85958507\">",
"     'Normal potassium balance and levels'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Rarely, normal homeostatic mechanisms can be overwhelmed by excessively large loads of potassium that may be delivered in intravenous fluids, parenteral nutrition, intravenous medications with a high potassium content (eg, potassium penicillin), or massive transfusions of stored blood. However, this is unlikely to occur with correct prescription and administration of these substances in a child with normal cardiovascular and renal function. Infants and small children are more likely to develop clinically significant hyperkalemia because for a given intake, the rise in potassium concentration is greater as these patients have a smaller volume of distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link&amp;anchor=H16#H16\">",
"     \"Administration and complications of red cell transfusion in infants and children\", section on 'Metabolic toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516407\">",
"    <span class=\"h2\">",
"     Transcellular movement of potassium",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266366784\">",
"    <span class=\"h3\">",
"     Cellular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakdown of normal tissue or rapid cell lysis can result in the release of large amounts of intracellular potassium along with other intracellular electrolytes into the extracellular space. This most often occurs in children in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhabdomyolysis from crush injury sustained in accidents or natural disasters (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link&amp;anchor=H7#H7\">",
"       \"Crush-related acute kidney injury (acute renal failure)\", section on 'Biochemical abnormalities'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extreme exercise resulting in significant muscle injury",
"     </li>",
"     <li>",
"      Tumor lysis syndrome in children with large tumor burden (eg, leukemia or lymphoma) while undergoing chemotherapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491877#H491877\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe hemolytic processes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512205#H11512205\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Potassium'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute kidney injury may also be present in patients with the above conditions, which exacerbates hyperkalemia due to impaired urinary potassium excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635271498\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, metabolic acidosis is the most common cause of intracellular potassium movement to the extracellular space without cellular injury. In this setting, the intracellular movement of hydrogen ions causes the potassium to shift into the extracellular space to maintain electroneutrality. Metabolic acidosis is often caused by or is associated with a decreased effective arterial blood volume, which may impact urinary potassium excretion. The re-establishment of adequate perfusion generally results in the restoration of both normal acid-base status and urinary potassium excretion. (See",
"    <a class=\"local\" href=\"#H23516430\">",
"     'Decreased effective arterial blood volume'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A similar transcellular shift can be seen in children with insulin deficiency and diabetic ketoacidosis and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Serum potassium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H635271519\">",
"    <span class=\"h3\">",
"     Hyperkalemic periodic paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with hyperkalemic periodic paralysis can present with hyperkalemia caused by transcellular relocation of potassium. Hyperkalemic periodic paralysis is an autosomal dominant condition that encodes for a protein of the sodium channel of skeletal muscles. In these patients, the sodium channel closes too slowly, leading to intracellular potassium movement into the extracellular space, which results in hyperkalemia and muscle weakness. Hyperkalemic periodic paralysis can present in infancy, and needs to be considered in any young child with hyperkalemia and concomitant muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516414\">",
"    <span class=\"h2\">",
"     Abnormalities in renal excretion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516423\">",
"    <span class=\"h3\">",
"     Acute and chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with acute or chronic kidney disease, urinary potassium excretion may be reduced due to a decrease in glomerular filtration rate (GFR)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266366929\">",
"    <span class=\"h4\">",
"     Glomerular filtration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is not commonly observed until the GFR falls below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . At this reduced level of GFR, urinary potassium excretion is impaired because the decreased distal delivery of sodium limits its exchange with potassium in the collecting tubule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266366936\">",
"    <span class=\"h4\">",
"     Tubular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired potassium excretion due to tubular dysfunction (eg, aldosterone insensitivity or deficiency) may occur in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoaldosteronism (type 4 renal tubular acidosis) &ndash; Hyperkalemia may be caused by either aldosterone deficiency or resistance even when the GFR is well preserved. Aldosterone resistance is a common finding in children with obstructive uropathy or reflux neuropathy and is often referred to as type 4 renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\", section on 'Hypoaldosteronism (type 4 RTA)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants &ndash; Infants have a relatively lower rate of urinary potassium excretion because of a normally decreased response to aldosterone and lower GFR. As a result, infants generally have higher baseline",
"      <span class=\"nowrap\">",
"       serum/plasma",
"      </span>",
"      potassium levels than older children (",
"      <a class=\"graphic graphic_table graphicRef86501 \" href=\"UTD.htm?9/29/9691\">",
"       table 1",
"      </a>",
"      ). This is especially true for preterm infants who have lower GFR and more immature tubular function than term infants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=see_link&amp;anchor=H1201172303#H1201172303\">",
"       \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Glomerular filtration rate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=see_link&amp;anchor=H30#H30\">",
"       \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Hyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyelonephritis &ndash; Infants with acute febrile urinary tract infection (ie, pyelonephritis) are at risk for hyperkalemia compared with patients who have other febrile illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/1\">",
"       1",
"      </a>",
"      ]. It is thought that interstitial inflammation due to pyelonephritis exacerbates the decrease response to aldosterone that is normally seen in young infants, thus causing further distal tubular insensitivity to aldosterone.",
"     </li>",
"     <li>",
"      Sickle cell disease &ndash; In children with sickle cell disease and renal tubular injury due to impaired medullary blood flow, impaired aldosterone sensitivity leads to reduced urinary potassium excretion and hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H8#H8\">",
"       \"Renal manifestations of sickle cell disease\", section on 'Renal infarction and papillary necrosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516430\">",
"    <span class=\"h3\">",
"     Decreased effective arterial blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of pediatric hyperkalemia is decreased effective arterial blood volume that leads to poor tissue perfusion and metabolic acidosis (which results in transcellular potassium movement), and a reduction in urinary potassium excretion. In these patients, sodium and water reabsorption is increased in the proximal portion of the nephron, resulting in a reduction in sodium delivery to the collecting tubule. This leads to functional impairment of urinary potassium excretion as there is a limited amount of sodium available for potassium exchange in the collecting tubule. Although this phenomenon is often referred to as a functional renal tubular acidosis (RTA), or impaired aldosterone mediated urinary potassium and acid excretion, there is no abnormality in the ion channels or mineralocorticoid receptors of the distal nephron. Such patients are at risk for developing hyperkalemia with potassium administration in intravenous fluids or medications. (See",
"    <a class=\"local\" href=\"#H635271498\">",
"     'Metabolic acidosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and young children are at risk of developing clinically significant dehydration and hemodynamic instability with acute illness as they have a higher surface area-to-volume ratio with proportionally greater insensible losses than older patients. In addition, they have an increased resistance to aldosterone. As a result, it is not uncommon to see hyperkalemia as an associated finding of impaired effective circulation in significantly ill infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some children with chronic marginal hydration and a diet that is low in sodium content, high potassium levels may be seen as a result of reduced distal delivery of sodium. This is most often seen in infants who have ongoing feeding problems and a dietary intake of breast milk or infant formula, both of which have low sodium content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23516437\">",
"    <span class=\"h3\">",
"     Decreased activity of the renin-angiotensin-aldosterone system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, congenital or acquired endocrine anomalies that impair the renin-angiotensin-aldosterone system can result in hyperkalemia, particularly in infants or young children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital adrenal hyperplasia (CAH) results in significant underproduction of mineralocorticoids (eg, aldosterone) and ensuing early sodium wasting and severe hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H11#H11\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Congenital adrenal hyperplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of primary adrenal insufficiency (PAH) are rarer than CAH and may also present with hyperkalemia. In a case series of 20 consecutive patients with primary adrenal insufficiency that was not due to CAH, about half of the cohort presented with serum potassium levels &gt;5",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      although almost all of the patients had hyponatremia and hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudohypoaldosteronism, which is even rarer than PAH, is caused by abnormal mineralocorticoid receptor activity resulting in salt wasting, hyperkalemia, metabolic acidosis, and high levels of serum aldosterone. In its autosomal dominant form (Liddle syndrome), only the renal tubular function is affected and its clinical impact may wane as the child grows with further maturation of tubular sodium transport. In its autosomal recessive form (pseudohypoaldosteronism type 1), severe mutations in the epithelial sodium channel in the distal tubule have been described, and affected patients generally present early in life, have salt wasting from aldosterone targeted organs (kidney, colon, and sweat glands), and require aggressive sodium supplementation to maintain electrolyte balance [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H23014111#H23014111\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'End-organ unresponsiveness'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications &ndash; Children being treated with potassium sparing diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) or one of the angiotensin converting enzyme inhibitors or angiotensin receptor blockers may develop hyperkalemia because of decreased mineralocorticoid production or activity. Use of these medications in children is rare outside of children with intrinsic renal or cardiac dysfunction, and these children may also be at risk of developing hyperkalemia due to other risk factors such as low GFR or decreased effective arterial volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266365994\">",
"    <span class=\"h2\">",
"     Pseudohyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pseudohyperkalemia, the elevated potassium level measured in the laboratory sample is not representative of the child&rsquo;s true potassium. In children, it is most commonly caused by hemolyzed blood samples due to difficulties in obtaining or handling blood samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This is especially true in young children, in whom a hemolyzed specimen is more likely to occur because a small needle (20 to 24 gauge) and syringe are often needed to obtain blood samples as vacuum devices are difficult to use in these patients with small vessels. In some settings, an indwelling small gauged intravenous catheter and syringe are used for blood sampling, which also requires significant suction to obtain sufficient sample volumes. Hemolysis is six times more likely to occur when a syringe is used compared with a vacuum device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children are also much more likely to resist phlebotomy attempts, and to cry and struggle throughout the procedure. In a child whose arm is being restrained, repetitive limb movement and contraction can lead to release of muscle cell potassium that may significantly raise the potassium content of the blood sample. In addition, hyperventilation accompanying sudden intense crying can cause acute respiratory alkalosis that causes potassium to shift out of cells and leads to rapid serum potassium elevations of up to 1",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with marked leukocytosis or thrombocytosis, there may also be potassium loss from these cells after clotting of the blood sample. However, this is unlikely to cause significant hyperkalemia with the possible exception of patients with leukemia or myeloproliferative disorders. In these patients, a plasma potassium assay decreases the chances of a falsely elevated result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7809914\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958315\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children are asymptomatic as they have mild (&lt;6",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    or moderate elevations of potassium (between 6 to 7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [6 to 7",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    In these patients, hyperkalemia is typically detected when plasma or serum electrolytes are obtained for monitoring or because electrolyte abnormalities are suspected. This usually occurs in children with signs or symptoms of renal disease (eg, hypertension, urinary abnormalities [hematuria and proteinuria], edema, and",
"    <span class=\"nowrap\">",
"     oliguria/anuria),",
"    </span>",
"    significantly decreased effective arterial blood flow (eg, shock, severe gastroenteritis, or heart failure), and considerable cellular injury (eg, trauma or tumor lysis syndrome). (See",
"    <a class=\"local\" href=\"#H266365934\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Asymptomatic children with mild to moderate hyperkalemia may have electrocardiographic changes as a result of hyperkalemic-associated cardiac conduction disturbances. (See",
"    <a class=\"local\" href=\"#H85958377\">",
"     'Cardiac conduction abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958344\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe hyperkalemia (potassium level &gt;7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may have the following clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/8\">",
"     8",
"    </a>",
"    ], which are similar to those seen in adult patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of hyperkalemia in adults\", section on 'Clinical manifestations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle weakness or paralysis &ndash; Muscle weakness is usually ascending, beginning in the legs and progressing to the trunk and arms, which can progress to flaccid paralysis. These findings may mimic those seen in patients with Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"       \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of cardiac conduction abnormalities &ndash; Patients with hyperkalemia may present with palpitations, syncope, or asystole depending on the severity of cardiac conduction disturbances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958377\">",
"    <span class=\"h2\">",
"     Cardiac conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is associated with significant and potentially life-threatening disturbances in cardiac conduction. Electrocardiographic changes (ECG) reflect the impact of increasing levels of serum and plasma potassium on the electrical activity of the heart including aberrant atrial (P wave) and ventricular (QRS complex) depolarization, and abnormal repolarization (T wave). These findings are based not only on the level of extracellular potassium, but also on how quickly the change in potassium level has occurred over time. ECG changes that generally occur at a concentration &gt;7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in children with chronic hyperkalemia may be seen at lower levels in children with an acute rapid rise in potassium resulting in a swift decrease in the transmembrane potassium gradient. This may be seen in patients with tumor lysis or significant crush injury. In infants, ECG changes are usually seen at greater levels of potassium as the normal range is higher in this group of patients (",
"    <a class=\"graphic graphic_table graphicRef86501 \" href=\"UTD.htm?9/29/9691\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following is the general range of",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    potassium levels expressed as",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and the corresponding ECG changes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 5.5 to 6.5 &ndash; Tall peaked T waves with a narrow base and shortening of the QT interval (",
"      <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"UTD.htm?11/50/12068\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Between 6.5 to 8.0 &ndash; Peaked T waves, prolonged PR interval, decreased or disappearing P wave, widening QRS complex, and amplified R wave (",
"      <a class=\"graphic graphic_waveform graphicRef63569 \" href=\"UTD.htm?17/18/17702\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Greater than 8.0 &ndash; Absent P wave, bundle branch block, progressive widening of QRS complex that eventually merges with the T wave to form a sinusoidal pattern. This is followed by ventricular fibrillation or asystole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all children with hyperkalemia will manifest ECG changes, and the absence of ECG change does not preclude the need for potential therapy for significant potassium elevation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=see_link\">",
"     \"Management of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958478\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperkalemia is made by the detection of an elevated plasma or serum potassium level. In infants, the normal range of potassium is greater than in older children and adults because of their reduced urinary potassium excretion (",
"    <a class=\"graphic graphic_table graphicRef86501 \" href=\"UTD.htm?9/29/9691\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because a common cause of high serum potassium values is due to hemolyzed specimens, which are due to difficulties in obtaining blood samples in children (ie, pseudohyperkalemia), an elevated potassium level should be confirmed in any child in whom the clinical setting makes hyperkalemia unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/5\">",
"     5",
"    </a>",
"    ]. Repeat testing should be done with a nonhemolyzed specimen (free flowing venous blood sample). If it is not possible to obtain a free flowing venous blood sample, an arterial blood sample should be acquired prior to instituting any diagnostic evaluation or potassium lowering therapies. (See",
"    <a class=\"local\" href=\"#H266365994\">",
"     'Pseudohyperkalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85958605\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic patients, the primary differential diagnosis is pseudohyperkalemia, which is differentiated from true hyperkalemia by a normal repeat potassium level, as discussed above (see",
"    <a class=\"local\" href=\"#H266365994\">",
"     'Pseudohyperkalemia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H85958478\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In symptomatic patients, diseases associated with specific symptoms are differentiated from hyperkalemia by the finding of an elevated potassium level.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute muscle weakness and paralysis &ndash; Conditions that present with muscle weakness include infections (eg, polio and West Nile virus infection), toxins (eg, botulism), hypocalcemia and hypermagnesemia, and Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=see_link\">",
"       \"Etiology and evaluation of the child with muscle weakness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpitation and syncope &ndash; Hyperkalemia is differentiated from the large number of other causes of palpation and syncope (",
"      <a class=\"graphic graphic_table graphicRef52851 \" href=\"UTD.htm?32/61/33756\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"       table 4",
"      </a>",
"      ) by an elevated potassium level and characteristic echocardiographic findings. In children with palpitations and syncope, rapid assessment is imperative as these symptoms may be associated with a life-threatening condition such as cardiac conduction abnormalities. Initial evaluation is focused on determining whether the patient appears ill or not, if there is an underlying life-threatening cause, and if there is a risk of imminent shock (",
"      <a class=\"graphic graphic_algorithm graphicRef78536 \" href=\"UTD.htm?4/22/4448\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 2",
"      </a>",
"      ). The evaluations for palpitations and syncope are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22056?source=see_link\">",
"       \"Approach to the child with palpitations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520951\">",
"    <span class=\"h1\">",
"     EVALUATION TO DETERMINE UNDERLYING ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because hyperkalemia is a potentially life-threatening condition, initial management of elevated potassium takes precedence over any diagnostic evaluation. The urgency and type of intervention are based on the degree of potassium elevation, presence or absence of symptoms, and electrocardiographic findings. These measures include stabilizing the cardiac membrane, decreasing extracellular potassium level, and reducing bodily potassium stores [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25848/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=see_link\">",
"     \"Management of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the initial management, further evaluation focuses on determining the etiology as subsequent care is based on the underlying cause of hyperkalemia. The assessment includes a focused history and physical examination and, if needed, laboratory testing. (See",
"    <a class=\"local\" href=\"#H266365934\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2675768\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination often clearly point to the underlying etiology, and there is little need for further extensive diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2675791\">",
"    <span class=\"h3\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical clues may be indicative of a specific etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of chemotherapy in a child with a large tumor load is indicative of tumor lysis syndrome",
"     </li>",
"     <li>",
"      History of an unusually large intake of potassium due to intravenous fluids, parenteral nutrition, medications (eg, potassium penicillin), or massive transfusion",
"     </li>",
"     <li>",
"      Known renal disease",
"     </li>",
"     <li>",
"      Decreased urine output may be suggestive of renal disease or reduced effective arterial perfusion.",
"     </li>",
"     <li>",
"      History of massive trauma, excessive exercise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      muscular cramp (which also can be a finding of hyperkalemia) is suggestive of rhabdomyolysis",
"     </li>",
"     <li>",
"      History of significant hemolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464781\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following physical findings are suggestive of an underlying etiology for hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension and edema may be indicative of renal disease",
"     </li>",
"     <li>",
"      Decrease peripheral pulses, low blood pressure, tachycardia, and delayed capillary refill are often signs of significant reduced effective arterial perfusion",
"     </li>",
"     <li>",
"      Muscular tenderness may be seen in patients with rhabdomyolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464798\">",
"    <span class=\"h3\">",
"     Further laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, an elevated potassium value should be confirmed prior to any further extensive testing in patients in whom there is a high index of suspicion for pseudohyperkalemia. (See",
"    <a class=\"local\" href=\"#H266365994\">",
"     'Pseudohyperkalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In some children, the cause of a persistently high potassium level is not evident and further laboratory testing is performed as follows (",
"    <a class=\"graphic graphic_table graphicRef85976 \" href=\"UTD.htm?38/49/39707\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum blood urea nitrogen (BUN) and creatinine to assess renal function.",
"     </li>",
"     <li>",
"      Urinalysis to detect kidney disease.",
"     </li>",
"     <li>",
"      Complete blood count, platelets, and serum lactic dehydrogenase to assess for blood dyscrasia or hemolysis.",
"     </li>",
"     <li>",
"      Serum creatine kinase to detect muscle injury and, if present, its severity.",
"     </li>",
"     <li>",
"      Blood electrolytes to detect other electrolyte abnormalities such as metabolic acidosis.",
"     </li>",
"     <li>",
"      Serum aldosterone and plasma renin activity in patients in whom there is clinical suspicion for underlying endocrinopathy.",
"     </li>",
"     <li>",
"      Urine chemistries should be obtained in selected patients at the same time or shortly after the measurement of blood studies to assess renal tubular function regarding sodium reabsorption and urinary potassium excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urine potassium levels &ndash; In most children, hyperkalemia should result in a random urinary potassium level that exceeds 20",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      and often exceeds 40",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      Very high random urinary potassium values (&gt;80 to 100",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      are very suggestive that hyperkalemia is due to excessive potassium intake or cellular release and",
"      <strong>",
"       not",
"      </strong>",
"      due to an abnormality in urinary potassium excretion.",
"     </li>",
"     <li>",
"      Urine sodium levels &ndash; Low random urinary sodium values (&lt;20",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      demonstrate that there is avid renal sodium absorption, which may limit the amount of sodium available for potassium exchange at the distal renal tubule. Optimizing the effective volume and providing more sodium to the child will increase distal tubular sodium delivery and improved potassium excretion.",
"     </li>",
"     <li>",
"      Transtubular potassium gradient &ndash; Although the transtubular potassium gradient (TTKG) had been used to distinguish hypoaldosteronism from other causes of hyperkalemia, on further evaluation, the assumptions underlying the use of this tool were found not to be valid. As a result, TTKG should not be used to evaluate patients with hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H249933336#H249933336\">",
"       \"Causes and evaluation of hyperkalemia in adults\", section on 'Transtubular potassium gradient'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19286524\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Hyperkalemia is usually defined as a serum or plasma potassium greater than 5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     (mmol/L).",
"    </span>",
"    Although children are less likely to develop hyperkalemia than adults, hyperkalemia is not an uncommon occurrence, and severe hyperkalemia (potassium level greater than 7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     [mmol/L]",
"    </span>",
"    is a serious medical problem that needs immediate attention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric hyperkalemia is caused by derangements of the normal hemostatic mechanisms that regulate potassium balance, which are the same as those that occur in adults (",
"      <a class=\"graphic graphic_table graphicRef85965 \" href=\"UTD.htm?18/36/19020\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23516385\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Large increase in potassium intake is an uncommon cause of sustained hyperkalemia in healthy children. This may occur infrequently due to a large infusion of potassium through intravenous solutions (including parenteral nutrition), potassium containing medications, or massive transfusion. (See",
"      <a class=\"local\" href=\"#H23516400\">",
"       'Increased potassium intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcellular movement of intracellular potassium into the extracellular space can cause pediatric hyperkalemia due to either cellular injury (eg, rhabdomyolysis, tumor lysis syndrome, or severe hemolysis) or significant shift of potassium seen in patients with metabolic acidosis, diabetic ketoacidosis, or hyperkalemic periodic paralysis. (See",
"      <a class=\"local\" href=\"#H23516407\">",
"       'Transcellular movement of potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased renal excretion of potassium is the most common cause of persistent hyperkalemia. Etiologies include renal disease, decreased effective arterial circulation, or decreased activity or sensitivity to the renin-aldosterone system. (See",
"      <a class=\"local\" href=\"#H23516414\">",
"       'Abnormalities in renal excretion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudohyperkalemia is common in children because hemolyzed specimens are often observed due to difficulties in obtaining blood samples, especially in infants and small children. As a result, we recommend that an elevated potassium level should be confirmed in any child in whom the clinical setting makes hyperkalemia unlikely (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H266365994\">",
"       'Pseudohyperkalemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H85958478\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with hyperkalemia are asymptomatic as they have mild (serum or plasma potassium &lt;6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      or moderate elevations of serum or plasma potassium (potassium between 6 to 7",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [6 to 7",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"      In these patients, hyperkalemia is typically detected when plasma or serum electrolytes are obtained because electrolyte abnormalities are suspected (eg, renal disease). Clinical manifestations in children with severe hyperkalemia (potassium potassium level &gt;7",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      include muscle weakness or paralysis, and palpitations and syncope due to cardiac conduction abnormalities. (See",
"      <a class=\"local\" href=\"#H7809914\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemia is associated with significant and potentially life-threatening disturbances in cardiac conduction. Electrocardiographic changes (ECG) reflect the impact of increasing levels of serum and plasma potassium on the electrical activity of the heart including aberrant atrial (P wave) and ventricular (QRS complex) depolarization, and abnormal repolarization (T wave). (See",
"      <a class=\"local\" href=\"#H85958377\">",
"       'Cardiac conduction abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hyperkalemia is made by the detection of an elevated plasma or serum potassium level. In infants, the normal range of potassium is greater than older children and adults because of their relatively lower urinary potassium excretion (",
"      <a class=\"graphic graphic_table graphicRef86501 \" href=\"UTD.htm?9/29/9691\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H85958478\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients, the primary differential diagnosis is pseudohyperkalemia, which is differentiated from true hyperkalemia by a normal repeat potassium level that should be obtained from a free flowing venous blood sample to reduce the risk of hemolysis. (See",
"      <a class=\"local\" href=\"#H85958478\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H85958605\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In symptomatic patients, an elevated potassium level and potassium-associated ECG changes differentiate hyperkalemia from conditions that may also present with muscle weakness and paralysis, or syncope and palpitations (",
"      <a class=\"graphic graphic_table graphicRef52851 \" href=\"UTD.htm?32/61/33756\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"       table 4",
"      </a>",
"      ). For patients with syncope",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palpitations, rapid assessment is imperative as these symptoms may be due to a life-threatening disorder (including severe hyperkalemia) (",
"      <a class=\"graphic graphic_algorithm graphicRef78536 \" href=\"UTD.htm?4/22/4448\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H85958605\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22056?source=see_link\">",
"       \"Approach to the child with palpitations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After acute management of potentially life-threatening or serious hyperkalemia, further evaluation focuses on determining the etiology as subsequent care is based on the underlying cause of hyperkalemia. The assessment includes a focused history and physical examination, and if needed, laboratory testing (",
"      <a class=\"graphic graphic_table graphicRef85976 \" href=\"UTD.htm?38/49/39707\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H520951\">",
"       'Evaluation to determine underlying etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=see_link\">",
"       \"Management of hyperkalemia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/1\">",
"      Gil-Ruiz MA, Alcaraz AJ, Mara&ntilde;&oacute;n RJ, et al. Electrolyte disturbances in acute pyelonephritis. Pediatr Nephrol 2012; 27:429.",
"     </a>",
"    </li>",
"    <li>",
"     Kim M, Somers MJG. Fluid and electrolyte physiology and therapy. In: Oski&rsquo;s Pediatrics, 4th ed, McMillan JA, DeAngelis CD, Feigin RD (Eds), Lippincott Williams and Wilkins, Baltimore 2006. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/3\">",
"      Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab 2011; 96:E925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/4\">",
"      Schweiger B, Moriarty MW, Cadnapaphornchai MA. Case report: severe neonatal hyperkalemia due to pseudohypoaldosteronism type 1. Curr Opin Pediatr 2009; 21:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/5\">",
"      Baer DM, Ernst DJ, Willeford SI, Gambino R. Investigating elevated potassium values. MLO Med Lab Obs 2006; 38:24, 26, 30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/6\">",
"      Dickinson H, Webb NJ, Chaloner C, et al. Pseudohyperkalaemia associated with leukaemic cell lysis during pneumatic tube transport of blood samples. Pediatr Nephrol 2012; 27:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/7\">",
"      Krapf R, Caduff P, Wagdi P, et al. Plasma potassium response to acute respiratory alkalosis. Kidney Int 1995; 47:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25848/abstract/8\">",
"      Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. Arch Dis Child 2012; 97:376.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14274 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25848=[""].join("\n");
var outline_f25_15_25848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19286524\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23516378\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85958507\">",
"      NORMAL POTASSIUM BALANCE AND LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23516385\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266365934\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23516400\">",
"      Increased potassium intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23516407\">",
"      Transcellular movement of potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H266366784\">",
"      - Cellular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H635271498\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H635271519\">",
"      - Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23516414\">",
"      Abnormalities in renal excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23516423\">",
"      - Acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H266366929\">",
"      Glomerular filtration rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H266366936\">",
"      Tubular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23516430\">",
"      - Decreased effective arterial blood volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23516437\">",
"      - Decreased activity of the renin-angiotensin-aldosterone system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266365994\">",
"      Pseudohyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7809914\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85958315\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85958344\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85958377\">",
"      Cardiac conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85958478\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85958605\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H520951\">",
"      EVALUATION TO DETERMINE UNDERLYING ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2675768\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2675791\">",
"      - Historical clues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H464781\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H464798\">",
"      - Further laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19286524\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14274|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/22/4448\" title=\"algorithm 1\">",
"      Pediatric palpitations algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 2\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14274|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/29/9691\" title=\"table 1\">",
"      Normal serum potassium levels in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/36/19020\" title=\"table 2\">",
"      Causes of pediatric hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/61/33756\" title=\"table 3\">",
"      Causes palpitations child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37660\" title=\"table 4\">",
"      Causes of syncope children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/49/39707\" title=\"table 5\">",
"      Further laboratory testing for pediatric hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14274|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/50/12068\" title=\"waveform 1\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/18/17702\" title=\"waveform 2\">",
"      Intermediate case 11 answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22056?source=related_link\">",
"      Approach to the child with palpitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=related_link\">",
"      Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=related_link\">",
"      Etiology and evaluation of the child with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=related_link\">",
"      Management of hyperkalemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25849="Pediculosis capitis";
var content_f25_15_25849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediculosis capitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25849/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/15/25849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three distinct varieties of lice are specifically parasitic for humans (",
"    <a class=\"graphic graphic_figure graphicRef52420 \" href=\"UTD.htm?4/8/4226\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/1\">",
"     1",
"    </a>",
"    ]. Two of them,",
"    <em>",
"     Pediculus humanus capitis",
"    </em>",
"    (the head louse) and",
"    <em>",
"     Pediculus humanus humanus",
"    </em>",
"    (the body louse), are closely related variants of the same species, despite their different habits. The third is Phthirus pubis, the pubic louse commonly known as the \"crab.\" The clinical manifestations, diagnosis, and treatment of pediculosis corporis and pediculosis pubis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=see_link\">",
"     \"Pediculosis corporis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1511?source=see_link\">",
"     \"Pediculosis pubis and pediculosis ciliaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The head louse is an adaptable creature that is found worldwide, and infestations occur in individuals of all socioeconomic backgrounds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"     2",
"    </a>",
"    ]. Children are affected most commonly; with the exception of the common cold, pediculosis capitis affects a greater number of elementary school students in North America than all other communicable diseases combined. It has been estimated that in 1997 approximately one of every four elementary level students in the United States was infested [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Males appear to be less susceptible to lice infestations than females [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], and in the United States, black children are affected much less frequently than whites and others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/8\">",
"     8",
"    </a>",
"    ]. The reasons for these findings are uncertain. It is possible that the lower incidence in black children in the US may be related to the prevalence of lice in the US that are less capable of grasping the shape or width of certain types of hair [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/8\">",
"     8",
"    </a>",
"    ]. Studies investigating the impact of long hair length on the risk of louse infestation have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/5,6,9\">",
"     5,6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interaction with playmates, cross transfer from articles of clothing on adjacent hooks in school cloak rooms, and shared combs, hair brushes, headphones, towels, and beds are important modes of disease spread [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The head louse is a gray-white, mobile insect 3 to 4 mm in length (",
"    <a class=\"graphic graphic_picture graphicRef80788 \" href=\"UTD.htm?41/18/42274\">",
"     picture 1",
"    </a>",
"    ). The female is a little longer than the male. Both sexes are equipped with mouth parts adapted to sucking blood and legs adapted to grasping hairs. The life span of the female is about one month, during which time she lays 7 to 10 eggs each day, cementing them firmly to the base of a host hair. The eggs, commonly called \"nits,\" are oval capsules that hatch in eight days, releasing nymphs that require another eight days to mature (",
"    <a class=\"graphic graphic_picture graphicRef74790 graphicRef56619 \" href=\"UTD.htm?32/59/33720\">",
"     picture 2A-B",
"    </a>",
"    ). After hatching, egg cases become white and more visible. Adults feed voraciously both on the scalp and adjacent areas of the face and neck.",
"   </p>",
"   <p>",
"    Adult lice can survive up to 55 hours without a host [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/11\">",
"     11",
"    </a>",
"    ], although they probably dehydrate and become nonviable long before their death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"     2",
"    </a>",
"    ]. Lice do not jump, fly, or use pets as vectors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lice infestations are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/12\">",
"     12",
"    </a>",
"    ]; some children can harbor a surprisingly large colony of head lice with no apparent symptoms. Itching of the scalp, neck, and ears may occur as an allergic reaction to lice saliva, which is injected during feeding. Persistent or recurrent pyoderma about the neck and ears should always alert the examiner to search for lice. Cervical and nuchal lymph nodes are often enlarged, and febrile episodes associated with secondary staphylococcal infection may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by the visualization of live lice (",
"    <a class=\"graphic graphic_picture graphicRef80788 \" href=\"UTD.htm?41/18/42274\">",
"     picture 1",
"    </a>",
"    ). Systematically combing wet or dry hair with a fine toothed nit comb (teeth of comb 0.2 mm apart) better detects active louse infestation than visual inspection of the hair and scalp alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In a comparison study, a wet-combing technique resulted in a sensitivity of 91 percent for the detection of live lice, compared with a sensitivity of 29 percent observed with visual inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/13\">",
"     13",
"    </a>",
"    ]. Although it has been suggested that wet combing may be the most sensitive diagnostic technique, wet combing and dry combing have not been compared directly in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When performing wet combing, a lubricant such as a commercially available hair conditioner is used to wet the hair prior to the following procedure, which is also utilized for the dry combing method [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hair should be brushed or combed to remove tangles.",
"     </li>",
"     <li>",
"      The fine toothed comb is inserted near the crown until it gently touches the scalp, after which it is drawn firmly down and examined for lice after each stroke.",
"     </li>",
"     <li>",
"      The entire head should be combed systematically at least twice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nits are often more easily discovered than the lice themselves, which are elusive and not always readily apparent (",
"    <a class=\"graphic graphic_picture graphicRef65846 graphicRef74790 \" href=\"UTD.htm?26/18/26921\">",
"     picture 2A, 2C",
"    </a>",
"    ). Under Wood's light the nits fluoresce a pale blue, which facilitates harvest for microscopic examination (",
"    <a class=\"graphic graphic_picture graphicRef65013 \" href=\"UTD.htm?25/29/26078\">",
"     picture 3",
"    </a>",
"    ). Unlike seborrheic scales, root sheath casts, and hair spray residue, nits are cemented securely to the hair shaft and are difficult to dislodge. White piedra, a fungal infection that presents with white or tan nodules adhering to the hair shaft, may be mistaken for pediculosis capitis (",
"    <a class=\"graphic graphic_picture graphicRef69898 \" href=\"UTD.htm?6/47/6904\">",
"     picture 4",
"    </a>",
"    ). Light microscopy and a potassium hydroxide (KOH) preparation can be used to distinguish these disorders (",
"    <a class=\"graphic graphic_picture graphicRef56619 \" href=\"UTD.htm?38/3/38961\">",
"     picture 2B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=see_link\">",
"     \"Infections due to Trichosporon species and Blastoschizomyces capitatus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finding nits without lice does not necessarily mean that there is active infestation; nits may persist for months after successful therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"     2",
"    </a>",
"    ]. The Centers for Disease Control and Prevention (CDC) states that active infestation is suggested by the finding of many eggs within one-quarter inch (6.5 mm) of the scalp [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/8\">",
"     8",
"    </a>",
"    ]. However, even this criterion results in overdiagnosis. As an example, in a study in which 1729 elementary school children were screened for lice, 28 (1.6 percent) had active lice while 63 (3.6 percent) had nits without lice, of whom 50 completed follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/15\">",
"     15",
"    </a>",
"    ]. During two weeks of follow-up, only 9 of the 50 children who initially had nits alone (18 percent) converted to an active infestation. Having &ge;5 nits within one-quarter inch of the scalp was associated with a higher conversion rate than fewer nits (32 versus 7 percent). These findings have led some to recommend diagnosis based only upon finding a living, moving louse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of lice can be traumatic for some patients or parents and can lead to psychological disturbances such as delusions of infestation even after cure is complete. Tact, reassurance, and empathy on the part of the examiner will help to avoid problems of this sort. For patients who question the diagnosis, a microscope can be used to demonstrate a parasite or nit when necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical pediculicides, wet combing, and oral therapies have all been studied for the treatment of lice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Topical pediculicides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical insecticides are the initial treatment of choice for pediculosis capitis. Examples of these agents include pyrethroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    , benzyl alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     spinosad",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    . Pyrethrins may be combined with piperonyl butoxide, an ingredient that inhibits",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrin",
"    </a>",
"    catabolism in the louse and improves efficacy.",
"   </p>",
"   <p>",
"    The mechanisms of action of pyrethroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     spinosad",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    involve neurotoxic effects on lice. Benzyl alcohol 5% lotion is a newer treatment option that functions via asphyxiation of the parasite. Hair conditioners should not be used prior to the application of pediculicides; these products may result in reduced efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pyrethroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lotions containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    and piperonyl butoxide (RID&reg;, A-200&reg;, Pronto&reg;, Clear&reg;) are available without a prescription, as is a 1% concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    . Made from a natural chrysanthemum extract, creams with pyrethrins and piperonyl butoxide are neurotoxic to lice, but have extremely low mammalian toxicity, and allergic reactions are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/19\">",
"     19",
"    </a>",
"    ]. Permethrin is a synthetic pyrethroid, and is also well-tolerated.",
"   </p>",
"   <p>",
"    The scalp should be saturated with the pediculicide after the hair has been washed with shampoo, rinsed with water, and towel dried. The pediculicide remains on the hair for 10 minutes before rinsing off with water. A second treatment is indicated in 7 to 10 days, since resistance patterns have led to reduced ovicidal activity of pyrethroids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. One study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    found lice-free rates of 83 percent on day two, decreasing to 46 percent on day eight before a second treatment, and then increasing to 78 percent on day nine after the second treatment and staying there on day 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than three applications of the same product within two weeks is not recommended. Prescription strength",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    (5%) is also available, but is not more effective than the over the counter preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Malathion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     Malathion",
"    </a>",
"    is an organophosphate cholinesterase inhibitor that exerts neurotoxic effects on lice. The agent has both pediculicidal and ovicidal properties.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     Malathion",
"    </a>",
"    lotion 0.5% is available by prescription in the United States and over the counter in the United Kingdom. In the United States, malathion is available as a product that includes terpineol, an ingredient with additional pediculicidal properties (Ovide&reg;). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pediculicide resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One in vitro study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    0.5% with terpineol was most effective at killing head lice, compared with pyrethroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the treatment time with malathion is longer than other topical pediculicides. The lotion is left in place for 8 to 12 hours before washing off [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/22\">",
"     22",
"    </a>",
"    ]. A single application of malathion is sufficient for most patients. If live lice are visualized seven to nine days after treatment, a second treatment should be performed.",
"   </p>",
"   <p>",
"    Some studies have suggested that shorter application times may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one small, investigator-blinded, randomized trial, lice were eradicated in 98 percent of patients treated with one or two 20 minute applications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    with terpineol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     Malathion",
"    </a>",
"    is malodorous and its vapor is irritating to the eyes, which are unfavorable features for some patients. The potential flammability of the product due to the presence of alcohol has also been a concern; however, injuries have not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pediculicide selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Benzyl alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzyl alcohol 5% lotion (Ulesfia&reg;) is available for the treatment of pediculosis capitis in patients six months of age and older. Two unpublished randomized controlled trials revealed greater efficacy of benzyl alcohol over placebo for the eradication of live lice (76.2 versus 4.8 percent, and 75 versus 26.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of benzyl alcohol 5% lotion involves the asphyxiation of lice. After the benzyl alcohol component paralyzes the louse respiratory sphericles in an open state, the mineral-oil containing vehicle obstructs the sphericles.",
"   </p>",
"   <p>",
"    When treating pediculosis capitis, benzyl alcohol 5% lotion is applied for 10 minutes with saturation of the scalp and hair, and then rinsed off with water. Information on the amount of the product to apply based is provided in the package insert; long hair requires larger amounts. The treatment is repeated after seven days. Benzyl alcohol lotion may cause irritation of the skin, scalp, and eyes, as well as transient numbness at the site of application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lindane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     Lindane",
"    </a>",
"    shampoo is not a drug of first choice because it has been associated with rare neurologic adverse effects and widespread resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Lindane toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Lindane toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     Lindane",
"    </a>",
"    is an organochlorine insecticide that inhibits neurotransmission in parasitic arthropods. Neurologic toxicity resulting in seizures and death has been reported in humans following topical lindane therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/28\">",
"     28",
"    </a>",
"    ]. Most reports of these events have occurred after prolonged or repeated application of lindane, but in rare cases, have followed a single application [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the drug has been banned in some countries and the state of California [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    shampoo and lotion remain available by prescription elsewhere in the United States. The US FDA has placed a black box warning on the drug labels, cautioning that lindane shampoo and lotion should only be used as a second-line treatment in patients who cannot tolerate or have failed other therapies for the treatment of scabies or lice. Lindane is contraindicated in patients with skin disorders that may lead to increased systemic absorption (eg, atopic dermatitis, psoriasis). Other contraindications for the use of this drug are addressed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     \"Lindane: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     Lindane",
"    </a>",
"    should be given only as single application;",
"    <strong>",
"     retreatment should be avoided",
"    </strong>",
"    . Other measures to be taken to minimize toxicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prescribe one ounce of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       lindane",
"      </a>",
"      lotion or shampoo to treat an average adult; no more than two ounces should be prescribed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       Lindane",
"      </a>",
"      shampoo prescribed for pediculosis capitis should be washed off after four minutes.",
"     </li>",
"     <li>",
"      Caregivers applying the drug to patients should wear gloves that are less permeable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       lindane",
"      </a>",
"      (nitrile, latex, neoprene, or sheer vinyl). Natural latex gloves should not be used. Caregivers should thoroughly wash their hands after application.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Spinosad",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     Spinosad",
"    </a>",
"    (Natroba&reg;), a fermentation product of the soil bacterium Saccharopolyspora spinosa, is efficacious for pediculosis capitis. This topical drug compromises the central nervous system of lice by interfering with the nicotinic acetylcholine receptor, resulting in neuronal excitation and paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two manufacturer-sponsored phase 3, multicenter, randomized trials compared the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     spinosad",
"    </a>",
"    0.9% cream rinse to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    1% cream rinse plus nit combing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients who had residual live lice seven days after an initial treatment were instructed to repeat application of the same therapy. After treatment, approximately 85 percent of spinosad-treated subjects were lice free, compared with approximately 44 percent of those treated with permethrin. Individuals treated with spinosad were also less likely to require a second application.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     Spinosad",
"    </a>",
"    is supplied as a 0.9% topical suspension. Therapy with spinosad involves application of the product to completely cover the scalp and hair. The hair should be dry prior to treatment. After application is completed, spinosad should be left on for 10 minutes. Subsequently, the scalp and hair should be thoroughly rinsed with warm water to completely remove the product. Shampooing of the hair can be performed at any time after treatment. Treatment should be repeated if live lice remain seven days after the initial application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2579574\">",
"    <span class=\"h3\">",
"     Topical ivermectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    is an effective treatment that functions through binding to glutamate-gated chloride channels in lice, thereby inducing paralysis and death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/32\">",
"     32",
"    </a>",
"    ]. The use of topical ivermectin for pediculosis capitis is supported by two randomized trials that found that a single 10-minute application of topical ivermectin was superior to a placebo lotion for the eradication of lice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary efficacy end point in both trials was the number of index patients (youngest household member with at least three live lice detected on examination) who were louse-free at days 2, 8, and 15. A combined analysis of the trial results revealed that among the index patients, 131 of 138 (95 percent) treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    and 46 of 147 (31 percent) treated with the placebo lotion were free of live lice on day two. By day 15, live lice were absent in 74 and 18 percent of patients, respectively. In addition, patients in the topical ivermectin group were more likely to be free of pruritus on day two; 67 versus 43 percent denied pruritus. Adverse events were infrequent and occurred at similar rates in both groups.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    therapy is administered via a single application to dry hair. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    , a single application is sufficient because topical ivermectin has both ovicidal and pediculicidal properties. The lotion should thoroughly coat the hair and scalp. The lotion is rinsed off with water after 10 minutes.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    generally is well-tolerated. Potential adverse effects include ocular irritation, dry scalp, and a burning sensation on the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The safety of ivermectin in infants under the age of six months is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Choosing a pediculicide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pediculicide resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head louse resistance to topical insecticides is a growing concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/34\">",
"     34",
"    </a>",
"    ]. Resistance to particular agents varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/18,19,21,35-40\">",
"     18,19,21,35-40",
"    </a>",
"    ]. As an example, in an in vitro study, lice from South Florida had greater resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    1%, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrin",
"    </a>",
"    with piperonyl butoxide than lice from Panama [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/21\">",
"     21",
"    </a>",
"    ]. Only a United States formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    0.5% exhibited similar efficacy in both locations.",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    appears to be less prevalent in the United States than in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/18\">",
"     18",
"    </a>",
"    ]. It is unclear whether this is due to the history of limited use of the drug in the US, or that the US formulation of malathion also contains terpineol, a chemical with pediculicidal properties. In one in vitro study in Britain, fewer lice died after four hours of exposure to malathion 0.5% in isopropanol than after 30 minutes of exposure to the US product (42 versus 96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mutation in the louse kdr allele that results in decreased sensitivity of neuronal voltage gated sodium channels has been proposed as the primary mechanism for pyrethroid resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/42\">",
"     42",
"    </a>",
"    ]. However, this theory is brought into question by a study that found a poor correlation between mutations in kdr and treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/43\">",
"     43",
"    </a>",
"    ]. Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    occurs via increased production of enzymes that metabolize malathion and decreased sensitivity of neuronal acetylcholinesterase to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/18\">",
"     18",
"    </a>",
"    ]. Other pathways for resistance may also be involved. The mechanism of action of benzyl alcohol (louse asphyxiation) may make this agent less susceptible to the development of resistance than the topical neurotoxic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pediculicide selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in the prevalence of resistance to topical pediculicides makes it difficult to uniformly recommend one agent over another. Several direct comparisons of agents have been published, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 United States randomized trial, both a gel and lotion formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       malathion",
"      </a>",
"      0.5% with terpineol were superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      1% for the treatment of pediculosis capitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2002 in vitro study in the United States reported that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       malathion",
"      </a>",
"      0.5% with terpineol was superior to pyrethroids, and that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       lindane",
"      </a>",
"      was least effective [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/21\">",
"       21",
"      </a>",
"      ]. Among the pyrethroids, a product containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"       pyrethrin",
"      </a>",
"      , piperonyl butoxide, and benzyl alcohol was the most effective, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      1%, and pyrethrin with piperonyl butoxide.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"       Spinosad",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      1% in two phase three manufacturer-sponsored randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Spinosad'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benzyl alcohol and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    have not been compared to other agents, but appear to be effective for the majority of patients.",
"   </p>",
"   <p>",
"    In addition to efficacy, several factors may affect the selection of a pediculicide.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ease of administration and risks:",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       Malathion",
"      </a>",
"      requires longer application times, is malodorous, and is more expensive than pyrethroids. In addition, the drug has the potential for flammability and may cause respiratory depression if ingested. Unlike malathion, benzyl alcohol has a mildly pleasant odor.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       Lindane",
"      </a>",
"      is a less favorable choice due to a risk for neurologic side effects and its relatively poor efficacy.",
"     </li>",
"     <li>",
"      <strong>",
"       Drug cost:",
"      </strong>",
"      The high cost of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"       spinosad",
"      </a>",
"      and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      , the most expensive topical pediculicide agents, may be prohibitive for some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/32,45\">",
"       32,45",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       Permethrin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"       pyrethrins",
"      </a>",
"      are the least expensive topical agents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pyrethroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    , benzyl alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     spinosad",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    are all reasonable choices for therapy. The decision of which drug to use as a first-line agent should be based upon knowledge of local resistance patterns, drug adverse effects, and individual patient tolerability. The evidence for superior efficacy has prompted some authors to recommend malathion over pyrethroids for pediculosis capitis in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/18,25,44\">",
"     18,25,44",
"    </a>",
"    ]. In 2010, a panel of experts from the American Academy of Pediatrics recommended that in areas where resistance to pyrethroids has been documented, or in patients who have failed to respond to appropriately administered treatment with a pyrethroid, malathion 0.5% can be used in children over the age of two years, and benzyl alcohol 5% can be used in children over the age of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/46\">",
"     46",
"    </a>",
"    ]. Spinosad and topical ivermectin were not commercially available at the time these recommendations were published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    is not recommended for children under the age of two months, and benzyl alcohol and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    are not recommended for children under six months of age.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     Spinosad",
"    </a>",
"    is intended for use in patients ages four and older; the safety of this agent in younger children has not been established.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     Malathion",
"    </a>",
"    is contraindicated in children under the age of two. Although studies of the safety of malathion (an organophosphate cholinesterase inhibitor) in children under the age of six are limited, one randomized trial involving topical malathion therapy found no evidence of systemic acetylcholinesterase inhibition in children as young as two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, no cases of injury related to malathion flammability, and only a few cases of ingestion have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wet-combing is an alternative therapy for young children. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Wet combing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Wet combing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children or others in whom avoidance of topical pediculicides is preferred, mechanical removal of lice by wet combing is an alternative therapy.",
"   </p>",
"   <p>",
"    Combing is performed with a fine toothed comb; the hair should be wet, with an added lubricant such as hair conditioner, vinegar, or olive oil. The combing technique is the same as in the procedure used for the diagnosis of louse infestation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Combing is done until no lice are found in each session, with repeat sessions every three to four days for several weeks, continuing for two weeks after any session in which a large, adult louse is found [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"     2",
"    </a>",
"    ]. The procedure may take 15 to 30 minutes. Longer sessions may be required for patients with thick, long hair.",
"   </p>",
"   <p>",
"    The relative effectiveness of wet combing and medical therapy is uncertain. In one study in the UK, it was only half as effective as treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    (cure in 38 versus 78 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/47\">",
"     47",
"    </a>",
"    ]. Another UK study found that wet combing was much more effective than a single treatment with either malathion or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    (cure in 57 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/48\">",
"     48",
"    </a>",
"    ]. However, there were significant methodologic issues with this latter study including unblinded allocation of patients, the use of an inadequate regimen of pediculicide, and different lengths of follow-up in the two arms of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that over the counter nit removers or nit looseners hasten resolution when combined with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/2,20\">",
"     2,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Oral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy is generally reserved for patients who fail treatment with topical pediculicides.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Oral ivermectin is an alternative treatment for pediculosis capitis that is resistant to topical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/50-53\">",
"       50-53",
"      </a>",
"      ]. Ivermectin interferes with neurotransmission in arthropods and helminths, leading to paralysis and death.",
"      <br/>",
"      <br/>",
"      In a randomized, double-blind trial (n = 812), patients who failed home therapy with a pyrethroid or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       malathion",
"      </a>",
"      were treated with either malathion 0.5% lotion applied by study staff or oral ivermectin (400",
"      <span class=\"nowrap\">",
"       &micro;g/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/52\">",
"       52",
"      </a>",
"      ]. Participants in both groups were given two treatments separated by one week. Ivermectin therapy was associated with a significantly higher rate of eradication of head lice; 95 versus 85 percent of subjects were cured of infestation. The incidence of adverse effects was similar in both groups.",
"      <br/>",
"      <br/>",
"      Lower doses of ivermectin (200",
"      <span class=\"nowrap\">",
"       &micro;g/kg)",
"      </span>",
"      are used more commonly and also appear to be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/53-58\">",
"       53-58",
"      </a>",
"      ]. In a randomized trial of 80 children with pediculosis capitis, treatment with ivermectin (200",
"      <span class=\"nowrap\">",
"       &micro;g/kg)",
"      </span>",
"      was compared to malathion 0.5% lotion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/58\">",
"       58",
"      </a>",
"      ]. Patients were given a single treatment of ivermectin or malathion, which was followed by a second treatment on day eight if live lice were detected. Ivermectin and malathion were similarly effective; by day 15, 92.5% and 95% of patients, respectively, were cured.",
"      <br/>",
"      <br/>",
"      Ivermectin generally is well tolerated, and most serious adverse effects have occurred during treatment for severe microfilarial infections [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Ivermectin is not recommended for pregnant women or children weighing less than 15 kg, since safety has not been established in these populations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link&amp;anchor=H2#H2\">",
"       \"Anthelminthic therapies\", section on 'Ivermectin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Combination therapy with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      -sulfamethoxazole may be more effective than treatment with permethrin alone. The mechanism of action of trimethoprim-sulfamethoxazole may involve the death of symbiotic bacteria in the louse gut that produce B vitamins necessary for louse survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The combination of topical permethrin (1%, applied for ten minutes with a repeat application after one week if necessary) plus oral trimethoprim-sulfamethoxazole (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day trimethoprim in two divided doses for ten days) was compared to either drug alone in a randomized trial of 115 children [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/61\">",
"       61",
"      </a>",
"      ]. Compared with topical permethrin alone, dual therapy was associated with a higher rate of success at four weeks (93 versus 72 percent). Although rare, potential adverse effects of trimethoprim-sulfamethoxazole include Stevens-Johnson syndrome, neutropenia, hemolysis, and renal impairment. The authors of the study concluded that dual therapy should be reserved for resistant cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Physical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of a lotion that is applied to the head and then dried, with a goal of suffocating lice, reported a 96 percent cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/62\">",
"     62",
"    </a>",
"    ]; the author later reported that the lotion used in the study was Cetaphil&reg; cleanser (a synthetic detergent cleanser) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/63\">",
"     63",
"    </a>",
"    ]. The study had significant flaws including lack of a control group, lack of blinding, and potentially inappropriate diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/64\">",
"     64",
"    </a>",
"    ]. Further studies are needed before this approach can be recommended.",
"   </p>",
"   <p>",
"    A silicone-based material, dimethicone, is believed to work by coating lice and disrupting their ability to manage water. A single blind equivalence trial compared dimethicone 4 percent, applied for eight hours or overnight, with the pediculicide phenothrin 0.5 percent in 214 children and 39 adults with head lice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/65\">",
"     65",
"    </a>",
"    ]. Each treatment was applied twice, seven days apart, and cure rates were similar in the two groups (70 and 75 percent, respectively).",
"   </p>",
"   <p>",
"    Oily home products (eg, olive oil, butter, petroleum jelly) are sometimes used in the hopes of suffocating lice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/66\">",
"     66",
"    </a>",
"    ]. Lice are difficult to suffocate, and a small study of such products concluded they are not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Shaving hair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shaving hair has been anecdotally reported as a method of eradicating head louse infestation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/67\">",
"     67",
"    </a>",
"    ]. However, studies evaluating this method of treatment have not been performed, and the procedure may be psychologically distressing for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comb that uses an electric current generated by a AA battery to electrocute lice is marketed for the treatment of head lice. Although there are anecdotal reports of successful treatment with the device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/68\">",
"     68",
"    </a>",
"    ], we do not know of any published clinical trials demonstrating efficacy.",
"   </p>",
"   <p>",
"    An unblinded study reported louse eradication with high volume heated air blown at the scalp for 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/69\">",
"     69",
"    </a>",
"    ]. Few patients overall received the high volume heated air treatments, and patients younger than age six were excluded. While awaiting the results of larger controlled trials that compare methods of delivering heat and assess cure, safety, training, and costs, such treatments cannot be recommended outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of treatment failure are lack of compliance and continued contact with others infested and untreated, although resistance of head lice to topical treatments of one kind or another is becoming a troublesome problem in some geographic areas. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pediculicide resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RETURN TO SCHOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many school districts have rules that forbid the return to school of even adequately treated children with nits in place [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/19\">",
"     19",
"    </a>",
"    ]. It is estimated that children in the United States lost 12 to 24 million days of school in 1998 because of no-nit policies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lice have frequently been present for weeks prior to detection. Furthermore, the majority of children with nits do not develop active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, children should not be excluded from school based upon the presence of live lice or nits [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/46\">",
"     46",
"    </a>",
"    ]. Affected children should be treated promptly with a topical pediculicide or wet combing session.",
"   </p>",
"   <p>",
"    Control of outbreaks in schools may be facilitated by examination of teachers and pupils who may have had close head-to-head contact with an affected child, and by assigning students individual wall hooks or lockers for storing caps and coats [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     HOUSEHOLD RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Household members should be examined and treated if infested; bedmates should be treated prophylactically.",
"   </p>",
"   <p>",
"    Louse survival off the scalp beyond 48 hours is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/19\">",
"     19",
"    </a>",
"    ]. It is reasonable to recommend washing clothing and linen used by the infested person during the two days prior to therapy in hot water",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drying the items on a high-heat dryer cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/19\">",
"     19",
"    </a>",
"    ]. Temperatures should reach at least 130&ordm;F. Items that cannot be washed may be dry cleaned or stored in a sealed plastic bag for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/1\">",
"     1",
"    </a>",
"    ]. Vacuuming of furniture and carpeting on which the infested person sat or laid down has also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25849/abstract/8\">",
"     8",
"    </a>",
"    ]. Spraying the home with a pediculicide is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/5/43089?source=see_link\">",
"       \"Patient information: Lice (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/44/16065?source=see_link\">",
"       \"Patient information: Head lice (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=see_link\">",
"       \"Patient information: Pubic lice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediculosis capitis (head lice) is a scalp infestation that most frequently occurs in children. Affected individuals may be asymptomatic or may complain of scalp",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neck pruritus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediculosis capitis is diagnosed through visual examination. In cases of active infestation, louse eggs (nits) are found on hair shafts and crawling nymphs and adult lice are present. Wet-combing is a useful technique for locating adult lice or nymphs. The presence of nits alone does",
"      <strong>",
"       not",
"      </strong>",
"      confirm active infestation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several topical pediculicides are available for the treatment of pediculosis capitis. Resistance to topical agents that kill lice via neurotoxic mechanisms has been increasingly reported and varies geographically. The selection of a topical agent should be based upon local resistance patterns, drug adverse effects, and patient tolerability. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"       lindane",
"      </a>",
"      should be restricted due to the potential for neurologic side effects and the drug's relatively low efficacy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Topical pediculicides'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Choosing a pediculicide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-line treatment options for pediculosis capitis include pyrethroids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       malathion",
"      </a>",
"      , benzyl alcohol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"       spinosad",
"      </a>",
"      , and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      . The safety, low cost, and easy availability of pyrethroids have led to the widespread use of these drugs as initial agents. In areas in which pyrethroid resistance is significant, or in patients who have tried and failed pyrethroid therapy, we suggest treatment with 0.5% malathion with terpineol (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Benzyl alcohol, spinosad, and topical ivermectin are effective alternative therapies. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Choosing a pediculicide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment failure may occur secondary to lack of compliance with the treatment regimen or reinfestation. Clinicians should consider these factors, in addition to the possibility of resistance, when evaluating patients with an apparent lack of response to therapy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with pediculosis capitis do not need to be excluded from school. Household members and close contacts should be examined for infestation. Individuals who share bedding with the affected person should be treated prophylactically. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Return to school'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Household recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/1\">",
"      Ko CJ, Elston DM. Pediculosis. J Am Acad Dermatol 2004; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/2\">",
"      Roberts RJ. Clinical practice. Head lice. N Engl J Med 2002; 346:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/3\">",
"      Price JH, Burkhart CN, Burkhart CG, Islam R. School nurses' perceptions of and experiences with head lice. J Sch Health 1999; 69:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/4\">",
"      A modern scourge: parents scratch their heads over lice. Consum Rep 1998; 63:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/5\">",
"      Counahan M, Andrews R, B&uuml;ttner P, et al. Head lice prevalence in primary schools in Victoria, Australia. J Paediatr Child Health 2004; 40:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/6\">",
"      Suleman M, Fatima T. Epidemiology of head lice infestation in school children at Peshawar, Pakistan. J Trop Med Hyg 1988; 91:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/7\">",
"      Downs AM, Stafford KA, Coles GC. Head lice: prevalence in schoolchildren and insecticide resistance. Parasitol Today 1999; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     Head lice. Centers for Disease Control and Prevention. www.cdc.gov/lice/head/index.html. (Accessed on January 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/9\">",
"      Willems S, Lapeere H, Haedens N, et al. The importance of socio-economic status and individual characteristics on the prevalence of head lice in schoolchildren. Eur J Dermatol 2005; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/10\">",
"      Burkhart CN, Burkhart CG. Fomite transmission in head lice. J Am Acad Dermatol 2007; 56:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/11\">",
"      Chunge RN, Scott FE, Underwood JE, Zavarella KJ. A pilot study to investigate transmission of headlice. Can J Public Health 1991; 82:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/12\">",
"      Maunder JW. An update on headlice. Health Visit 1993; 66:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/13\">",
"      Jahnke C, Bauer E, Hengge UR, Feldmeier H. Accuracy of diagnosis of pediculosis capitis: visual inspection vs wet combing. Arch Dermatol 2009; 145:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/14\">",
"      Mumcuoglu KY, Friger M, Ioffe-Uspensky I, et al. Louse comb versus direct visual examination for the diagnosis of head louse infestations. Pediatr Dermatol 2001; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/15\">",
"      Williams LK, Reichert A, MacKenzie WR, et al. Lice, nits, and school policy. Pediatrics 2001; 107:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/16\">",
"      Dodd CS. Interventions for treating headlice. Cochrane Database Syst Rev 2001; :CD001165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/17\">",
"      Burkhart CG, Burkhart CN, Burkhart KM. An assessment of topical and oral prescription and over-the-counter treatments for head lice. J Am Acad Dermatol 1998; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/18\">",
"      Lebwohl M, Clark L, Levitt J. Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics 2007; 119:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/19\">",
"      Frankowski BL, Weiner LB, Committee on School Health the Committee on Infectious Diseases. American Academy of Pediatrics. Head lice. Pediatrics 2002; 110:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/20\">",
"      Meinking TL, Clineschmidt CM, Chen C, et al. An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice. J Pediatr 2002; 141:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/21\">",
"      Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol 2002; 138:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/22\">",
"      Malathion for treatment of head lice. Med Lett Drugs Ther 1999; 41:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/23\">",
"      Frankowski BL. American Academy of Pediatrics guidelines for the prevention and treatment of head lice infestation. Am J Manag Care 2004; 10:S269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/24\">",
"      Takano-Lee M, Edman JD, Mullens BA, Clark JM. Home remedies to control head lice: assessment of home remedies to control the human head louse, Pediculus humanus capitis (Anoplura: Pediculidae). J Pediatr Nurs 2004; 19:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/25\">",
"      Meinking TL, Vicaria M, Eyerdam DH, et al. Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix creme rinse (1% permethrin) for the treatment of head lice. Pediatr Dermatol 2004; 21:670.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA drug label. www.accessdata.fda.gov/drugsatfda_docs/label/2009/022129lbl.pdf. (Accessed on March 25, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/27\">",
"      Meinking TL, Villar ME, Vicaria M, et al. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol 2010; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration public health advisory on lindane. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110845.htm (Accessed on October 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/29\">",
"      Humphreys EH, Janssen S, Heil A, et al. Outcomes of the California ban on pharmaceutical lindane: clinical and ecologic impacts. Environ Health Perspect 2008; 116:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/30\">",
"      McCormack PL. Spinosad: in pediculosis capitis. Am J Clin Dermatol 2011; 12:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/31\">",
"      Stough D, Shellabarger S, Quiring J, Gabrielsen AA Jr. Efficacy and safety of spinosad and permethrin creme rinses for pediculosis capitis (head lice). Pediatrics 2009; 124:e389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/32\">",
"      Ivermectin (Sklice) topical lotion for head lice. Med Lett Drugs Ther 2012; 54:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/33\">",
"      Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med 2012; 367:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/34\">",
"      Burkhart CG. Relationship of treatment-resistant head lice to the safety and efficacy of pediculicides. Mayo Clin Proc 2004; 79:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/35\">",
"      Yoon KS, Gao JR, Lee SH, et al. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol 2003; 139:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/36\">",
"      Hunter JA, Barker SC. Susceptibility of head lice (Pediculus humanus capitis) to pediculicides in Australia. Parasitol Res 2003; 90:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/37\">",
"      Kasai S, Ishii N, Natsuaki M, et al. Prevalence of kdr-like mutations associated with pyrethroid resistance in human head louse populations in Japan. J Med Entomol 2009; 46:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/38\">",
"      Durand R, Millard B, Bouges-Michel C, et al. Detection of pyrethroid resistance gene in head lice in schoolchildren from Bobigny, France. J Med Entomol 2007; 44:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/39\">",
"      Downs AM, Stafford KA, Hunt LP, et al. Widespread insecticide resistance in head lice to the over-the-counter pediculocides in England, and the emergence of carbaryl resistance. Br J Dermatol 2002; 146:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/40\">",
"      Pollack RJ, Kiszewski A, Armstrong P, et al. Differential permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med 1999; 153:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/41\">",
"      Downs AM, Narayan S, Stafford KA, Coles GC. Effectiveness of ovide against malathion-resistant head lice. Arch Dermatol 2005; 141:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/42\">",
"      Soderlund DM. Pyrethroids, knockdown resistance and sodium channels. Pest Manag Sci 2008; 64:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/43\">",
"      Bialek R, Zelck UE, F&ouml;lster-Holst R. Permethrin treatment of head lice with knockdown resistance-like gene. N Engl J Med 2011; 364:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/44\">",
"      Meinking TL, Vicaria M, Eyerdam DH, et al. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Cr&egrave;me Rinse (1% permethrin) used as labeled, for the treatment of head lice. Pediatr Dermatol 2007; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/45\">",
"      Spinosad (Natroba) topical suspension for head lice. Med Lett Drugs Ther 2011; 53:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/46\">",
"      Frankowski BL, Bocchini JA Jr, Council on School Health and Committee on Infectious Diseases. Head lice. Pediatrics 2010; 126:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/47\">",
"      Roberts RJ, Casey D, Morgan DA, Petrovic M. Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial. Lancet 2000; 356:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/48\">",
"      Hill N, Moor G, Cameron MM, et al. Single blind, randomised, comparative study of the Bug Buster kit and over the counter pediculicide treatments against head lice in the United Kingdom. BMJ 2005; 331:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/49\">",
"      Dawes M. Combing and combating head lice. BMJ 2005; 331:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/50\">",
"      Burkhart CN, Burkhart CG. Another look at ivermectin in the treatment of scabies and head lice. Int J Dermatol 1999; 38:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/51\">",
"      Drugs for parasitic infections. Med Lett Drugs Ther 1995; 37:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/52\">",
"      Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 2010; 362:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/53\">",
"      Ameen M, Arenas R, Villanueva-Reyes J, et al. Oral ivermectin for treatment of pediculosis capitis. Pediatr Infect Dis J 2010; 29:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/54\">",
"      Currie MJ, Reynolds GJ, Glasgow NJ, Bowden FJ. A pilot study of the use of oral ivermectin to treat head lice in primary school students in Australia. Pediatr Dermatol 2010; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/55\">",
"      Pilger D, Heukelbach J, Khakban A, et al. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull World Health Organ 2010; 88:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/56\">",
"      Glaziou P, Nyguyen LN, Moulia-Pelat JP, et al. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994; 45:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/57\">",
"      Burkhart CG, Burkhart CN. Head lice therapies revisited. Dermatol Online J 2006; 12:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/58\">",
"      Nofal A. Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. J Dtsch Dermatol Ges 2010; 8:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/59\">",
"      Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003; 2 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/60\">",
"      Gardon J, Gardon-Wendel N, Kamgno J, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/61\">",
"      Hipolito RB, Mallorca FG, Zuniga-Macaraig ZO, et al. Head lice infestation: single drug versus combination therapy with one percent permethrin and trimethoprim/sulfamethoxazole. Pediatrics 2001; 107:E30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/62\">",
"      Pearlman DL. A simple treatment for head lice: dry-on, suffocation-based pediculicide. Pediatrics 2004; 114:e275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/63\">",
"      Pearlman D. Cetaphil cleanser (Nuvo lotion) cures head lice. Pediatrics 2005; 116:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/64\">",
"      Roberts RJ, Burgess IF. New head-lice treatments: hope or hype? Lancet 2005; 365:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/65\">",
"      Burgess IF, Brown CM, Lee PN. Treatment of head louse infestation with 4% dimeticone lotion: randomised controlled equivalence trial. BMJ 2005; 330:1423.",
"     </a>",
"    </li>",
"    <li>",
"     www.hsph.harvard.edu/headlice.html (Accessed on July 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/67\">",
"      Lwegaba A. Shaving can be safer head lice treatment than insecticides. BMJ 2005; 330:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/68\">",
"      Resnik KS. A non-chemical therapeutic modality for head lice. J Am Acad Dermatol 2005; 52:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25849/abstract/69\">",
"      Goates BM, Atkin JS, Wilding KG, et al. An effective nonchemical treatment for head lice: a lot of hot air. Pediatrics 2006; 118:1962.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4035 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25849=[""].join("\n");
var outline_f25_15_25849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Topical pediculicides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pyrethroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Malathion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Benzyl alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lindane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lindane toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Spinosad",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2579574\">",
"      - Topical ivermectin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Choosing a pediculicide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pediculicide resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pediculicide selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Wet combing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Oral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Physical agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Shaving hair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RETURN TO SCHOOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      HOUSEHOLD RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4035|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/8/4226\" title=\"figure 1\">",
"      Types of lice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4035|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/18/42274\" title=\"picture 1\">",
"      Pediculosis capitis louse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/27/22965\" title=\"picture 2A\">",
"      Head lice nits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/3/38961\" title=\"picture 2B\">",
"      Microscopic view head louse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/26/34212\" title=\"picture 2C\">",
"      Pediculosis capitis nits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/29/26078\" title=\"picture 3\">",
"      Microscopy pediculosis nit1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/47/6904\" title=\"picture 4\">",
"      White piedra",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=related_link\">",
"      Infections due to Trichosporon species and Blastoschizomyces capitatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=related_link\">",
"      Lindane: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/44/16065?source=related_link\">",
"      Patient information: Head lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/5/43089?source=related_link\">",
"      Patient information: Lice (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=related_link\">",
"      Patient information: Pubic lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=related_link\">",
"      Pediculosis corporis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1511?source=related_link\">",
"      Pediculosis pubis and pediculosis ciliaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25850="IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked";
var content_f25_15_25850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Melinda Braskett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Talal Chatila, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25850/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/15/25850/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/15/25850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term IPEX is an acronym for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunodysregulation",
"     </li>",
"     <li>",
"      Polyendocrinopathy",
"     </li>",
"     <li>",
"      Enteropathy",
"     </li>",
"     <li>",
"      X-linked",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IPEX is a rare, often fatal X-linked immune dysregulatory disorder that typically presents during infancy with a triad of enteropathy, autoimmune endocrinopathy, and dermatitis (MIM 304790). The pathogenesis, epidemiology, clinical manifestations, diagnosis, and management of IPEX will be discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defining feature of IPEX is immune dysregulation resulting in autoimmune disease and allergic inflammation.",
"   </p>",
"   <p>",
"    IPEX is caused by mutations in the gene for the transcription factor Foxp3 (FOXP3). Foxp3 is a member of the forkhead box P (FOXP) family of transcription factors, and is fundamental to the function of a subset of T lymphocytes known as regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/1\">",
"     1",
"    </a>",
"    ]. Regulatory T cells (Treg) exhibit potent immune suppressive effects, and thereby play a fundamental role in immune homeostasis, particularly with respect to tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to modulating autoimmune and allergic inflammation, Treg cells also appear to be involved in transplantation tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenotype of IPEX was first described in 1982, and the first genetic mutations in FOXP3 were identified in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. IPEX was previously designated X-linked polyendocrinopathy, immune dysfunction, and diarrhea (XPID), and X-linked autoimmunity and allergic dysregulation (XLAAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. Patients who present with a similar phenotype but without mutations in FOXP3 are described as \"IPEX-like.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview of T regulatory cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suppressive actions of Treg cells govern autoimmunity and atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. CD4+ Treg cells comprise 5 to 10 percent of the CD4+ T cell population and include natural Treg cells, derived from the thymus, and adaptive or induced Treg cells from the peripheral lymphoid tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1232172#H1232172\">",
"     \"Normal B and T lymphocyte development\", section on 'Regulatory T cells (Tregs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique subsets of Treg cells appear to utilize different functional mechanisms, including cell contact-mediated cytotoxicity, competitive sequestration of IL-2, and cytokine-mediated inhibition via IL-10 or TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Recent investigations using a mouse model suggest that FOXP3+ Treg cells may also modulate autoreactive B cell populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expansion of Treg cells appears to be a natural consequence of the human immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. However, in vitro, Treg cells are anergic and proliferate poorly. Treg cells require IL-2 to survive and exert their suppressive functions. However, they do not produce IL-2, and therefore they are dependent upon its production by other types of CD4+ T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1232172#H1232172\">",
"     \"Normal B and T lymphocyte development\", section on 'Regulatory T cells (Tregs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Normal function of Foxp3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foxp3 is a member of the forkhead box P (FOXP) family of transcription factors. The gene is located on chromosome Xp11.23. It encodes a 431 amino acid protein with multiple, well described functional domains (",
"    <a class=\"graphic graphic_figure graphicRef66800 \" href=\"UTD.htm?22/20/22862\">",
"     figure 1",
"    </a>",
"    ). In addition to the forkhead DNA-binding domain that interacts with the IL-2 promoter and other target genes, Foxp3 also contains an N-terminal proline-rich domain, which regulates transcription. A zinc finger motif may be involved in protein-DNA interactions, while a leucine zipper domain mediates homo- and heterodimerization with Foxp3 and other FOXP transcription factors. CpG methylation and other epigenetic changes appear to be important in Foxp3 isoform expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/19\">",
"     19",
"    </a>",
"    ]. A general discussion of transcription factors is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link&amp;anchor=H7#H7\">",
"     \"Principles of molecular genetics\", section on 'RNA transcription'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is overwhelming evidence that Foxp3 plays a fundamental role in the differentiation of CD4+ Treg cells and that high levels of Foxp3 expression are directly linked to the suppressive capacity of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/20\">",
"     20",
"    </a>",
"    ]. However, in vitro overexpression of human FOXP3 in conventional T cells is not sufficient to induce potent immune suppression, indicating that other factors (in addition to FOXP3 expression) are required to optimize suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mutations in FOXP3",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPEX is due to loss of function mutations in FOXP3. These mutations result in quantitative or functional deficiencies of Treg cells, and thereby cause autoimmune disease and allergic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/5-7,23-25\">",
"     5-7,23-25",
"    </a>",
"    ]. A large number of mutations have been described, many of which are familial, although sporadic cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Except for the zinc finger motif, disease-causing mutations have been described in each of the main coding regions, demonstrating that each functional domain is essential to the normal function of FOXP3 (",
"    <a class=\"graphic graphic_figure graphicRef66800 \" href=\"UTD.htm?22/20/22862\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/30\">",
"     30",
"    </a>",
"    ]. Equally important are mutations in non-coding regions, which can also cause IPEX. However, at present, there is no clear genotype-phenotype correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,25,28,31-33\">",
"     8,25,28,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mouse model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A naturally occurring mutation of the FOXP3 gene in mice causes the fatal autoimmune and inflammatory disorder called Scurfy. This X-linked recessive lymphoproliferative disease has many of the clinical and molecular features of IPEX in humans. Scurfy is characterized by multiorgan lymphocytic infiltration and cytokine dysregulation due to unregulated T cell activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Scurfy mice, a frameshift mutation omits the forkhead domain of the gene product, and demonstrates that a fully functional protein is essential for immune homeostasis. The phenotype can also be induced in knock out models and via hypomorphic mutations in FOXP3 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/11,21,35\">",
"     11,21,35",
"    </a>",
"    ]. As the physical manifestations of Scurfy are due to the lack of functional Treg cells, the phenotype of these mice can be reversed by bone marrow reconstitution, adoptive transfer of an enriched CD25+ T cell population, or the introduction of a FOXP3 transgene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPEX is a rare, X-linked disorder that classically presents in infancy. Published reports of patients with IPEX are limited and therefore the prevalence and incidence are unknown. Moreover, retrospective analysis suggests many cases may have been underreported or misdiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,38,39\">",
"     8,38,39",
"    </a>",
"    ]. A retrospective study of the incidence of neonatal diabetes in Australia identified 1 case of IPEX in 10 cases of neonatal diabetes contained in the national registry data from 1989 to 2007, and thus, these data provide an estimate of the incidence of IPEX at",
"    <span class=\"nowrap\">",
"     1/1,609,490",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/40\">",
"     40",
"    </a>",
"    ]. Most patients present in early infancy, although ameliorated phenotypes may present later in life. The literature contains a report of a patient diagnosed at 24 years of age, however, the age at onset of symptoms was not specified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family history may or may not be present, as mutations may be familial or sporadic. A history of infantile demise in maternal male relatives is suggestive of an X-linked disease process such as IPEX.",
"   </p>",
"   <p>",
"    In multiple large familial cohorts with varying mutations in FOXP3, female carriers do not appear to be at increased risk for autoimmune, allergic, or oncologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/6,27,33,41\">",
"     6,27,33,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of IPEX is a male infant with the following triad of disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Life-threatening chronic diarrhea due to an autoimmune enteropathy",
"     </li>",
"     <li>",
"      Autoimmune endocrinopathy (neonatal type 1 diabetes or thyroiditis)",
"     </li>",
"     <li>",
"      Dermatitis, usually eczematous",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most affected children have failure to thrive. Additionally, patients with IPEX may have immune-mediated cytopenias, severe food allergies, nephritis, and exaggerated responses to infections (",
"    <a class=\"graphic graphic_table graphicRef65512 \" href=\"UTD.htm?8/3/8251\">",
"     table 1",
"    </a>",
"    ). These conditions are variable among patients, and ameliorated phenotypes have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluctuations in disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute exacerbations of autoimmunity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic inflammation are referred to as \"disease flares,\" and may be triggered by infections, vaccinations, or dietary allergens. In this respect, patients with IPEX are similar to those with systemic lupus erythematosus or other autoimmune diseases. The signs and symptoms that comprise a disease flare can vary among different patients, and may vary from episode to episode for a given patient. Typical manifestations of disease flares include acute worsening of chronic diarrhea, exacerbations or new manifestations of dermatitis, cytopenias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory hyperglycemia in the setting of diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immune dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of IPEX are due to immune dysregulation leading to autoimmune disease and allergic inflammation. Tissue from patients with enteropathies and endocrinopathies are characterized by lymphocytic infiltrates with or without associated autoantibodies. Allergic inflammation manifests as eczema, food allergies, eosinophilia, and elevated total and antigen specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic and autoimmune disease processes may interact. As an example, both the characteristic enteropathy and dermatitis may have concurrent active autoimmune and allergic features. Additionally, exposure to known food allergens may cause a flare of enteropathy, endocrinopathy or dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common presentation of IPEX in infancy is chronic intractable diarrhea with failure to thrive. In addition to the characteristic autoimmune enteropathy, IPEX patients may have multiple gastrointestinal manifestations of autoimmune",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic inflammation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IPEX typically presents with severe watery diarrhea that can be mucoid or bloody. This diarrhea frequently worsens if the affected infant is switched from breast-feeding to formula, and may improve with dietary modification.",
"     </li>",
"     <li>",
"      Metabolic derangements can result from profound dehydration and malabsorption, including hypernatremic dehydration, metabolic acidosis, renal insufficiency, weight loss, and failure to thrive. Protein losing enteropathy may also be present [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"       \"Overview of the causes of chronic diarrhea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=see_link\">",
"       \"Neonatal hyperglycemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link&amp;anchor=H17#H17\">",
"       \"Approach to the child with metabolic acidosis\", section on 'Newborns and infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Grossly, the bowel may demonstrate loss of the normal architecture, ulcerations, and hyperemic mucosa. The small bowel is typically most significantly affected, although the colon may demonstrate similar findings. Biopsy findings in IPEX and other autoimmune enteropathies vary and include villous atrophy, crypt hyperplasia or abscesses, and an extensive mixed cellular infiltrate, notably lymphocytic infiltrates of the bowel mucosa (",
"      <a class=\"graphic graphic_picture graphicRef54190 \" href=\"UTD.htm?9/28/9669\">",
"       picture 1",
"      </a>",
"      ). These lesions are not specific for IPEX, and resemble those in other immune mediated enteropathies, such as graft versus host, celiac disease, and other autoimmune enteropathies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe food allergies are common. These are typically associated with antigen specific IgE, although non-IgE mediated conditions, similar to food protein induced enterocolitis syndrome (FPIES) have also been described. IPEX patients may develop increased diarrhea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dermatitis, as well as other manifestations of disease flare following ingestion of dietary allergens. Typical manifestations of IgE mediated food allergy, such as acute urticaria, vomiting, or anaphylaxis, may also occur.",
"     </li>",
"     <li>",
"      Autoimmune hepatitis is frequently seen in conjunction with autoimmune enteropathy, although the hepatosplenomegaly characteristic of mouse models is rarely present in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset autoimmune endocrinopathies, typically diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thyroiditis, are hallmark features of IPEX. IPEX is a leading cause of permanent neonatal diabetes due to autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/40,43-46\">",
"     40,43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 diabetes is most common and onset is generally during the first year of life; hyperglycemia may be present at birth. Disease progression results in the complete immune-mediated destruction of islet cells; these patients may or may not have detectable anti-islet cell antibodies in addition to lymphocytic infiltration of the pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,47\">",
"       8,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thyroiditis may result in either hypo- or hyperthyroidism, although hypothyroidism with elevated anti-thyroid antibodies is most common [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,29\">",
"       8,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other immune endocrinopathies are uncommon; however, atypical findings of growth hormone deficiency and hypoadrenalism have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third component of the IPEX triad is dermatitis, which typically consists of an eczematous rash (ie, atopic dermatitis) that ranges from mild to severe (",
"    <a class=\"graphic graphic_picture graphicRef78215 \" href=\"UTD.htm?12/47/13055\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The presence of atopic dermatitis correlates with elevated titers of serum IgE and peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/49\">",
"     49",
"    </a>",
"    ]. The rash typically appears in early infancy, and its appearance may be concurrent with the onset of clinical manifestations of enteropathy and endocrinopathy.",
"   </p>",
"   <p>",
"    Other skin findings may include diffuse erythema, alopecia universalis, psoriasiform rashes, painful fissurary cheilitis, and pemphigoid nodularis; most are characterized by lymphocytic infiltrates that may respond to treatment with topical steroids or other immunomodulators [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29,49-51\">",
"     29,49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;About half of the patients demonstrate evidence of immune-mediated cytopenias, and patients frequently have associated autoantibodies. Coombs positive hemolytic anemia, autoimmune thrombocytopenia, and autoimmune neutropenia are most common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancies are not generally reported. However, EBV-induced lymphoma was recently described in an IPEX patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased susceptibility and exaggerated responses to infections have been observed in IPEX patients since the original report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/2\">",
"     2",
"    </a>",
"    ]. Over half of a 50 patient cohort had significant infections, including sepsis, meningitis, pneumonia, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29\">",
"     29",
"    </a>",
"    ]. The most commonly reported pathogens are Enterococcal and Staphylococcal species, Cytomegalovirus, and Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to the vulnerability of IPEX patients to infection, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compromised barrier functions of the skin and gut",
"     </li>",
"     <li>",
"      Indwelling catheters",
"     </li>",
"     <li>",
"      Immunosuppressive therapy",
"     </li>",
"     <li>",
"      Autoimmune neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In several patients, infection occurred prior to commencing immunosuppressive agents, and patients may experience fewer infections when disease control is obtained with appropriate immune suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29,54\">",
"     29,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections can also trigger flares of autoimmunity, even if the infection is relatively minor. As with patients with systemic lupus erythematosus and other autoimmune diseases, infections can mimic disease flares in patients with IPEX and thereby cause a diagnostic dilemma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This complexity may confound decisions regarding the appropriate diagnosis and management. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Management of acute medical events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease is reported in up to one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29,57-59\">",
"     29,57-59",
"    </a>",
"    ]. Interstitial nephritis is the most frequent disorder, and other findings range from mild hematuria and proteinuria to rapidly progressive glomerulonephritis. Renal disease may also be worsened",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induced by treatment with calcineurin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H38\">",
"     'Immune suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neurologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental delay is common and may be a sequela of chronic failure to thrive since infancy. Seizures are also reported in some patients, usually associated with metabolic derangements resulting from severe diarrhea or diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection-related pulmonary disease is well described in IPEX patients. Viral and other pneumonias are reported, and Pneumocystis carinii may follow the initiation of immune suppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/54,60\">",
"     54,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, primary lung involvement in IPEX patients remains poorly characterized, although interstitial lung disease has been observed anecdotally in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, there is a report of a child with IPEX and allergic bronchopulmonary aspergillosis (ABPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/62\">",
"     62",
"    </a>",
"    ]. Primary lung disease is a feature of the murine model, and is characterized by both perivascular and interstitial lymphocytic and mixed inflammatory cell infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, these findings have not been validated in studies of patients with IPEX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPEX should be considered in any male infant presenting with chronic intractable diarrhea with failure to thrive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infantile onset of type 1 diabetes. The presence of dermatitis, autoimmune cytopenias, or thyroiditis further supports the diagnosis. The diagnosis is established by mutational analysis of the FOXP3 gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Approach to an infant with suspected IPEX",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with suggestive signs and symptoms should be evaluated in consultation with a clinical immunologist familiar with IPEX and the other diseases listed in the differential diagnosis. Referral to a pediatric tertiary care center is highly advised.",
"     </li>",
"     <li>",
"      If hospitalized, infants with possible IPEX should be placed in isolation and managed similarly to a severely immunocompromised patient, as even minor infections can trigger significant flares of autoimmune and allergic disease. Blood products should be CMV negative and irradiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"       \"Approach to the septic-appearing infant\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Preliminary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation for IPEX requires extensive laboratory testing (",
"    <a class=\"graphic graphic_table graphicRef66990 \" href=\"UTD.htm?12/25/12700\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete blood count",
"      </strong>",
"      &mdash; The complete blood count (CBC) with differential typically demonstrates eosinophilia, and may demonstrate neutropenia, anemia, or thrombocytopenia. If cytopenias are present, studies for antibody-mediated disease should be conducted including direct and indirect Coombs test, anti-neutrophil and anti-platelet antibodies.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum glucose and anti-islet antibodies",
"      </strong>",
"      &mdash; Serum glucose should be monitored given the high association with type 1 diabetes mellitus. Studies should be sent for anti-islet antibodies, although direct T cell pancreatic infiltration in the absence of anti-islet antibodies has been described. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"       \"Prediction of type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid function and anti-thyroid antibodies",
"      </strong>",
"      &mdash; Abnormalities in thyroid function may be accompanied by elevated anti-thyroid antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"       \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anti-enterocyte antibodies",
"      </strong>",
"      &mdash; When present, anti-enterocyte antibodies confirm the diagnosis of autoimmune enteropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/65\">",
"       65",
"      </a>",
"      ]. Additionally, gut and kidney antigen specific (AIE-75) and anti-goblet cell antibodies have also been associated with autoimmune enteropathies including IPEX [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/42,57,66\">",
"       42,57,66",
"      </a>",
"      ]. However, autoimmune enteropathy may be seen in the absence of these antibodies, and it is unclear whether they are pathogenic or represent an epiphenomenon.",
"     </li>",
"     <li>",
"      <strong>",
"       Immunoglobulins",
"      </strong>",
"      &mdash; Most patients with IPEX have significantly elevated total and antigen-specific IgE, and more than half of the patients also have an elevated IgA [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/24,29\">",
"       24,29",
"      </a>",
"      ]. Serum IgG and IgM levels are generally normal. However, hypogammaglobulinemia may be seen, particularly in association with protein losing enteropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/33,67\">",
"       33,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Food hypersensitivity testing",
"      </strong>",
"      &mdash; Hypersensitivity to food antigens may be a feature of IPEX or a competing diagnosis. IgE mediated food allergy is common in IPEX [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/6,33\">",
"       6,33",
"      </a>",
"      ]. In patients with concurrent dermatitis, serum testing for allergen-specific IgE is generally preferred to skin prick testing to evaluate for the presence of food specific IgE. Evaluation for non-IgE-mediated food allergy, including food-protein induced enterocolitis and celiac disease, should also be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"       \"Diagnostic evaluation of food allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphocyte subsets and proliferation assays",
"      </strong>",
"      &mdash; Lymphocyte subsets are non-diagnostic but should be performed to exclude a primary immunodeficiency syndrome. B and T cell subsets are normal in most IPEX patients. Similarly, mitogen and antigen stimulation studies typically demonstrate normal lymphoproliferative responses. There are reports of cytokine dysregulation consistent with TH2 skewing, including low interferon gamma and elevated IL-4 levels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H2#H2\">",
"       \"Laboratory evaluation of the immune system\", section on 'Defects in cellular immunity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Advanced investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;If preliminary studies are suggestive of IPEX, then further testing is recommended (",
"    <a class=\"graphic graphic_table graphicRef66990 \" href=\"UTD.htm?12/25/12700\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Endoscopy with intestinal biopsy",
"      </strong>",
"      &mdash; Endoscopy with intestinal biopsy is required to characterize small bowel enteropathies. Staining biopsy samples for Foxp3 is available at some research institutions, and has been suggested as a potential diagnostic tool for IPEX [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gastrointestinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin biopsy",
"      </strong>",
"      &mdash; The skin rashes associated with IPEX are typically eczematous, although other unusual dermatologic conditions have been described. Biopsy specimens demonstrating lymphocyte infiltration may be required to characterize the process as autoimmune disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Skin findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Regulatory T cell immunophenotyping and functional studies",
"      </strong>",
"      &mdash; Quantitative analysis via flow cytometry and fluorescence-activated cell sorting (FACS) analysis, as well as functional assays of Treg cells are indicated, although these tests are only available at selected research institutions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CD4+CD25+Foxp3+ cell population of the patient should be compared to that of an age-matched healthy control subject. CD4+ Treg cells normally comprise approximately 5 to 10 percent of the CD4+ T cell population, although more precise age-specific standards have not been established for children or adults. Cells identified as CD4+CD25+CD127lo correlate well with the CD4+CD25+Foxp3+ population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/69-71\">",
"     69-71",
"    </a>",
"    ], although the two populations are not identical [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/72\">",
"     72",
"    </a>",
"    ]. Absence of CD4+Foxp3+ cells confirms a Treg cell deficiency and is consistent with a loss of function mutation in FOXP3. Additionally, absence of CD4+CD25+ cells confirms a diagnosis of CD25 deficiency. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'IPEX-like syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, detection of CD4+Foxp3+ cells does not rule out IPEX, as missense mutations may result in present but either partially functioning or non-functional Foxp3 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/23,25,73\">",
"     23,25,73",
"    </a>",
"    ]. Functional studies of Treg cells such as cell suppression assays can help identify hypomorphic mutations in FOXP3. Various methods have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/31,74\">",
"     31,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, when the clinical picture is consistent with IPEX, gene sequencing of FOXP3 should be performed, regardless of the results of FACS analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis requires gene sequencing to identify a mutation in FOXP3. Testing is commercially available, and should be obtained when the clinical picture and other investigations are consistent with a diagnosis of IPEX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other disorders can mimic IPEX or components of the IPEX phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     IPEX-like syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cohort of over 100 patients with the IPEX phenotype, more than one-half lacked mutations in FOXP3 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/27\">",
"     27",
"    </a>",
"    ]. The underlying defect in these patients is generally unknown. One report described a girl from a consanguineous family with autoimmune enteropathy, recurrent infections, and a deficiency of CD4+ Foxp3+ Treg cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/75\">",
"     75",
"    </a>",
"    ]. She also had low immunoglobulins. No abnormalities at the FOXP3 locus were identified, although this presentation and others suggest that autosomal recessive genes may play a role in some IPEX-like syndromes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD25 deficiency &mdash; Of the IPEX-like syndromes, only CD25 deficiency is well characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. CD25, the alpha chain of the IL-2 receptor, is a cell surface marker found on both Treg and activated T cells. Non-functional alleles at both loci of this autosomal gene are required to result in the clinical features of IPEX.",
"     </li>",
"     <li>",
"      STAT-5 deficiency &mdash; A female patient with severe growth hormone resistance due to a STAT-5 deficiency also demonstrated an IPEX-like syndrome. In addition to a homozygous missense mutation at STAT5b, she had significantly diminished FOXP3 expression, absence of functional CD4+ Treg cells, and decreased levels of CD25 expression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Enteropathies of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an infant with intractable diarrhea includes unusual presentations of common illnesses (ie, infections, food sensitive enteropathies). The autoimmune enteropathies and other considerations are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/80\">",
"     80",
"    </a>",
"    ]. Celiac disease is of particular interest given its association with type 1 diabetes and thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/81\">",
"     81",
"    </a>",
"    ]. Rare genetic conditions to consider include microvillus inclusion disease or enteroendocrine cell dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Inflammatory bowel disease is also a consideration, although it usually affects older children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Eosinophilic enteropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eosinophilic enteropathies can manifest in infancy and childhood with malabsorption, eczema, food allergy, eosinophilia, and elevated total and specific IgE. Eczema and other manifestations of atopy may also be present. Eosinophilic enteropathies may be distinguished from autoimmune enteropathies by the presence of a predominantly eosinophilic, rather than lymphocytic, infiltrate in the gastrointestinal mucosa on biopsy. However, treatment with systemic steroids prior to biopsy may significantly reduce the eosinophilic infiltrate and complicate diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other causes of neonatal diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several well characterized syndromes associated with neonatal diabetes (ie, diabetes developing within the first six months of life), which can be transient, permanent, or recurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. IPEX is a leading cause of neonatal diabetes due to autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Severe combined immune deficiency (SCID)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A male infant with chronic diarrhea and significant dermatitis is also a classic presentation for severe combined immune deficiency (SCID). Omenn syndrome is most consistent with the IPEX phenotype, as it is associated with rash, eosinophilia, and elevated IgE. Additionally, graft versus host disease due to engraftment of maternal T cells in patients with SCID may also share clinical features with IPEX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other rare syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NOMID or CINCA &mdash; Patients with neonatal onset multisystemic inflammatory disease (NOMID) classically present in early infancy with fever, urticarial rash, aseptic meningitis, deafness, developmental delay, and arthropathy. NOMID is caused by loss of function mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, which encodes cryopyrin. This disorder is also known as chronic infantile neurological cutaneous and articular (CINCA) syndrome and reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H7#H7\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Neonatal onset multisystem inflammatory disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ALPS &mdash; Autoimmune lymphoproliferative syndrome (ALPS) is caused by defects in Fas, Fas Ligand, or caspases 8 or 10 that interfere with programmed cell death and result in the failure to delete autoreactive clones. As with IPEX, there is diffuse autoimmune disease; however, the dominant clinical features are chronic lymphadenopathy with splenomegaly, autoimmune anemia, and thrombocytopenia. Enteropathy is rare. In addition, T cell subsets are remarkable for increased double negative (CD4-CD8-) gamma delta cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H9#H9\">",
"       \"Apoptosis and autoimmune disease\", section on 'Autoimmune lymphoproliferative syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      APS I or APECED &mdash; Various autoimmune polyendocrine syndromes are well characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/29\">",
"       29",
"      </a>",
"      ]. Autoimmune polyglandular syndrome type 1 (APS I), also denoted autoimmune polyendocrinopathy, candidiasis, ectodermal dysplasia (APECED), is caused by defects in the autoimmune regulator (AIRE) transcription factor. Autoimmune disease results from the failure of AIRE to regulate the expression of tissue-specific antigens on thymic medullary epithelial cells. Thus, autoreactive T cells are not identified and deleted. As a result, type 1 diabetes mellitus and other endocrinopathies may be found in APS I. Unlike IPEX, APS I is characterized by chronic mucocutaneous candidiasis, as well as autoimmune disease of the parathyroid and adrenals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE MEDICAL EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with IPEX may present acutely ill as a result of various factors. These emergent events may comprise the initial presentation or may occur in previously diagnosed patients. Sudden decompensations may be associated with exposures to infection, immunization, dietary antigens,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an unknown trigger of a disease flare. The following medical emergencies may occur in patients with IPEX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic derangements and severe dehydration due to infantile-onset diabetes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enteropathy-related diarrhea",
"     </li>",
"     <li>",
"      Disease flares due to infection, immunization, dietary allergens,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other unknown triggers",
"     </li>",
"     <li>",
"      Invasive infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These acute medical events require a multidisciplinary effort tailored to the specific presentation. We suggest the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Isolation to prevent nosocomial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, hospitalized IPEX patients should be placed in isolation, because even minor infections can trigger significant flares of autoimmune and allergic inflammation. Blood products should be CMV negative and irradiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"     \"Approach to the septic-appearing infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Multispecialty intensive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and aggressive therapy is critical and should be initiated by a team of pediatric subspecialists. Supportive care generally includes fluid resuscitation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , insulin, antimicrobials, albumin, thyroid hormone replacement, and blood products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Increased immune suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant immunosuppression may be required during acute medical events (including minor infections) to stabilize disease flares. Acute decompensations due to disease flare generally warrant induction immunosuppressive therapy for initial presentations, or an increase from the patient's baseline maintenance therapy for previously diagnosed patients. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fluctuations in disease activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, infections can mimic disease flares in patients with IPEX and thereby cause a diagnostic dilemma. Moreover, continued steroid therapy in the setting of on-going invasive infection may increase the risk of sepsis. This complexity may confound decisions regarding the appropriate diagnosis and management, and resemble the conflicts encountered in the treatment of patients with rheumatologic disease and organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/55,56,84-86\">",
"     55,56,84-86",
"    </a>",
"    ]. If concerns are raised regarding invasive infections, a reduction of steroid therapy to physiologic or stress dosing is advisable, until this diagnosis is excluded. Generally maintenance therapy with steroid-sparing agents is continued despite concerns of invasive infection.",
"   </p>",
"   <p>",
"    Decisions regarding appropriate immunosuppressive therapy during an acute illness should be individualized, based upon the patient's underlying conditions, prior presentations, and objective evidence of disease flare",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive infection. However, at times, empirical dosing may be warranted with vigilance for evidence of infection. Acute immunosuppression is generally achieved with high-dose intravenous glucocorticoids (ie, 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Management of enteropathy flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common presentation of IPEX in infancy is chronic intractable diarrhea with failure to thrive. These infants usually require periodic hospitalization, gut rest, and nutritional support with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN), which can be life-saving interventions. A nutrition consult should be obtained to evaluate for malnutrition, as well as vitamin and mineral deficiencies. Immune suppression is generally required to achieve sufficient improvement in the diarrhea.",
"   </p>",
"   <p>",
"    Once the stooling pattern has normalized, feeds should be reintroduced slowly. Food antigens are well-described triggers of disease flares. Patients should receive either breast milk or extensively hydrolyzed formula. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Nutrition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic management of patients with IPEX and \"IPEX-like\" syndromes typically includes a combination of intensive immune suppression and dietary modifications to avoid food allergens and optimize nutrition. Hematopoietic cell transplantation (HCT) offers the potential for cure, but has substantial risk and may not be available for all candidates.",
"   </p>",
"   <p>",
"    The literature on this rare and heterogeneous disorder consists of case reports and limited series; controlled trials have not been performed for any of the interventions discussed. Therefore, recommendations for management consist of expert opinion.",
"   </p>",
"   <p>",
"    Unfortunately, no single or combination therapy has been uniformly effective and each has potentially devastating adverse effects. The variable success and considerable risk of each therapy render the medical decision making process extremely complex and dependent upon unique aspects of each patient's presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Immune suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression can be effective in ameliorating autoimmune and allergic disease. However, long-term use of these medications has been associated with significant adverse side effects, and growth is often compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,87\">",
"     8,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose glucocorticoids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , are typically used for induction therapy at the time of presentation and for management of disease flares because of their rapid onset of action.",
"   </p>",
"   <p>",
"    However, the possibility of an on-going invasive infection should be ruled-out prior to initiation of high dose steroid therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Infectious diseases'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32\">",
"     'Management of acute medical events'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Decisions regarding the timing and dosing of glucocorticoid therapy should be individualized, although typical doses range from 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     Betamethasone",
"    </a>",
"    has been reported to be effective in some patents that do not respond adequately to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or solumedrol therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/60,88\">",
"     60,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A steroid-sparing agent should be added in conjunction with glucocorticoid therapy. Once disease control is obtained, a slow glucocorticoid wean should be attempted, and the steroid-sparing agent should be continued as maintenance therapy. Multiple immunosuppressive agents may be required to obtain disease control, and it may not be possible to wean the patient entirely from glucocorticoid therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Steroid-sparing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    are the most commonly used steroid-sparing agents in the treatment of IPEX. Other immunosuppressives have been attempted with less efficacy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcineurin inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      A, have been successful both as monotherapy and in conjunction with glucocorticoids or other agents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,38,87\">",
"       8,38,87",
"      </a>",
"      ]. It is our practice to administer tacrolimus as an initial steroid-sparing agent, unless there is a significant contraindication.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      (also called rapamycin) has the theoretical advantages of reduced toxicity and preferential suppression of effector T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]. In vitro studies, animal models and clinical investigations related to solid organ transplantation are increasingly reporting quantitative and functional increases in Foxp3+ Treg cells with the use of sirolimus in conjunction with other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/91-94\">",
"       91-94",
"      </a>",
"      ]. Its use has been associated with significant benefit in a small number of IPEX patients, although rare serious adverse effects have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/33,52,54,60,95\">",
"       33,52,54,60,95",
"      </a>",
"      ]. Most significantly, sirolimus therapy was associated with an EBV-induced lymphoma in one patient and an inflammatory pneumonia in another [",
"      <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/52,60\">",
"       52,60",
"      </a>",
"      ]. As a result of these reports, we suggest that a detailed and documented informed consent is obtained prior to initiation of sirolimus therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with possible or confirmed IPEX should be fed breast milk or extensively hydrolyzed formula to reduce exposure to food allergens. In patients with diarrhea or failure to thrive, a nutrition consult should assess the extent of malnutrition and evaluate for vitamin and mineral deficiencies.",
"   </p>",
"   <p>",
"    If allergic sensitization to specific foods has been identified in the infant, breastfeeding mothers may need to follow a restricted diet that excludes those foods. Mothers of these infants should also be evaluated by a dietician with expertise in food allergy, to ensure that the restricted diet is providing adequate nutrition for both mother and child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Avoidance of vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;All vaccinations are best avoided in patients with known or suspected IPEX, since immunizations (like infections) can trigger severe and even fatal disease flares. If vaccinations are considered essential, consultation with a clinical immunologist is strongly encouraged. Increased immune suppression will likely be required, although this may inhibit the efficacy of the vaccination.",
"   </p>",
"   <p>",
"    The administration of supplemental immunoglobulin is a potentially safer alternative to vaccination in patients with IPEX that experience frequent infections or require protection against a specific infection. IVIG has been administered to IPEX patients without significant adverse effects. Therapy with specific immune globulins may also be a consideration if there is evidence of exposure to",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ongoing infection with a specific pathogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is currently the only curative therapy available to IPEX patients. However, success has been limited and morbidity and mortality are considerable. Many of the features of IPEX remit after successful transplantation, although endocrinopathies frequently persist due to permanent organ damage.",
"   </p>",
"   <p>",
"    HCT has been described in a limited number of IPEX patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,27,28,67,96-101\">",
"     8,27,28,67,96-101",
"    </a>",
"    ]. The longest reported post-transplant survival is six years in a boy that underwent peripheral blood HCT from a matched unrelated donor after nonmyeloablative conditioning at 11 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/99\">",
"     99",
"    </a>",
"    ]. Potential complications of HCT in IPEX patients include macrophage activation syndrome, infection, graft versus host disease, and growth failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8,28,67,96-98\">",
"     8,28,67,96-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced intensity conditioning regimens have been increasingly used, which offer the potential benefit of decreased myeloablation and less risk of mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/67,98-101\">",
"     67,98-101",
"    </a>",
"    ]. Selective engraftment of donor CD4+CD25highFoxp3+ cells with resultant normal levels of FOXP3 expression following nonmyeloablative conditioning has proven sufficient to prevent manifestations of autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. Sources of stem cells have included cord blood, peripheral blood, and bone marrow from matched related and unrelated donors.",
"   </p>",
"   <p>",
"    Early HCT offers the greatest potential to correct the underlying disease process and thereby minimize end-organ damage. As with SCID, patients may be more likely to survive the peri-HCT period if they are less compromised at the time of conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/28\">",
"     28",
"    </a>",
"    ]. Therefore, extensive evaluations are required to determine availability of appropriate donors, and determine the optimal timing of the procedure for each individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling should be offered to female family members of IPEX patients, who may be carriers of the defective FOXP3 gene. Prenatal diagnosis can identify affected male fetuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If untreated, infants with IPEX are likely to succumb in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Despite efforts to manage the disease with immunosuppressive therapy or attempts at curative therapy with hematopoietic cell transplantation, the prognosis for these patients remains poor. Although ameliorated phenotypes have been described, most reported cases have proved fatal.",
"   </p>",
"   <p>",
"    Early diagnosis may improve prognosis. A 2002 report compiled clinical information for 56 patients with IPEX and \"IPEX-like\" processes, and described only six patients who survived [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/8\">",
"     8",
"    </a>",
"    ]. However, results from a 2007 series were more encouraging, as 28 of 51 IPEX patients were alive at the time of publication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/15/25850/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPEX (Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-linked) is a rare and potentially fatal autoimmune lymphoproliferative disorder, in which regulatory T cells (Treg) are quantitatively or functionally deficient. These defects are caused by various mutations in FOXP3, a transcription factor fundamental to the functional differentiation of Treg cells. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IPEX classically presents in male infants with a triad of enteropathy, dermatitis, and autoimmune endocrinopathy (usually type 1 diabetes or thyroiditis). Some patients have severe food allergy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immune mediated cytopenias. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for IPEX should be considered in any young male infant with type 1 diabetes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic intractable diarrhea with failure to thrive. Diagnostic testing should be performed in consultation with a clinical immunologist familiar with IPEX, when possible. The diagnosis is confirmed by mutational analysis of the FOXP3 gene. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Management of acute illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPEX patients may deteriorate acutely due to metabolic derangements, infections, vaccinations, or exposure to dietary allergens. In this setting, IPEX patients should be admitted to an intensive care unit and isolated to prevent nosocomial infections. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Management of acute medical events'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune suppression may need to be increased in the setting of most acute medical events, including minor infections, in order to prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      control exacerbations of autoimmunity and allergic inflammation. In contrast, if invasive infection is suspected, glucocorticoids should be administered at the minimum stress doses required. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Increased immune suppression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Long-term interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic management of patients with IPEX involves immunosuppressive therapies to control autoimmune and allergic disorders combined with dietary modifications to avoid food allergens and optimize nutrition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of high-dose glucocorticoid therapy as initial immunosuppressive therapy and for management of disease flares (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Typical doses range from 1 to 2 mg per kilogram per day. Steroid-sparing agents should be initiated simultaneously. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Immune suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteropathy associated with chronic diarrhea and failure to thrive typically requires periodic hospitalization for gut rest and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      . As with other disease flares in IPEX, increased immunosuppression may be required to control symptoms. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Management of enteropathy flares'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that infants with possible or confirmed IPEX be breastfed or given extensively hydrolyzed formula to reduce exposure to food allergens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Breastfeeding mothers may need to avoid foods to which the infant has demonstrated sensitivities. Consultation with a dietitian is helpful to ensure that nutrition is adequate for both infant and mother.",
"     </li>",
"     <li>",
"      In patients with possible or confirmed IPEX, we suggest avoiding routine vaccinations, which can trigger fatal disease flares (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Avoidance of vaccinations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with appropriately matched donors and the ability to tolerate the peri-transplant course, hematopoietic cell transplantation offers the potential for cure. Although increasing success is being reported, the prognosis for patients with IPEX remains poor. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H45\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/1\">",
"      Ochs HD, Oukka M, Torgerson TR. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 2009; 123:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/2\">",
"      Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005; 116:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/3\">",
"      Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/4\">",
"      Powell BR, Buist NR, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 1982; 100:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/5\">",
"      Bennett CL, Yoshioka R, Kiyosawa H, et al. X-Linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. Am J Hum Genet 2000; 66:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/6\">",
"      Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000; 106:R75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/7\">",
"      Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/8\">",
"      Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/9\">",
"      Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005; 203:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/10\">",
"      Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/11\">",
"      Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/12\">",
"      Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/13\">",
"      Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/14\">",
"      Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/15\">",
"      Leonardo SM, Josephson JA, Hartog NL, Gauld SB. Altered B cell development and anergy in the absence of Foxp3. J Immunol 2010; 185:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/16\">",
"      Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003; 100:8886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/17\">",
"      Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003; 198:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/18\">",
"      Haribhai D, Lin W, Relland LM, et al. Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 2007; 178:2961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/19\">",
"      Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114:3727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/20\">",
"      Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/21\">",
"      Lin W, Haribhai D, Relland LM, et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/22\">",
"      Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/23\">",
"      Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/24\">",
"      Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/25\">",
"      d'Hennezel E, Ben-Shoshan M, Ochs HD, et al. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N Engl J Med 2009; 361:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/26\">",
"      Owen CJ, Jennings CE, Imrie H, et al. Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. J Clin Endocrinol Metab 2003; 88:6034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/27\">",
"      Ochs HD, Torgerson TR. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked inheritance: model for autoaggression. Adv Exp Med Biol 2007; 601:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/28\">",
"      Gambineri E, Perroni L, Passerini L, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008; 122:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/29\">",
"      Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007; 120:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/30\">",
"      Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007; 7:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/31\">",
"      Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/32\">",
"      Fuchizawa T, Adachi Y, Ito Y, et al. Developmental changes of FOXP3-expressing CD4+CD25+ regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clin Immunol 2007; 125:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/33\">",
"      Torgerson TR, Linane A, Moes N, et al. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 2007; 132:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/34\">",
"      Lin W, Truong N, Grossman WJ, et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol 2005; 116:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/35\">",
"      Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/36\">",
"      Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/37\">",
"      Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 2005; 25 Suppl:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/38\">",
"      Levy-Lahad E, Wildin RS. Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: Further evidence for an X-linked lethal syndrome. J Pediatr 2001; 138:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/39\">",
"      Marquis E, Robert JJ, Bouvattier C, et al. Major difference in aetiology and phenotypic abnormalities between transient and permanent neonatal diabetes. J Med Genet 2002; 39:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/40\">",
"      Wiedemann B, Schober E, Waldhoer T, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes 2010; 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/41\">",
"      Tommasini A, Ferrari S, Moratto D, et al. X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. Clin Exp Immunol 2002; 130:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/42\">",
"      Patey-Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol 2009; 22:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/43\">",
"      Iafusco D, Stazi MA, Cotichini R, et al. Permanent diabetes mellitus in the first year of life. Diabetologia 2002; 45:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/44\">",
"      Babenko AP, Polak M, Cav&eacute; H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/45\">",
"      Hamilton-Shield JP. Overview of neonatal diabetes. Endocr Dev 2007; 12:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/46\">",
"      Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 2009; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/47\">",
"      Scaillon M, Van Biervliet S, Bontems P, et al. Severe gastritis in an insulin-dependent child with an IPEX syndrome. J Pediatr Gastroenterol Nutr 2009; 49:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/48\">",
"      Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/49\">",
"      Halabi-Tawil M, Ruemmele FM, Fraitag S, et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 2009; 160:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/50\">",
"      Nieves DS, Phipps RP, Pollock SJ, et al. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Arch Dermatol 2004; 140:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/51\">",
"      McGinness JL, Bivens MM, Greer KE, et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol 2006; 55:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/52\">",
"      Lucas KG, Ungar D, Comito M, Groh B. Epstein Barr virus induced lymphoma in a child with IPEX syndrome. Pediatr Blood Cancer 2008; 50:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/53\">",
"      Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/54\">",
"      Yong PL, Russo P, Sullivan KE. Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol 2008; 28:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/55\">",
"      Whitelaw DA, Gopal R, Freeman V. Survival of patients with SLE admitted to an intensive care unit-a retrospective study. Clin Rheumatol 2005; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/56\">",
"      Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005; 38:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/57\">",
"      Kobayashi I, Imamura K, Yamada M, et al. A 75-kD autoantigen recognized by sera from patients with X-linked autoimmune enteropathy associated with nephropathy. Clin Exp Immunol 1998; 111:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/58\">",
"      Moudgil A, Perriello P, Loechelt B, et al. Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: an unusual cause of proteinuria in infancy. Pediatr Nephrol 2007; 22:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/59\">",
"      Hashimura Y, Nozu K, Kanegane H, et al. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr Nephrol 2009; 24:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/60\">",
"      Taddio A, Faleschini E, Valencic E, et al. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur J Pediatr 2007; 166:1195.",
"     </a>",
"    </li>",
"    <li>",
"     Chatila T, unpublished observations.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/62\">",
"      Ohshima M, Futamura M, Kamachi Y, et al. Allergic bronchopulmonary aspergillosis in a 2-year-old asthmatic boy with immune dysregulation, polyendocrinopathy, enteropathy, X-linked. Pediatr Pulmonol 2009; 44:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/63\">",
"      Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991; 138:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/64\">",
"      Huter EN, Punkosdy GA, Glass DD, et al. TGF-beta-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur J Immunol 2008; 38:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/65\">",
"      Russo PA, Brochu P, Seidman EG, Roy CC. Autoimmune enteropathy. Pediatr Dev Pathol 1999; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/66\">",
"      Hori K, Fukuda Y, Tomita T, et al. Intestinal goblet cell autoantibody associated enteropathy. J Clin Pathol 2003; 56:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/67\">",
"      Lucas KG, Ungar D, Comito M, et al. Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome. Bone Marrow Transplant 2007; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/68\">",
"      Heltzer ML, Choi JK, Ochs HD, et al. A potential screening tool for IPEX syndrome. Pediatr Dev Pathol 2007; 10:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/69\">",
"      Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/70\">",
"      Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/71\">",
"      Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/72\">",
"      Klein S, Kretz CC, Krammer PH, Kuhn A. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 2010; 130:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/73\">",
"      McMurchy AN, Gillies J, Allan SE, et al. Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. J Allergy Clin Immunol 2010; 126:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/74\">",
"      Hilchey SP, Bernstein SH. Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies. Immunol Invest 2007; 36:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/75\">",
"      Zuber J, Viguier M, Lemaitre F, et al. Severe FOXP3+ and na&iuml;ve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. Gastroenterology 2007; 132:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/76\">",
"      Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Invest 1997; 100:3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/77\">",
"      Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A 1997; 94:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/78\">",
"      Caudy AA, Reddy ST, Chatila T, et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/79\">",
"      Cohen AC, Nadeau KC, Tu W, et al. Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 2006; 177:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/80\">",
"      Sherman PM, Mitchell DJ, Cutz E. Neonatal enteropathies: defining the causes of protracted diarrhea of infancy. J Pediatr Gastroenterol Nutr 2004; 38:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/81\">",
"      Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/82\">",
"      Murch SH. Toward a molecular understanding of complex childhood enteropathies. J Pediatr Gastroenterol Nutr 2002; 34 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/83\">",
"      Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 2006; 355:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/84\">",
"      Alm&eacute;ras C, Foulongne V, Garrigue V, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008; 85:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/85\">",
"      Chou NK, Ko WJ, Chi NH, et al. Sparing immunosuppression in heart transplant recipients with severe sepsis. Transplant Proc 2006; 38:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/86\">",
"      Taylor JL, Palmer SM. Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med 2006; 21:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/87\">",
"      Kobayashi I, Kawamura N, Okano M. A long-term survivor with the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. N Engl J Med 2001; 345:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/88\">",
"      Kobayashi I, Nakanishi M, Okano M, et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. Eur J Pediatr 1995; 154:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/89\">",
"      Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/90\">",
"      Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/91\">",
"      Pahwa R, Jaggaiahgari S, Pahwa S, et al. Isolation and expansion of human natural T regulatory cells for cellular therapy. J Immunol Methods 2010; 363:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/92\">",
"      Zhang W, Zhang D, Shen M, et al. Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J Immunol 2010; 185:4750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/93\">",
"      Kawamoto K, Pahuja A, Hering BJ, Bansal-Pakala P. Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs. Transpl Immunol 2010; 23:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/94\">",
"      Lange CM, Tran TY, Farnik H, et al. Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin. Transpl Int 2010; 23:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/95\">",
"      Bindl L, Torgerson T, Perroni L, et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 2005; 147:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/96\">",
"      Baud O, Goulet O, Canioni D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001; 344:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/97\">",
"      Mazzolari E, Forino C, Fontana M, et al. A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 2005; 35:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/98\">",
"      Rao A, Kamani N, Filipovich A, et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007; 109:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/99\">",
"      Seidel MG, Fritsch G, Lion T, et al. Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood 2009; 113:5689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/100\">",
"      Dorsey MJ, Petrovic A, Morrow MR, et al. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Immunol Res 2009; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/15/25850/abstract/101\">",
"      Burroughs LM, Torgerson TR, Storb R, et al. Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J Allergy Clin Immunol 2010; 126:1000.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3924 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25850=[""].join("\n");
var outline_f25_15_25850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview of T regulatory cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Normal function of Foxp3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mutations in FOXP3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mouse model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluctuations in disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immune dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neurologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Approach to an infant with suspected IPEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Preliminary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Advanced investigations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IPEX-like syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Enteropathies of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Eosinophilic enteropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other causes of neonatal diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Severe combined immune deficiency (SCID)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other rare syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      MANAGEMENT OF ACUTE MEDICAL EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Isolation to prevent nosocomial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Multispecialty intensive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Increased immune suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Management of enteropathy flares",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Immune suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Steroid-sparing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Avoidance of vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Management of acute illnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Long-term interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3924|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/20/22862\" title=\"figure 1\">",
"      FOXP3 org mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3924|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/28/9669\" title=\"picture 1\">",
"      IPEX GI biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/47/13055\" title=\"picture 2\">",
"      IPEX eczematous skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/3/8251\" title=\"table 1\">",
"      IPEX clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/25/12700\" title=\"table 2\">",
"      IPEX lab eval",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=related_link\">",
"      Approach to the diagnosis of chronic diarrhea in children in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_15_25851="C-S rate by Bishop score and PG";
var content_f25_15_25851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Failed induction rate and cesarean delivery rate after induction by Bishop score and parity, circa 1997 (prostaglandins available)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bishop score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Failed induction rate, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-3",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;3",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cesarean delivery rate after induction, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-3",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Xenakis, EM, Piper, JM, Conway, DL, Langer, O. Obstet Gynecol 1997; 90:235.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25851=[""].join("\n");
var outline_f25_15_25851=null;
var title_f25_15_25852="EMI with cardiac devices";
var content_f25_15_25852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Documented sources of electromagnetic interference (EMI) in patients with implanted cardiac devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     &nbsp;",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Electromagnetic fields",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Daily life*",
"       </td>",
"       <td>",
"        Faulty home appliances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metal detectors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-theft equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slot machines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Work and industrial environment",
"       </td>",
"       <td>",
"        High voltage power lines&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Welding equipment&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electronic motors while \"on\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction furnaces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Degaussing coils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"9\">",
"        Medical/hospital environment",
"       </td>",
"       <td>",
"        Magnetic resonance imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defibrillation or cardioversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Device-device interaction",
"        </p>",
"        <p>",
"         (eg, pacemaker and neural stimulator)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency ablation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrocautery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcutaneous nerve stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapeutic diathermy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithotripsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation therapy&loz;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There are many potential sources of single-beat inhibition. However, single-beat inhibition is not clinically significant and does not merit specific mention.",
"     <br>",
"      &bull; If working at or near the level of the power line. There is no convincing evidence that being under the power lines at ground level will cause interference.",
"      <br>",
"       &Delta; Although all welding equipment is capable of causing interference, it most commonly occurs with equipment that operates at &ge;150 amps.",
"       <br>",
"        &loz; Radiation therapy may cause electromagnetic interference but may also result in direct damage to the pulse generator resulting in sudden no output or \"runaway\".",
"        <br/>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pinski SL, Trohman RG. Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol 2002; 25:1367. Copyright &copy;2002 Blackwell Publishing.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25852=[""].join("\n");
var outline_f25_15_25852=null;
var title_f25_15_25853="Cyanide poisoning - Rapid overview";
var content_f25_15_25853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cyanide poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanide poisoning is rapidly lethal unless treated with antidote",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ascertain if patient has access to cyanide, or if patient was part of a high-risk event (eg, fire, industrial exposure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Initial symptoms nonspecific: headache, anxiety, confusion, abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vital signs: initial hypertension/tachycardia/tachypnea progresses to respiratory and circulatory collapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin: may be flushed with \"cherry red\" color",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurologic: seizures and coma as poisoning progresses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Obtain the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fingerstick glucose, acetaminophen and salicylate levels, electrocardiogram, and pregnancy test (when appropriate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Basic chemistries and serum lactate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Elevated anion gap acidosis, with elevated lactate, expected in cyanide poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Venous blood appears bright red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Central venous blood gas with concomitant arterial blood gas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Narrowed venous-arterial PO2 gradient supports cyanide toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Carboxyhemoblobin and methemoglobin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rule out dyshemoglobinemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Use nitrites (see below) cautiously or not at all in presence of dyshemoglobinemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyanide poisoning can cause: renal failure, hepatic failure, rhabdomyolysis, pulmonary edema; obtain relevant studies as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Secure airway, breathing, and circulation.",
"        </strong>",
"        Intubation is usually required. Administer high-flow oxygen by nonrebreather face mask regardless of pulse oximetry reading.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         DO NOT perform mouth to mouth resuscitation",
"        </strong>",
"        in cases of suspected cyanide toxicity. Patients with dermal exposure must be decontaminated using proper precautions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain assistance from medical toxicologist or poison control center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antidotal treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Administer cyanide antidote",
"        </strong>",
"        when cyanide poisoning is clinically suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In countries where hydroxocobalamin is available:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sodium thiosulfate (25 percent): 1.65 mL/kg up to 50 cc IV, may repeat once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hydroxocobalamin 70 mg/kg up to 5 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In countries (eg, US) where hydroxocobalamin is not available and cyanide toxicity is known or strongly suspected:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sodium nitrite 10 mg/kg up to 300 mg slow IV infusion, may repeat once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sodium thiosulfate (25 percent) 1.65 mL/kg up to 50 cc IV, may repeat once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In countries (eg, US) where hydroxocobalamin is not available and cyanide toxicity is possible but not certain, or the patient has contraindications to nitrite administration:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sodium thiosulfate (25 percent) 1.65 mL/kg up to 50 cc IV, may repeat once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Details of nitrite treatment for children and patients with anemia, of treatment in cases of unlikely cyanide poisoning, and of decontamination are found in the text",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25853=[""].join("\n");
var outline_f25_15_25853=null;
var title_f25_15_25854="Pott disease in an adult";
var content_f25_15_25854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pott disease in an adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterioanterior thoracic spine film from a patient with Pott disease shows the contours of a tuberculous paraspinal mass (arrows) with destruction of the T7-8 disc space and adjacent vertebral bodies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles E Putnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25854=[""].join("\n");
var outline_f25_15_25854=null;
var title_f25_15_25855="Relationship between BPS and perinatal mortality and morbidity";
var content_f25_15_25855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Relationship between biophysical profile score and perinatal mortality and morbidity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 376px; background-image: url(data:image/gif;base64,R0lGODlhQgJ4AeYAAP///4CAgAAAAEBAQMDAwKCgoCAgINDQ0P8AADAwMBAQEPDw8ODg4P+AgHBwcFBQULCwsAAz/2BgYJCQkICZ//9AQP/w8ABmM/Dz/8DN///AwP8QEP/g4P9gYEBm/xBA/4Czmf8gIDBZ//+goODm/6Cz/2CA/yB5TfD28/8wMLDA/0CMZlBz/6DGs//Q0BBwQCBN//+QkNDZ/5Cm//9wcP9QUODs5nCN//+wsNDj2TCDWcDZzXCpjZC8pmCggFCWc7DQwL8MPzBW7wAGAw8v7+8yP6+g3x8s3wAZDKCmo0BmU0B5XCBySSAmIwATCe9zgD9W7wBSKcDTyVBwYABGI4Cslt8mPxBpPDB8ViAyKTA8NoBwcODm46DAsAAfDzBiSQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABCAngBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6errwwQEtQQC8vIAA/MJEOz6+/zIAQHwBBj4B9DeBAgJBOTrx7Chw0ML3LH6FzCBuwP1BLw7IPBhMHfuFngcmcqBvIWpKC7S0KCly5cwY8p0qQFRvHkDMr4DQI9kr3kCFOz0SRSUAXkSVqlUxHKm06c0bQqwSACjvXcLghbdRc8kwK1gNUEQMEGBAJEpv86Kl3PQ1QUS/wSoDVtLXoAEBhjQ3VspLoO4BVQtlcWWkL15Dvjakjfg6FzFkBVlFdB4quDHsCJiHHQAJNrIsnr2BE3a0AQBEv6Z3XxqcOl98gicNvC6tqCEaE0mRuXatjqgA1j7Hn6ZuPHjyBX1Ts68+evlzqNLDwt9uvXrDqvDI6B3EIOqhDoLx06+PCHwghYUCFDgM4QAE7oj0r6q8KACZpECWHC444Gj8tBWSADA8TTPA+OZpyBkBxDYFgAJ2ZOAICYloIAC8hlCnyr2AcCRASJBkJQ9DxBQwISrefjgIA7+E1hs+GG44IyQHdbWWA8A8IBCWSkAwGm7AUAAQf8MgJkhGVCg5P+STDbp5JNLZiDVgxwp4AAEIjHQESFmSVBAhiyi5o5ePZ2WFI1o0mUfgQCxWViHQxJpJCNJQmnnnVFOSYhJ8xTQoSD4zZOUAwMUCgCB8wDU05/WWFABAghUYEGalG6yplyHyvUmZYlsmAqjDBQQlwAfGrIABA6YZSJBmUowpoGC4KjNo5BGWumtl9gHJAAmTcDRhLLOd6Qr8VDVmQQYlUqiiRMOkM8CR4HJJiH0MJDQUNfUWisHuHYbyQGnWbSAlgYQEC0AR0GwY2DCBoTTAfkJlGxCAaI7jwLsEjLtIEDhu422kHorsCP9aQRAAUcZwO4BCVmp3LCtRATSZuIVUrH/IN9hS8h3GYKkMTYhaFvBwCS3BnHJiGiwAa2SouxyKJ6+DEAHDQjCrcw4cxKzyxwgMGnOQG+yM8oddBD00ZkMTbIFCNyM9NOTKD1wA0ZDbXUkUo8i8UWMEOpIZ/J1FhIh7wWApXfoAZBx2obotfXYrliwQU1X191I1qLcxBgj6zUy2YSCFBzYAgkZYM+D9KKFqDyAc+aA4UICZbArMYxs9+UPV8T1oesNUMABDzwgUt8MmE0oZgXM091VVQIQ15kLTIBxn4KwSbjBBzw+VXz7uZO6AGCqEgLdmBc/4MmC7ADC8sw37/zz0DO/g1QKDCBBd4ybZUBCIwoQOWVm5Xub/wK76gSrWZ8NYlLqgNt+7uEfu47aKyOEYPz9+iIPgPLR9++/9Ig4QGokJAhOEegdnLJH5AAylrlo6XpbsocEdpQUeiCqLQagzbkWJ4CF6S4BvJsd8F4RghHg74R4K4VocnJAnuREgfEASAz3JJDD5ENCRhLJtRhwmpyMpXpmSQyBJGAW2YXncQ963Ss0YL8T4i+FoAjAAwJwuAKy0GAJ9N4MZzgIBQxEigLI0VXIJpAC9FBHcgmASXzkJnkky2MEWMhNgpeKCsTAiU/UXyogACDRWTFTCHyhFjHFRQCMZTeT4c/kBoEQxk0gK41LyHswVSFFFigjQWKFyn7GEIngcf8ZUEQTzR4Syk/SopQL6hknGYJKU/AQPgm6hNgIgJbvUGwncAPbdVppnqJ5hJej+F1l4lcJwWWKVBkpIFnUZpdhOApSLXMGMLHDNKc1BDpNgYo2t/kS4rUtKJuBwAFKF8fACHAADkCLuqz3jnW6yjAaad0Fk2kg2vBJj7agFTSfMc3rUG0k2OSmQLfpzUKUbxDxMMsAGKCABASgoQcLoxTZI9EpwhOB3nMQWRTIk3R5EVPCAFjTpIlPXMmtoKwsqSumNQ93CGA3p8mHScA1Ffb8qKbiy8gE53dAAzTUey58wIX2FQyR8lOllaocSfr5ibHkhADX4mILp3oYIVYVngn/yCEg9WbFQxIVGPq0FUl5oRlBdCZ93lEbHA1RtqG8EiXNGN5SkdoK7kFVI1zkSIl8+iMHmCiME/Br6nLklkUCMiNA5RQtv/qLZ0ZqlaCkK4c4ZT7HQY6DQEUoUPLB0J9mUhn18wlTPwEXsyjgAd8B6cGOkgCM8FEeonttGNM3xjC9Q0uJfRBjfzGCGlizGaOtxJAIEDqM2GeMuWMt7zJmEgGh7aY56RUA0BdXE871cjSoWTQ2FCciEQmX3vUueP9BzBZdKHJfPMo74HeIo+T0PvMbY22VwURsrM2Tbx2EetiD1nbZrQI4kAZ3w/tdQXSXwOMNQHkNZhKXSm4jHwxh/0SdWwhoyUi+hkWGHbGBWbVdKCG7iZBlGBFc82zgt8CVrCimilfKztdDSByEew/xHwVsZkf5SEgsibFJ+7qjubxaJvpkhWMSq9hbHNjANEocNbJA4LzHxR0cF0IgCiu2SxQZ7FgojIxRbmPGGB4SpnZ7YCoeuVs4sNx2z/yJKssrcm3BcIEWYBa4GlByFDJLa5ehym2kTkBhnhaZvTunujWABktmsydaSBJffrmDgiiyjncl3UUwGTs1sO6aa8Foj1RzG1WG7wO2zMxyncvSiq5UCFyQ6Jf9Uxt0Vsie9LwZhJXxbqlOE9OocWnfnBQsvdbEK9vTCq+FxzMYQ09nDP9MS7NyZxUaSAGvcx0dpQKb2sG8pM4yfAiOFpZ2iLJKYpeJW2w/IgZVE7C5mSPXa9PpTlICQJ2gFO95Pyneh9CSUDwEkAUQCllqUzAEviTwwPzFepshgASsBwEJGnzhADfkAB5wlEKwTivz5Gi97rmKDtyx1SULLXX0Z28n1Rvegih5k/BtmpcWwkJ3wVBCKTPzhTb0oT4qFhUpPhUHMNSh5x2LQyt+UVhpdAIa96hjVpEClI61ZCWkS7Av8VWOJGYsE4jHbrQuCDNRUSM76k7pDOb1q4SdnoXdaVJ6+lMrClUBuy2Fz6ZdsvpKfd2fSN2DUitDTYFUqqghCAO8fdj/IQqeo4TPSFYDIJIDctWFXlXtKVzQRJAPbMN398VRjPSAnHiRuKTiYl6nAgECOICmriKIpn5V+tOz6bUWN2wLD/PHxUreFL2txtRB02NjHAAjE3hvK3ZvCQbsSCCyY9itRa/aRk5FLwE4igIgwICj5Mj5CWCAIjOY2cDJ3mC4/WPtbl+K7Ooe78TxsjES4ABEwXWl6CcPgM8/sD4fQyMDSEDoZEF85pyY/gLjaPfnVSsCf1aTZNbQf3vxachwfAWwf7GggMeRZgkYf7XxashgfOnkLPxngdbREhXoLb+mDLO0Y8UBNZkGDPv1SOmxHsTWKR5IGtaWDHyyNxEYg9Kx/2q/cDv2oAA6RBkj5l+40m7JEBQEIXxKgYPOsWu/UCw6QWSyJoSVInLKMBC2IIHEoQFq1gu3gxdrN2aqVWaFditRlwzusHAT04FQg4FcSESstQCCFoaEpoR8YXdFKDmUBQtYOBweBwynARA7Ah8uV2mHsIc+gXnJQGBIeIJI03TAwD539SUCYS4jJIVo0nvLME5mRUdJCDUIIAypIhBfYWsKkzmVon7LUGhUpIZIY4cAmCb2R4ID4EWFUj2seDS5dw2G6BECqAx6Iw/Td4tBY366SIdgwYDN4ACLOHzGiBwV4HSbliZsyAyGwmnNeBwjVYy6NjfQsIrWiDQIyGHX6P8TM+gMJlEo6DQJw4YxE2A2+uWC/VWI4zgcFCiOaUKEl4ABHhABEeABGBALBVOAjZA61ZMjnQVitwGEjWOKQQOC9kgjVIgJ+8iP/ZiBAvEZ0jVkYYRG7yePSFMBmhaCNFKGmUCRFEkCxLIAs8Q2jRAuRWQ+VxGHmCGG8+gbOviQC+KKl1ACJsmPr4B/2uYIQ/RkwBNoYDiTc3g0TIiTCoKI+fgBMGCSHvAKARAqRLKMh/CHOiFppEJpy4RqR6OF2rCL/ICJl0AB/jiR/igLZSUJ5PJkPqhlHUEulMiJ+XM00/iKvaRdmIABH4BvKCkLvzMV8bgIpLgZobhnq3VrRnb/NH2YDWSpD7F4CTdgArjgRWo0Pzd4NI4ImTXJEL1oCSQQAYFpC/vGKwI5EZ/5Gp84lqu5D8h4CSZgmbZwhn6lcISlh6/Je5XHlNiRl5QgAx/wj4uBh6nZiUCTi55pHiMokRSAC4oojDJDjMtZHuVoCRkwnNe0m5HxjKDGneqAj5bgATOQHeCpGNlYndgRkZZQAjBASue5F+HomuVBkpcAAyUAn0BTj/SJHTpZCSUgAr2gfOZiRLoJNA7Zn9fhlJXglyyXCxYiFMZ2oDkDktwQmedglpWAlr6gEAMwJMfJiDJzkwo6HajYoH/pC+TjLAZwJhQqM0tZCPrIj2v5dNMx/5mVcAMs8AscREwi6jJieQgTSaNHdR2hSQmjWZq9gHSjNgsYuhfACQA9SZo2Gh2xWQmzCQzN9o0485iGMKVFOh1RGgkk8AFKygsS1JEGiDOdaQhDWpFV2hzNOZ7P+Yj0YgAGSpXxGRateQgYEJX9SJwpZqUsA1mSkJ2CCgwHUEWbKTPRlggYEAEYcKbM8KTgEFZbOAkeUKd2Cox5uqYvo5yGUAI7qm7RIVIo9ggq8J7CkKantKdbQZ1I8qBxehwaYFSVgJ/tUJig6jLe2Q2Wyg1auAEhUyuZCgnuKQy0tJImmBY4M3fACqvYwAEdsAENYAGOFU2S8Ke0ygtAiRPSSf8y8zmrdEccFtABCEADkJWqj8ChwlCV63GE4Tow/GkIJlCellcbFtAAG9AB7Iqi3QpQ0uoTCWoIIhCwlTqw0cCvFcBqnkABpdqq6IiOn8WMMjN/iBABegka9fOrnpCkxICHeegIb7MZ+dWC/IVrMrMBDoskAlquvGmfnpCl3fCLOXGQLgchCqmyLhOjhTADtJmvdVgBMvuxZuoNxcI1GXkWUKimx/MyQXoI97qxYcEBNWCthuoJm/oNCWU9emGUbUJ+NOlqiIYIB0u1RUGtCHCtpYCo3yBAX9csBhOTR2kIY+syNfBxh6CxaEsS+4oA/noKW5uBr2IJ9MCVNJUYhAj/gy/TpoWQAS8Ls0Sxryvzr5+wqok6DJbEGLw6H1NURXJJG3R5agxZMn1qCEArkkTRsdAoCrp6DM1VKEdRsYsgW37EK7QGKAmDlbWjsA/xqIiQAQiLC/v1Ffv1gpb4EDgQAuJpCskaCSiwAhdwASuAAgCZSROqpy4TAzWQiQolICK2kBriu7yghUV7CjCgApIgvdNLvbHwAAngJ8ySm9qLMrJ6DEfBGk3LuA/hAhVgra7grpHQvu1rA7AwFpLjtD8qMB77uMNrCx9ifZkStmpxtwxBrVjrCg46CQQ8vYSxcOzkpOTbENBqCCyQn004FZEokwiVlP1gATQAuJZrCgIc/wnsO70rMAsZY5fISTIuoGR+KqmkoIkewsOMwBFXJIiK+5UeCZv8GriwUKaU2ggo8AI6gMPWmxkB2bm8McL9UK+EQKqloIoh6gjpskOTSLrjqw7ZujKtqwo0Kwk/wAOCYMCyELuVQbs9PDV8WQgnPAqLSouzWMaNoHz+spilyL/oEFbSNgsgKwk9cAJZTAvpqD6EbDIog7EyKsR5IznBqJrqgKqzwAKcCgk28ALTYwvwK78nQr+9KjAsewhiXArK2KjogKux4LbrS8e3gMCbNa+34rOD8MelEDvyCsrpgKmzMLiREMmTXJsg/E7AXClRSwiRmrmhEJAWmw63Ck1Zu/8KGQAD2MwIp5zKKVUyhybLEUsKKrw5e2wOozTDqfC6NszLuRB9AQKewToSeXsIwnsKDmXL5tAz8pwKz9vMOvDMtnAakvOp2zwwjssKj3PM70wONJBus5C+kpADL5ADuzBxYtd500wpp9sK2ozM5iA3BY0KNfwIOgACaIpaGCPSAt0twOvAqMCsD10ODXCsr7DBkQACOrCkeOjQKO0t3Cu1+HoK71E6zToK+xwL3EgLLd0IOXABHt0L+CyKIkwy9ysIZ3sKfEJcLrrA4TACPu0KZSoDkvDSouXF+tDAg8C3p6AAEmAR3ljR4XC+rhDHjyDUxVAAemzWlVLCgwC5qYD/fwp3yTAD16ewvLXwyI9w1VndC/e12CNNIz98CKmLCvlnADti1KYQ1a5gobRgAjfQ1j0ADJg1sq98K2AsCFOb0/mRAFy8Yo5dChr6Crr8CDyQw1p6IegIOTV9KwU7CGH9KU9NCqTNCjXQx7HAzI6wAy9gx8AwoXldv96iyYRA16cAvx5Wk82tCjjK29r5CChwAqstDAzAGu2d2TMSy48buacQhdnrrONwpK8gAijs28C9FeMNmyUtCJ2NCvbN2FGU26Jwpa9w0NNd3SMnMNV82A/8CULlAIuL3+EwpqxAz1Ss3uAANye7H/DIs92SzrLwH4xz240tDnMKCzMwlZDw/9vg8Du39WE5G74mjispmOIXs9PegNa0ANQPrtCgONiNwFCxEWSyo5E5UmRg6S0RLW8V/gnVqN3fEAIBNgtVrQhVDATIsHCWgI5zW+ZiRsF268LdMuAAQMx7JL5H3Q3s+dMfwNaP8AM/kAxlQdGOUBaDZ+Y6wcKFYMG3ctODcM2rcNJ6rQ0pEJKw4NeMAAQvYOTDoOgE82CI65WifZfdgm6jus6oQCgUC+Tb8J9qTaWO8OUk6DHLbTHukBCPFLqlVpeN2S1f7eYXquCeUAHQ/QqoDQl4vgz+FhxNOgm1lZi1trs7XilyjeirQKB4SurZkGTfDM7n3QiSTunEcHy4Cf/f5mHYADDLqxChpofgbabrnNABZQsLMxqoVPwCYL4MGwWi3k4elGfC/a0KHkrvcT7t6fkKbyrjizDHzbDvE1fv65mpzr4KK8pHZa3h28DhqTClU0wIztwMRPRRvDva6D4Oxy3uSgEUPsrcHY8JctOysACmilDOzrAAO+IwCL+gW07hr8CkClwKAR4KPS0LGHADPSnwiLAC9gwaOa8O/0cLLNnv19C8qyADIuABMqCW4zwIF+8MhozkEA+LbB4x9GLuLb4NI9DIrzADH1DKFT8ILP8Mm5cQ3Fn06DDh/8wK7JMQG4/b3MDXp4ABLAADVU4IQh8NUUjTL0opKD4Is63/FIAT0K9dDaaOCuHMAlOfCD2Q0NvFLgHw8NI+Iz2O3H3fZullJHV/7tvAoKlAAR+Q747A0ZX9DAVjg4s/I+Lp3YJhnJkvDbttCiQgAiJg55Hg1tIg6hOL9Thf8uBQ0ojdCmVmU0o/DSd6CirwAak9CYA9HG5vDoYOAAUODtWfCQStChhgAh+gvpNA2cSx/eTg6YRw+NpP/JKg36Pg9DU6Cb5P/ezfDSea3OuPDSqdCjMACBEUAISFhoeIACA6iY2Oj5CRkpOUlZaPAQGXm5ydnp+glxUahxGhp6iemamsrQANNa6OGCwwMp45FzmyvJ0TBL2cq8HExcaXCBaGGSLH/86dw8/ShRukxhkfJhifOj3T3wMCBhMM34nR5unqny4hhzMm6/KF6PO8IxXHNx8loDwr9oodcGBAgIAHEOTVC8iwIb5DGTI0TLdw4qkQI4qRECGCBKgdL2xY5LWggAKDB9dVHMlSWoMGLVMdIFAOQMkABRZg0hQz1Ah3xEp8uBEKxQlvrhaEEzBA5zwHKCUUkDBAJc+eWI9VwJH104GTPBMwFZBgZ1dPFTL2wmDig8RQ/3gtNVh13oAEOQOuPMs31AYOy972hSRWgCYIKR8ISNho7+BGGjYEkwHDw7ZQIEUmRYmy5jqahA54Vuf4selJHBAcYtHv9DkFUDUFMAxg9v9VAplyD7jq+lENmLxmRJiByijSVhBOchZgbzehAHWt9p5eSUO+QhgiXKYO4MBi27VpgyeEOzd03twNcdigzBUGDyJufUKx4sKFEwBlQYAwl6m8AwMoYMAAAUZHGnrpJVhIAzQYUgILCs7GWQATCOAAAFBN4EhpvXXQgSwqZLOdJ/XZd0F+qBTAGCFK0eWUOgQsp8CKBypooyE1qEUIawoyQAABEgggAQMMiENAQaMdwuFpFiAAWCv7qICKiSZqBgoBAxhAYyFJruNAAZ6UtyIDEwSw4k15RbLkjY+FYA0A2Y2Y4HgFFGQAmBsimF4DH7IiA0ceTUnlBaEw8IACeir/GCNKmjCggAJiXQiAWOGUpWaibPamWiEPZioMpr1ZUA0rQg3CSon2ocjJAlA58GJLAmDJmYGS+AhAAf5lCMBJCyD2AACKbXkOqJ4OpkEKhvBYrCVrDhbDdafQ4pYruaSKgioKPNAlSwMMRCCBklpSwKEJhQOMueCNZ0h5uhG77Fkx9Amndu9W0mxfbqJCGQtynoKCDjwAYOUmEAwITL2GOJCAAmCaCwC64tF2CLuZOIewax0AB0CnF0ty71k/oULBB8TJ4oOqnUCAJ1/fthzuJQYBu9ikAhxQ4YW6QvJxxw2NUkhEPF96Ywo6bvJeBBHAEB8vLbxwbScqnrYcXcw+/xCAYgbcehBiWRdpwJECbKuku0GPlEzZlOyMlQZAdeIB0kh7wEsuu3CCpZZoA1AwXQcQ4sBJCfR9q50rm5V3V+0c7jHZfVWgMSdwwx0oK8ZxYiii1C1QZiaFU8S44vI8RAjQoI+toAvsfRI50rKs8MMmrFr4qmuKoUSrOWqX7pLGJpSs+3Ofd9VBg5/AELncrSzytL3Zim2ahbFaLN3vLG1ViAiC/Z47S6k92ckNIrwdgWWtgFQ3JQUPcHCCsSrAAHTzbE99MX8VYsr8tQWPFQ3yciKUfJNLhQ1e0IJLqIxNDHuAARRwu2/ID3+8WM/PmoG/BzZEVN7bhAym1QuAVf8iap4qQAG+ogDBTQ+CAbFOIeABQQsypAHQMhoMfGcyRkzibsJSkGhC47xnuBCFqWBQIXrXQv3FJF9ui0cvmra8R1zOiI+xGPwUAkUg8iJH18ue9qpokREg63si6FcqcvCCHUQidq5aFoAERCAGxo+LVmxFCFxgPxT+cB4Y6YRQAtiKf4FATc2r16JQMqM3xnEemwIAM+wIR4bgoG2XkEEEtNiKH7wuES0SAAPXh7AvNeSOh+zEsVaoxAo2MiBp4QQG+BGMHpygiYboTwOX5YCXGTKU6YjXzyipO1CmIzLtuYQISikL82ESV8vpIZuo8slT4tITHYhBKH1pjoxxwgT/FOQFCgh4iJIopnacCdoEEMW5Wz5zGil4kxWpOY3UBLMSQhFjKnTgg0J48yB5kWXQ9EnFc37jbIrkZS+duQ4PaTAC8uEFD3RwLQJ8M00sWkpTgjaTHxHAhDXy5zMSt6PWFNE1GLwECVjZCyCEhDwQTYQyl3VRvRBUo5QYQSzmJc/SsfMZsLgEBoYZjBxcYQqcROFXDJKA2eHupTCVBA2AwzFGMmlUljAB8mRREi0cJKgQNIABAvA3CZgzqcSwHgCU5VTTiK4SM4BBTT1xTy8owagojNVzZimNm4IVEfWL0zqROo0QcKUS2EgoKhyKzyq88pkGeAABIJAAr/bzrsGQ/+DGILRXs0JSEiP1aCoIkBe6nROZmsSo5yAbDBxch6xlHUwqKbFTopyiJEGtnD8PQKGVHsOupH1Fg/RaWWNJphIsmCpbx3XVQ6ygnhqtaEsfm1tXYLGpQMRtMBxXCQqEcbgPNaryNApO/zC3uayYY0APKd0Ipm4SIRLsJDIplgek1BAmPd85yZKbzh0VvK1o0jnLKwuDTmKDUroEPxsxQCAkdQC2/C5+P2GBCiAAARV4Z2/P0r1J7NRUlkBMMhvxr4AllQAMBNclaIsTLpXpTAXACVwRwV+NOvjBCCiCQOfXYlbwiRIsoKwl/jY1R/jAhklVDtUswZkLOQpSFiIEpf/IsrgFnwLGMDbCNPlaDFHRURLgW6tKE5AABgz4EEy8K2w8ASbvMEdXvPKVzHJoOid7wgINgPKDZ0y9GoOiwQ8+LyT+l+Ex20SicCWjGe/qAPX9SLSU8NrD5Aox2UhsXeY5j5s78cgKpADKQcClnT/x4gfHsBEbpHMi/iYsscn2rl+uRLAWfa5YpevRhaCYpCdtCQ7UYAMZwTMCrAAFTVOZF3J20iMwMMNKMIDLti2EJXOb4vpeokV4WrVYbJbknBmO1pNowAZoIGEOsHDKWQk2JDxAzEgkJ8GQ2C62a0WpTDAAVwgRBwC8BraVbhp/bKvAlRFBRHD3RANy/vQhslz/if1YwpjrlsQgDQIMHgeOEHUSh32HlXBH2HoD0nQE9nzdE20/y9MSdtAH+OgIg19imwWs+H1VfghtdyDkpXjmvS3hghSkwHsZRIQkRV0Ik0w8EvRk+cqFfqx0RmKRHB9JDDbwOEisUrOP+BuiJbFQ8Fr06lOfxszzZoEOYHwS3/Z3QzhQAfFSgqeSkMDDL9G0gUF2at49YcKX/vJIHC0C1xV7QHCwbZg7ApuSWACXVwwJQeM30uVU8KSPhcRIiC9uSbeHBW79V0rEMxLHlgDhH+FHoWeU1l1neiVWFwGSf9QebKuB3x0hSfUm4iuO3cQPUAZek9juq04ewQZqkPNI/5C+Y2SikFPQtPmtJ4IGX7dEZs3NsE64Epbg1SpTFBD7zy/YBWVXJ2ZFsDrhvmsullqypRrz60vUvAK9tzvaIXFATnh20os5c/VHu2ALIL/pkgjRDe5OvotBYAELUBCLlRgzQx6RJj3mEAMIgH+TIFXsx2aUgHLYFisJcDV05UPllze6h36XECWGYHoIgySvdhsHmIGSQHYpsG+WkFZrRWqfcFzr1lgSgm5aZ4I8g31+JVKAojs3Ex6OhinGp3vcxgmB5QjH1mWcQB9VonIToCG4l1RwtoCr5wj69ztQ4Vg9aG0sZoONMHlQtQnL1wjnRiJUQnsL5kkAUCZPeE66hv8AKlgJKhBgpYM1mUATRoIkeSINkaF6ndBajuCCnjAoF+B24LUABNBYP/IAF+gMxscdnQZhcCiH1LMcmhBxd3JtVYZ8RcNa4vMB3sclyOYJLXACgkhrC2cQ8zd0MBVs6ZcIHnh4XFgI59eKjnc8iTCGnTCKJ9ACqHIitPY+A5IJE7B5jBiLmdIB4hYJG9ERTtZicZZxkLM6JGdym6CLKaeEJwJ9C7ZDDNGIHZICjyhwiFCFblZeKPiGl/B7qGCNiUCIbnYAiihiindIk5cCFqBrEQYJr1iONrh0xOMJFNB9hkCNlsCOnncIhTFkchdKFmBz70SLhLCMINhcdjV5jUf/hByRAeLTfxhSSAV5Art4kIkgALgCABJgjELzTA3ZP/k3FAl3U3zHh33YFjQ0OUeYbIVgkCKJCLHyNYW2hiiEOiyZf5JIa9RkfxtQef7zASwAgrhICTq5k4iwVUGSEvMIQajDgFRYlOvmS+3AgZ1AAh4AAzMGiJMQlVKJCAdwAAvwAA9AjLeFkr0RGZs4bCzwAVyJbaDkcZ6AAQFJASOSSXeBhGcJkimXlmfhjV0xAghQl1TIlFrWjATFATaHjoBVGa7XH1lTmCGJmJBgewppfRCke5aZCNKSly/JRbqWAqLXh3cJdYUwNSuFlp7ZCCfxLTRYV3L5GMhXmuMImTu5/z2P+EWcMAMi4gg99gi0WZu2mZuqOD8dYHaNcHcwgJdpuT2sqEEiQJaPAFqhCWaGyZyU4ACpaAmG6BnBh2Iq1mT403X2OG62eJ1clIyVgAH7gGGNgCsTAGiJsJzi6QippnCKwRNHFilKNhbjh4m605DvCQmkN5EVJ5xQJo6PoAKVAaFaszLb4p//+YcuAzMGwRNoJgC9QoAQSA+7mRUrOYWEoALqKJXbg48s+oEeYJ2fSZLKGZ4dWlcS4zCN5oOIIGsICDo1N5Su+AHcBzef6HkWBJGIMDL7Fwm48nMAwKE72gjdUmi4uQnj4aOuFjEIIqQpGhOo84+OIJH8F5ldif+SzLA0UoqjhYCNK6CjV1oJ0TMrXCox0lYzWSgATqigeYM6jnkI5FgIGKpy/MUWJDMJU2pcVHICdWoOQCIkwABvXDNvdxg2Kak4jDmohrCPHVpeQtGUlCBCiCCI7hipkUAgnrAcfgM4gmOJVGoIimkPuqeUiSCRkYpbYsmdkkCQhbADvWgfqsqli1iDiqNtvtmiLqmqN+WXgqCmt9J8hmADPvACINCLZliskAAVW3qVCON1y9qiqPmf7JQBmDmeJVStPnABPHAtcqqN3PoIAepAY8oQHdCg87qp0fKalaB2JoQCIPACPkCIqbqviXmv89Bg+toIcYiwoGSc2kAJglf/VIQgsC+wAgeLsJXAKt2CEEBZLA0pk44gFOW6o9vDf8zgq5OQeU4xiiswaBwLCrUDJL8CrplCmUZ6CG3hes7KRY+HNPgpCbBHCEAAkjI7s6Dgp+ozRQuZKW24s9jBAnkHsVz0oAXXfMLamUp7CouhPgNws0/LJuE4bCLAL0q7PS86CSqTAyuArV3LChLwKAUxq8VYL9mZCBtUblbrNvFJCdaKrfIat53QlprknBj4LgAnZw5LUl2bshsprRCQBO3qA4NLuOlRq8RgHSFwaTBGoQ9LuBZ0qD03BFRQsJjbClCBOS6VsxXAdPf4YvmYuuR3DBIwBEsgX7QbChrGcK1r/yMc4HUN0G2JELqpy19dkAUJIAW72woBYAAAuFW/mx5dhwB1h2U2erw2uANM4ARv2bzOmwA/gohZp5vU63JOaqg7uLt2JaxRMATlCb6gICF4irNnAWcbAJYt6VrNy0428LZfMAR2K7+cUAAtI49j2xc/4TOUAKrsy1eBCwIoAKwE7Cma6wk/YXROt5HrK793JLAXgLoV3DEXvAmM56mHELQwMML50wlyOrA/IBIUzMKZUsLVUXYo/IElgLUVvD29WEYQR600vCw2fIKvO7yRIAPWFQEssLYezEWo2pHlO8QRorCbELywCwkqYAIwAAMmEGBBu6QP3AmlCLBUXC9F3P+FyHi9jZABTSwCFKBeacrCPkwlWDB4Z4zGVjwJ+NsB6ScDM/AWGVACGEq6okssP9IIXIAEBoEETaB5sYZVCifJkZDIm2DJlYDJmUzJkKDJlODJn8zJCJPGhYC/+gsnKkABb+PFPJfHwKMziaKZbcYsUJQ7O6M2uFzLVUTK5ssJMpoKbVh5GcDF40MBKiCtrvzKgEoIskmrusylu2xEuQzN1FzNeSOhMJYCL7HN3NzN3vzNDeC5D1YEAZYBM+CzycyeeTiSrurM1mwv0XwJ0yzPz/zO1EFiUzzLyCBnGQPO/gzOTxBsUpbOjUB8y+zOiZBq80zLn0LP9jwJC83Q6cH/NQVxogi9CcFGARq90YK80R7N0aOz0SJAnwSNCOJ30Cha0Px50fD80BAtzfUs0TI909Mxbd6RoCgdCUGAaSbw0R390R790wG5059b0rdoorF2gLuBeOZBIExtHieJeE791FQNHUtd1Uw91Vid1Ve91brR1V5dMWAd1lod1mJt1kqN1qJsDzEDAG2dCM121mhtHkRA1EFABHNd1RFQ1w8WBFuQ14Ad2II92IRt1mtNEWCa1IW92Izd2I792JAd2ZF22PLQ1m+NCHFd2EKANEcQAULQ2JvN2Z/92GXN2KXd2Ke92KkdAJTtQIlt1LrDKwugScWAAaHNkaBg23GDzGlD/2U3xU687Ah9+qewrThBkglCYgyZYMjwzNw0HQq//WvB3Qj0hoetsFw2kWLv1Qo3gZIzgZOeEHzDSAwGvSyGexBweQrAnYHUFN2uMN35STitQFtxd9K8MFRZYgxDFYvgRwz2LZnvzd6+XX7r/TsSRQhqtmqyUBD5zAqFEYv/F4ByxQsJXoALBsqhgOGnoOFh0tqXwOEdTj0xUhcjKAveIX1i2wsBABuwRgzWLQslXtwynsneFePXTRaHCKf3/R0t3gs9qOKvPeNC3sneNdwm7h/qAuOUWAxXSAxGPuRQ/noVIr4LUN2auuCLIRYebjk/EiRDQgx0yNq9YOXgHeVUjP/J/VGp8g3ilSzJByAWQkweW74uopzkvLDkkdwJoCyrEzPnEITd5T1cwpcUzcYK380K4p3e66Xdin4j9yI/H2PLe6zODt3bd0Xf0fHfq7JkCtDok4Dfm3kK+80K/X0Kmk7CwQPp+iPpMbE9jz7pvXHgeoPUes5kDpMKDN4KD84KES6AvEvrPPPqqrDq8dwSrp7qsN4bI/4cQQ47YpEABhC/nXDiBZHin7DisYHlZd4YzX4xwg4NxN7Qxs5F3w5Wyw6kdm6ec1sQFjtYOC4WA0y0PP5rPz6/3T7KY13VQ8os+a7vu9zvkh3Y+542AJ/Vye4a5/7knFAhmjCgMoHkPZ7/pxPCCk1+CgrfMbL21U/t55DG1VTN8QCQ8YW92oMN8iH/1Ktt8qVDbVRO5mT27jp+ChWt5YXS5UKy7Y8Q5irPJZmK8xYsl/Ddwq1+8AqS5oMjcaDAY9Jr6HAe7/YS8a068aHA53UG9ES/zuNu5lrvCGzOCl0vD1//GTu/9WRf9mZ/9mif9mq/9mxvD6Axbz4P1/ZliBZlWwvQ4FJqtwxgQqZKDA6A90T7IkTS9iXNZEIP3WG6VXVItIhL6YlwKE7BX+pj8eGydoSfzIYBJquwAOehEz8iQu8GHSPkluXgUAMAyQuBJYfAAFQh5gVQDu82bzlxFQFQ5VSxMtAhATOh/4ioDyoMEO14EgASQBV9E/oD4ISsPwB4MkK/sFjEzx+OZcAWM/mFspm/bxOtD3E2AwG07+mXX6ckWharcJK14VXYXgBHQgABWPsT4FU71P6HH2uKL+ZfY5KaMPmqr/oG0DcHAAgGAAYECw8FAA4SAAcQBwwAE4sBAQCWl5gTDhAPlgEPCwcKAASECwaQpocAAwYBBAEDDKKIq4UAqwMEmLy9vrwJB5EOAAm7DpWtr8akCb/P0NHS09TV1tQEu9e+Bw8DiNYH35ji4Jbl1QPE1gUDwtLt79uXCxLqDgOM4/P8/f7/vQQACFCAEoBRlkYZJJWP1S4C+RZMeJAg30JMBP+MZZvlbGCyh/kgRlokoYA4SwQ6KVhAb2JFj9CCHWS5UJdIhydJddLlqRIAgTAZxHLlEOAlTcUOHHAVwF5RAAVImjNKtarVaQKAVhPQEJMBBa96ERDgUyxZjGcvCdWGtSu2AJCkBRDAlp8EAQ4KFCSV9qrfv/wELkhgUKvAhTd5ikwwYYHIi5duomxoUHHIiAZOOW4oUmuxxo/L9mLAdYACRDWzNbTJOR9PmD97MjAAAeZro7NnN8tGQNhtBaIACx8OMCumdgMe1AbAaYAEAgUEuIoLVXqlBbGUA7g7oFLKAQMm8BU9VtGA2msBLMAn4R3BCd0tcYUvIVRYWMLgq2P/AAuSRPDi4eOcMHPVVRBE9UEF1wSQwKddKWQxsNdYPiEnHnEYDgdUAEQ92Aliq4H0E0vtwIaRWwuslEgl2pV4kz2LzDSQePscIACJFonGC1LMfXjdKIntomIANGqz0IbLWCLBR1YlQJh6wJ3z1EBEZWjllb8Yd8kDyBgggIQCPPBJAA4IoIA7l5R5ZjFgJSDAAW4aYNGSAwhQAIVoueLmAXgm0KYCkJjpwAMCiJdVAl5KQFonhDJwFzLGFMgKXg6M4kqlgkh6SZ0SlLmTmXSVOagAEBSgAFfiCISnqIReiOWr/gCVYiXigEegT0EyBJWcTkGG0pngIVJAAt54x+tl/+d8aQkETiZY63kFHGtiLzIlhJ2cCdSWK7MJJPjakT1tV5GYUxoVXVxwDvDkbaSxBOu7GWppiVCt0DWBAISBw1VA+djY3V2vpCURRWThGdlZEBRMlo3EJGxoRPvuu8C+dS6KS5hhFWhjjJAQgM+pA9GFSZ2WuDmpuwo4M/GnlpCMpwJM7QvvzDTz42vNOGMYVc48GyUvAylHJXIsWREjMyb7jtUdJdmk5ecE9wZM3lkUVk31WTJH3NC+0blZWz1uklqgwcyFyexhIm8KFMkky7e1a2urijVTBPVs99033633P6js7TdWZDEdJkT2OgBdmD8RQt1PDSlwGgET3Gl24v8eKzz1c3u+TAihwuBLwF0Puw2lmUpOUPkEkjoOAbNzBQCBlyHXVSfkiLd9MQRz0Rj3eBe/stffwAcv/PDEE5/V8duZ6SYBr2cFSshvIt1QN1nRNuko0XFlOVqnnsY7nNLp6zheojOuJPkDdU+MpNRzNZh0sGvasnTuT0oPoQqs07bLZ9XTvY7FC6AAB0jAAhqQKkeLibL8YrsDOvCBEKyGXjLklgha0C8J/IW/ANPAC3rwgwbMGwZBSMISmvCEKHzXdxLUFHsIQ0KxuFBKHmAkofAHAi6EgHMsIaDleCaFQAyiEIdIxEs8YiQDAUVwSlEIVOQmN4yDSyxm4b1VfK3/bz8sIs/QEQ0dogkg+PhFGOOhxTKasWYDe0lqgoQ6TxjqEuCCicdMs4ssnnFmZPsFaQizuH50UG2kgMsdB0lI4jBmM7BhTctg4ZPCwNEnSGKWb+pYyJqVxx7LcdSAkjeO5sgwAAe4k07U4a5L6PABsBulA1jiMrgc4D6gVCVNTAJKWMqjkrgc5I2gkiMo6QonHUGTVuJICTKphxl2zGWGxqKnNwGNMI4rhnQ2ESZRhexUrqsm4kyJLw4JJGFcqh3aCGCxRoHTUz851ZcQ1yhlutOM0XKORbClrRANxEmQfKR8ejKY5CDzna/CU8KIJAA60QVPhGKJn0K2HEJRIpWW/2gnyRzqTftJqk4pygdFYYcvtVkMoCANqUiLhycKzWVJlODPWfY3zvkVUzQsndRLLSqy6NwFEXWa6dG6RqqR+vSnQMXZWDD3Jhtly2N8OkvUwBk7S9yLhjjEROuaF4nBRZVkkpqYmVjyVOYt4mgpIl1Qx0rWsgJmLN0Dx9nwpVKfVCpMNEkblZyHiQXUyQCp9KY4m5q8GM0VcQl8lFkHS9jCDtJNfTSsYhfLWAtusLGQjaxkJ0vZylr2spilSjaMwptbAIA/G8EE7lzHizBGoxv7+AcXeUFGdWT2tbD1m7yokcGfHE8Bu5jL8RbxPnX1xX7R+EpYAJJHOA5tKrFNrv9y3zVb5GinR8453HSQJpAyVaJ1p3jTXNbRiJGRyjnuslB1iLKeTQ6Elp+F0S3VYw+Hqic7tZFU3do4o/cmR1ugvBN9ibTc/voXcJjgkjfBJCYxqemL8iELoiDRukkdjiux9G6nEMeqQh2YTQHwU6DU+cwARBMTblLEWfyUYe2KbF93UUpBMbynuWAzxRv7r4xnTF1M0MtLtMtX+ahbr+typUyCSN/xptI2k8GMElpjBPkc9pOO3MugbIkxhfzVlMCdOCR4uVdvIAywuSynPGVaL43HnNyfBe0uua0T+WqrJePMhVf+OUeZ3BJT61ACEUm7WiVkdtJiUqekClvaKyTXJTMDOEkQSismLOT6FUOT+dHLzYqiBzc7TRyuE9IhJ3Vpl6nfxuJOAPMu7RhVsL3IDGYpiZ7MjAoBpNID1dY9yOMiR+iGlCktjtNvQeSqW1dB+teYPZ5x7pIyujQPrtC7pbDR1ODIqLlKajvVAFjiPzPteXpx0ldX1pqAxZlKe7QilHRwd+V5ZQVd4qaN/EizS2C7+90hTZhf4U3vehOSUHWxt773ze9++/vfAA+4wAdO8IIb/OAIT7jCF87whjv84RCPuMQnTvGKW/ziGM+4xjfO8Y6/MxAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The relationship betwen the fetal biophysical profile score (BPS) result and the occurance of various perinatal morbidities. The incidence of fetal distress in labor (FD), cesarean section for fetal distress (LSCS-FD), low 5-minute Apgar score, and venous cord blood acidemia exhibit a very significant linear inverse relationship to test score. These data are based on observations made in more than 26,000 high-risk fetuses. B) The relationship betwen the fetal BPS and perinatal death (PNM), both gross and corrected for fatal anomalies. Unlike morbidity, the mortality rate increases in an inverse exponential fashion as the BPS score decreases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data published in: Manning, FA. Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score. Clin obstet Gynecol 1995; 38:26.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_15_25855=[""].join("\n");
var outline_f25_15_25855=null;
